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Physiological and Pathological Characterization of Alpha-Synuclein Oligomers 
 
Abstract 
 
α-Synuclein (αSyn) is highly abundant cytosolic protein whose conversion into insoluble 
fibrils is a pathological hallmark of Parkinson’s disease (PD) and other synucleinopathies. 
Despite decades of research, fundamental questions regarding αSyn biology are unresolved. 
Soluble, prefibrillar oligomers, not their fibrillar end products, are believed to be neurotoxic in 
humans and in disease models, but their mechanism of action remains unknown. Evidence from 
our lab and others increasingly suggests that, in healthy cells, αSyn does not exist purely as an 
unfolded monomer, as the field has long believed, but also as aggregation-resistant, α-helical 
oligomers; however, their physiological role remains controversial. Thus, my aim was twofold: 
to characterize toxic αSyn species in the context of mitochondrial dysfunction, a central 
phenotypic feature of PD; and to purify helical αSyn oligomers from human brain to enable 
further characterization of physiological αSyn.  
Because the neuronal populations vulnerable in PD are characterized by cytosolic Ca2+ 
oscillations that burden mitochondria, I investigated the direct relationship between αSyn 
aggregation and mitochondrial dysfunction in the context of mitochondrial Ca2+ stress. Using a 
reductionist system comprising isolated mitochondria and recombinant αSyn in various carefully 
characterized aggregation states, I observed that soluble, prefibrillar αSyn oligomers, but neither 
fibrillar nor monomeric αSyn, decreased the ability of mitochondria to retain Ca2+, promoted 
!!iv 
Ca2+-induced swelling and depolarization, and accelerated cytochrome c release. These changes 
were seen only when mitochondria were energized with complex I substrates and were prevented 
by cyclosporin A, implicating the involvement of the mitochondrial permeability transition pore.  
Then, I developed a protocol to successfully purify soluble αSyn from postmortem, non-
diseased human cortex. CD spectroscopy revealed that brain-derived αSyn contained 
significantly more helical content than recombinant protein. Application of a crosslinking 
reagent to intact neurons and to partially purified αSyn samples showed for the first time that 
abundant αSyn oligomers exist natively in the brain, and that they survive several, but not all, 
purification steps. Together, my results suggests that factors which shift the equilibrium of native 
αSyn oligomers toward aggregation-prone monomers can drive the generation of prefibrillar 
oligomers that then contribute to the selective degeneration of Ca2+-challenged neuronal 
populations in PD. !
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Chapter 1 
 
Introduction 
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Parkinson’s Disease 
In 1817 James Parkinson first described the “shaking palsy” that would come to bear his 
name. In the many years since this initial characterization of six cases, Parkinson’s disease (PD) 
has come to be diagnosed as the 2nd most common neurodegenerative disorder. PD is diagnosed 
in 1% of individuals by the age of 65 and 5% by age 85 (Van Den Eeden et al., 2003). In total, as 
many as 0.3% of Americans suffer from the disease, with the total number of diagnosed 
individuals projected to more than double by 2050 (Kowal et al., 2013). PD costs our nation over 
$14 billon annually, and as our population ages, PD is poised to present even more of a clinical 
and financial burden (Kowal et al., 2013). While several genes have been implicated in familial 
forms of PD over the last 2 decades, the vast majority of cases, greater than 90%, are sporadic 
with no known inherited cause (Dauer and Przedborski, 2003). 
The principal clinical features of PD are resting tremor, rigidity, bradykinesia or slowness 
of movement, and postural instability (Dauer and Przedborski, 2003). The cause of classical 
parkinsonian symptoms, the loss of dopamine stimulation of the striatum, was not discovered 
until over a century after they were initially described. In the central nervous system, initiation of 
movement takes place partly in the midbrain, specifically in a collection of neuronal clusters 
called the basal ganglia (Shulman et al., 2011). The basal ganglia consist of the striatum, globus 
pallidus, subthalamic nuclei, and substantia nigra (SN). Synapses that connect the basal ganglia 
nuclei with each other as well those that link the basal ganglia with the motor cortex via the 
thalamus form the so-called basal ganglia motor loop. The activity of the SN serves to modulate 
the activity of this loop through two different dopaminergic pathways originating in the striatum: 
the direct pathway, which increases the output of the motor cortex and therefore movement; and 
the indirect pathway, which ultimately has the opposite effect. Depletion of striatal dopamine 
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would be expected to 1) reduce activation of the direct pathway and 2) remove inhibition of the 
indirect pathway – both of which would result in the inhibition of movement (Shulman et al., 
2011). Indeed, this is exactly what happens in the brains of individuals with PD.  
Striatal dopamine is reduced in PD patients because the cells the produce and deliver this 
dopamine, the neurons of the substantia nigra pars compacta (SNc), are targeted by the disease 
(Ehringer and Hornykiewicz, 1960). It is believed that by the time parkinsonian symptoms 
appear, 80% of striatal dopamine and 50-60% of SNc dopaminergic neurons have been lost 
(Bernheimer et al., 1973; Riederer and Wuketich, 1976). This notable for two reasons: on one 
hand it suggests that one can lose an impressive number of these cells before there are noticeable 
behavioral implications; but on the other, it indicates the extent of disease progression before 
patients seek medical attention - both of which highlight the importance of efforts to develop 
sensitive biomarkers for early detection. At this point, the only effective molecular treatments for 
parkinsonian symptoms are L-3,4-dihydroxyphenylalanine (L-DOPA), a dopamine precursor that 
serves to ameliorate motor dysfunction by increasing the amount of dopamine produced by SNc 
neurons, and other drugs that act to increase the activity of dopamine in the nigrostriatal 
pathway. Unfortunately, enhancing dopaminergic tone does not affect the underlying cause of 
nigral degeneration, and, after many dopaminergic neurons are lost, such treatments can lose 
their efficacy (Olanow and Schapira, 2013). 
Aside from selective neuronal loss, the other pathological hallmark of PD is the presence 
of insoluble aggregates in the soma and neurites of cells called Lewy bodies and Lewy neurites, 
respectively. These proteinaceous inclusion bodies appear as a dense core surrounded by a 
diffuse halo and are found areas affected by neuronal loss (Spillantini et al., 1997). Lewy 
pathology contains ubiquitin and other proteins such as synaptophysin (Nishimura et al., 1994) 
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and synphilin (Katsuse et al., 2003), but it is primarily composed of 10-14 nm in diameter fibrils 
of the protein α-synuclein (αSyn) (Spillantini et al., 1997). Though they are present in diseased 
regions, it is becoming increasingly clear that Lewy bodies themselves are not toxic, but rather 
they may represent an attempt by cells to sequester other toxic αSyn species (Reeve et al., 2012; 
Tanaka et al., 2004; Tompkins and Hill, 1997).  
 
α-Synuclein in Familial and Sporadic Parkinson’s Disease 
 αSyn is present in peripheral tissue such as cells of the erythroid lineage (Barbour et al., 
2008; Dettmer et al., 2013), but it is most highly expressed in brain - with estimates that it 
represents 0.2%-1% of the total brain protein (Iwai et al., 1995; Tofaris et al., 2005). αSyn is a 
140 amino acid protein that is localized primarily to presynaptic terminals. Its N terminus is 
marked by seven imperfect, 11-residue repeats that mediate the binding of αSyn to membranes – 
primarily small diameter vesicles and negatively charged phospholipids such as 
monosialoganglioside (GM1) (Martinez et al., 2007) and cardiolipin (Nakamura et al., 2008) – 
and the adoption of N-terminal helicity (Davidson et al., 1998). The vast majority (>90%) of the 
protein is soluble (Dettmer et al., 2013; George et al., 1995; Kahle et al., 2000), however, 
indicating that interactions with membranes may be transient. αSyn also contains an unfolded, 
acidic C-terminal tail and a highly hydrophobic central NAC domain (residues 61-95), so named 
because this peptide was identified as a non-amyloid-β component of plaques in Alzheimer’s 
disease (Culvenor et al., 1999; Uéda et al., 1993). 
Genetic evidence indicates that αSyn plays a causal role in the pathogenesis of PD.  To 
date, 5 missense mutations (A53T, A30P, E46K, G51D, H50Q) have been discovered that lead 
to dominantly inherited PD (Kara et al., 2013). These patients display similar symptoms to those 
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suffering from idiopathic PD, though some mutations are more aggressive than others (Lesage et 
al., 2013; Zarranz et al., 2004). Duplication and triplication of the wild type αSyn locus are 
sufficient to cause PD with an onset and severity that varies with the gene dosage (Chartier-
Harlin et al., 2004; Singleton et al., 2003). Aside from its involvement in familial PD, the 
presence of Lewy pathology in sporadic PD indicates that αSyn plays an important role in these 
cases as well. 
Though the exact molecular stimuli remain unclear, under pathological conditions, this 
normally soluble protein undergoes a conversion into β-sheet-rich, insoluble fibrils found within 
Lewy pathology. This aberrant, amyloid-type aggregation of αSyn is dependent on the NAC 
domain (Giasson et al., 2001), which is absent in its aggregation-resistant family member β-
synuclein (βSyn) (George, 2002). In vitro studies of recombinant protein have shown that 
aggregation from an unfolded monomer into fibrils occurs by way of a heterogeneous pool of 
soluble oligomeric intermediates (Breydo et al., 2012). Because of their correlation with 
neuronal loss in PD, Lewy bodies were long thought to be toxic to neurons; however, recent 
evidence suggests that these inclusions may serve to sequester soluble αSyn oligomers, now 
believed to represent the true neurotoxic species (Volles and Lansbury, 2003) - a hypothesis 
reminiscent of the changing attitudes regarding Aβ aggregates in the pathogenesis of AD (Haass 
and Selkoe, 2007).  
Several lines of evidence from PD patients support the hypothesis that soluble αSyn 
oligomers, rather than insoluble fibrils, are the main neurotoxic species in PD and other such 
synucleinopathies. First, not all αSyn mutations that result in early onset PD lead to enhanced 
fibrilization (Conway et al., 2000). These familial PD mutations may have other effects on the 
structure and stability of physiological αSyn that will be addressed later. Second, insoluble Lewy 
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bodies are found in asymptomatic individuals (Knopman et al., 2003). And third, cells containing 
Lewy bodies are thought to be healthier than nearby neurons that lack Lewy bodies (Tompkins 
and Hill, 1997).  In vitro data support this theory, as well.  Oligomers produced from 
recombinant αSyn have been shown to permeabilize vesicles and create plasma membrane pores 
that result in Ca2+ influx and initiation of caspase-3-dependent cell death (Danzer et al., 2007; 
Volles et al., 2001).  
The in vivo toxicity of oligomer-forming αSyn was elegantly addressed by recent 
publications. αSyn of different aggregation propensities were expressed in C. elegans and 
Drosophila. The authors observed an inverse correlation between β-sheet content/insolubility of 
the variants, as determined biophysically or by immunostaining, and neurotoxicity in these 
model organisms (Chen and Feany, 2005; Chen et al., 2009; Karpinar et al., 2009). Winner and 
colleagues (2011) similarly engineered αSyn mutants that either promote oligomerization or 
fibrilization as determined in vitro. Oligomer-forming, but not fibril-forming, variants resulted 
dopaminergic neuron loss when overexpressed in rat SN neurons by lentiviral infection. As 
analyses of PD brains have shown, however, there is no evidence indicating that αSyn oligomers 
exist only in brain regions that undergo neurodegeneration.  This suggests that, on their own, 
soluble αSyn oligomers may not be inherently toxic but rather result in cytotoxicity when they 
are stabilized and present in an environment particularly vulnerable to their effects. 
 
Phenotype of Vulnerable Neuronal Populations 
The classical PD motor symptoms and their source, the stereotypical degeneration of SNc 
dopaminergic neurons, have been well characterized. Dopamine itself is often pointed to as the 
culprit for this selective loss since cytosolic DA is readily oxidized into toxic metabolites 
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(Greenamyre and Hastings, 2004); however additional evidence suggests that presence of 
dopamine on its own is not sufficient to explain the pattern of cell loss in PD. For one thing, if 
dopamine itself were leading to toxicity, it would be difficult to explain how chronic 
administration of the dopamine precursor L-DOPA can alleviate, rather than worsen, 
parkinsonian symptoms (Fahn, Parkinson Study Group, 2005). In addition, distinct dopaminergic 
populations are differentially susceptible in PD. For example, compared to the nigral 
dopaminergic neurons, those of the neighboring ventral tegmental area (VTA) are relatively 
spared (Dauer and Przedborski, 2003). Perhaps most importantly, non-DA areas are also 
targeted. PD-related degeneration in areas such as the cholinergic dorsal motor nucleus of the 
vagus (DMV), the noradrenergic locus ceruleus (LC), and serotonergic raphe nuclei (RN) are 
responsible for symptoms such as constipation, sleep disturbance, and depression, respectively 
(Surmeier and Schumacker, 2013).  
The neuronal populations vulnerable in PD share a distinctive physiological phenotype in 
which they deal with high transmembrane Ca2+ current. Unlike their relatively spared VTA 
counterparts, SNc dopaminergic neurons possess an unusual, age-dependent reliance on Ca2+ 
influx through Cav1.3 L-type voltage-gated Ca2+ channels that contribute to their pacemaking 
activity (Chan et al., 2007) and lead to detectable oscillations in intracellular Ca2+ levels 
(Guzman et al., 2010). Moreover, their slow firing rate and extended spike duration allow for 
excessive Ca2+ influx through presynaptic voltage-gated Ca2+ channels. Elevated Ca2+ flux is also 
a feature of broad-spiking, spontaneously active neurons of the DMV, LC, and RN, among other 
vulnerable regions (Surmeier and Schumacker, 2013). 
Careful regulation of intracellular Ca2+ is critical for proper neuronal function.  Ca2+ 
regulates neurotransmitter release, stimulates ATP production, mediates synaptic plasticity, and 
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activates a host of transcription programs that result in, among other changes, cell growth, 
proliferation, and differentiation.  The specific pathways activated in response to Ca2+ transients 
generated either by influx of extracellular Ca2+ or release from intracellular stores are dependent 
on the temporal and spatial dimensions, amplitude, and subcellular localization of the signal 
(Wojda et al., 2008). Excessive intracellular Ca2+ can lead to activation of Ca2+-binding calpain 
proteases and caspases that can cleave enzymatic and structural proteins leading to cell death 
(Berliocchi et al., 2005; Wojda et al., 2008).   
In addition to ATP-dependent plasma membrane pumps, neurons rely on fixed cytosolic 
Ca2+ buffering proteins (such as calbindin, calretinin, and parvalbumin) combined with uptake 
into intracellular Ca2+ stores to keep the cytosolic concentration low. Neurons at risk in PD 
display a reduced intrinsic buffering capacity. Nigral dopaminergic neurons have significantly 
lower levels of calbindin-D mRNA and protein in PD cases compared to controls (Iacopino and 
Christakos, 1990) and dopaminergic and non-dopaminergic regions lost in PD contain lower 
levels of Ca2+ binding proteins than those that are more resistant to the disease (B. G. Kim et al., 
2000; McCarthy et al., 2012; Mouatt-Prigent et al., 1994; Yamada et al., 1990), suggesting that 
they rely more heavily on intracellular storage. 
The cytosolic Ca2+ oscillations that occur in vulnerable populations place a substantial 
metabolic burden on mitochondria. Mitochondrial ATP is needed to operate transporters on the 
plasma and endoplasmic reticulum (ER) membranes that pump Ca2+ out of the cytosol in an 
effort to re-establish the steep concentration gradient that is reduced upon Ca2+ influx. Besides 
their critical role in ATP generation, mitochondria are also important Ca2+ buffering organelles 
in both physiological and pathological situations. Under physiological conditions, mitochondrial 
Ca2+ uptake through the ruthenium red-sensitive Ca2+ uniporter spatially and temporally 
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modulates intracellular Ca2+ transients and stimulates the production of ATP by activating 
multiple enzymes of the tricarboxylic acid cycle (Szabadkai and Duchen, 2008).  L-type-
mediated Ca2+ influx in particular can act to modulate ryanodine receptors and stimulate Ca2+-
induced-Ca2+-release from the ER that, due its close proximity to mitochondria, results in an 
increase in mitochondrial Ca2+ concentration (Szabadkai and Duchen, 2008). Under pathological 
conditions, it is instrumental for execution of excitotoxic pathways (Stout et al., 1998), as 
mitochondrial Ca2+ overload leads to opening of the mitochondrial permeability transition pore 
(mPTP) (Baumgartner et al., 2009). 
The mPTP is a multi-protein complex that is believed to consist of the mitochondrial 
outer membrane protein VDAC (voltage-dependent anion channel), the inner mitochondrial 
membrane protein ANT (adenine nucleotide translocator), and the matrix modulator cyclophilin-
D. If the matrix Ca2+ concentration passes a critical threshold, cyclophilin D binds to ANT - a 
process prevented by the mPTP inhibitor cyclosporin A (CsA) – and allows ANT and VDAC to 
form a large conductance pore (Norenberg and Rao, 2007). Pore formation allows for the 
diffusion of solutes smaller than 1500 Da across both mitochondrial membranes, effectively 
abolishing mitochondrial membrane potential (∆Ψm). This permeability increase also results in 
the osmotic influx of H2O due to the high concentration of matrix solutes, ultimately leading to 
mitochondrial swelling, outer membrane rupture, the release of cytochrome C, and downstream 
initiation of apoptosis (Petit et al., 1998). Oxidative stress favors the opening of the mPTP by 
inducing the crosslinking of matrix-facing cysteines residues of ANT that promotes binding of 
cyclophilin-D (Halestrap and Brenner, 2003). 
Recent work has revealed that the mitochondria of vulnerable neurons do indeed exhibit 
signs of stress. The Surmeier lab used a mitochondria-targeted, redox-sensitive GFP and 
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observed brighter fluorescence (corresponding to a more oxidized matrix environment) in 
neurons within at-risk populations, including the SNc and DMV, compared to neurons from 
areas that are relatively spared, like the VTA (Goldberg et al., 2012; Guzman et al., 2010). The 
fluorescence/oxidation state of GFP could be reduced by antagonizing L-type Ca2+ channels or 
by blocking the mitochondrial Ca2+ uniporter with Ru360, suggesting that mitochondrial Ca2+ 
uptake contributes to this oxidative environment (Goldberg et al., 2012; Guzman et al., 2010). 
Mitochondrial Ca2+ uptake occurs due to the electrical and chemical gradient inside the matrix 
and its uptake partially dissipates the ∆Ψm needed for ATP synthesis. In order to re-establish the 
∆Ψm to allow for optimal ATP synthesis and buffering of further cytosolic Ca2+ elevations, 
mitochondria must increase activity of the electron transport chain (ETC) and its associated 
proton pumping. In case of vulnerable neurons whose cytosolic Ca2+ concentrations are 
constantly oscillating, there are likely cycles of mitochondrial depolarization due to Ca2+ uptake, 
and repolarization due to stimulation of respiratory chain activity. Though the precise 
mechanisms linking ETC activity and the production of reactive oxygen species (ROS) are not 
fully understood, a greater flux of electrons into the respiratory chain raises the probability that 
some single electrons will be inappropriately transferred to O2 prior to reaching complex IV (Lee 
et al., 2001; Rigoulet et al., 2011) especially under conditions of compromised ETC activity (see 
below). Regardless of how it is achieved, the basal level of oxidant stress in the mitochondria of 
vulnerable neurons may put them at risk of dysfunction caused by an additional stressor. 
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Mitochondrial Dysfunction in Parkinson’s Disease 
In the context of PD, mitochondrial stress could come in the form of the accumulation of 
damaged or dysfunctional mitochondrial components. For example, two proteins implicated in 
familial PD, Parkin and PINK-1, are believed to function in a mitochondrial quality control 
pathway. The mitochondrial network is constantly undergoing cycles of fission and fusion that 
serve to exchange membrane content (including proteins and lipids) and intra-mitochondrial 
components (such as mitochondrial DNA). Loss of function mutations in these PD-related genes 
may result in defective autophagic clearance of damaged or dysfunctional mitochondria 
(mitophagy) and their subsequent accumulation within the cell (Narendra et al., 2012). 
Parkinsonism has repeatedly been linked to deficits in the activity of mitochondrial 
complex I, an inner mitochondrial membrane protein complex of at least 45 subunits and 
multiple assembly factors that serves as the entry point for NADH-linked substrates into the ETC 
(Koopman et al., 2010). Complex I catalyzes the transfer of electrons from NADH to ubiquinone 
via iron sulfur clusters and a flavin mononucleotide while also pumping protons from the matrix 
to the intermembrane space, thereby contributing to the proton gradient that is harnessed for ATP 
production (Mitchell, 1961). In 1983, Langston (1983) reported cases of illicit drug users who 
developed progressive parkinsonism with degeneration of the SN after inadvertently injecting 1-
methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP). MPTP is oxidized by monoamine oxidase 
in glia to MPP+, which is selectively taken up into dopaminergic neurons via dopamine 
transporter where it binds to and inhibits the activity of complex I (Langston et al., 1984). 
Epidemiological data indicate that exposure to pesticides such as rotenone, another specific 
complex I inhibitor (but one that is not selective for dopaminergic neurons), is also associated 
with PD (T. M. Dawson and V. L. Dawson, 2003). Use of MPTP and rotenone in primates, 
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rodents, and cell culture have become useful PD models since they reproduce features of the 
disease including oxidative stress, motor deficits (in animal models) and αSyn accumulation 
(Betarbet et al., 2002). 
Multiple types of complex I dysfunction have been reported in the brains of sporadic PD 
patients. Spectrophotometric measurements of the enzymatic activity of mitochondrial ETC 
complexes harvested from post-mortem tissue revealed specific deficits in complex I activity 
compared to control tissue even in areas spared from frank cell loss (Keeney et al., 2006; Parker 
et al., 2008; Schapira et al., 1990). This supports the idea that certain brain regions are 
preferentially susceptible to the downstream effects of compromised mitochondrial function. In 
line with reports of reduced complex I activity, Keeney and colleagues (2006) detected elevated 
levels of protein carbonyls, a marker of oxidative damage, in the complex I subunits of PD 
patients that inversely correlated with proper complex I assembly and function. Furthermore, 
mitochondria from PD patients contain a higher proportion of mitochondrial DNA (mtDNA) 
mutations than do mitochondria from control tissue – an observation indicative of an oxidative 
matrix environment. These mtDNA mutations are likely both a consequence and cause of 
oxidative stress. ROS such as H2O2 are known to produce double-stranded DNA breaks. 
Mutations in mtDNA can lead to reduced expression of mitochondrial gene-encoded proteins or 
the expression of non-functional variants. Of the 13 proteins encoded by mtDNA, seven are 
complex I subunits and the others are subunits for complexes III and IV (Reeve et al., 2008). 
Improper ETC complex formation can impair the proper flow of electrons and lead to the 
generation of ROS, especially from complexes I and III (Rigoulet et al., 2011). ROS can act 
locally to oxidize ETC components and membrane lipids or target mtDNA, further contributing 
to oxidative challenges and bioenergetic failure. 
! 13 
 
!
α-Synuclein Accumulation Impairs Mitochondrial Function 
 It is becoming increasingly apparent that the accumulation of αSyn, as occurs in PD, is 
associated with a mislocalization of a pool of αSyn to the soma and processes (Roy, 2009) as 
well as a partial redistribution from the cytosol to the mitochondria. Cole and colleagues (2008) 
proposed that this redistribution might be heightened in times of oxidative or metabolic stress. 
Accordingly, another group used immunoelectron microscopy (immuno-EM) to demonstrate a 
preferential association of αSyn with mitochondria in rat SN neurons compared to cortical 
neurons (Zhang et al., 2008). Though it is still unclear how this transition occurs in vivo, PD 
patients and models show increased mitochondrial αSyn content that is associated with 
mitochondrial dysfunction, including complex I dysfunction, elevated ROS, reduced ∆Ψm, 
altered Ca2+ homeostasis, and enhanced cytochrome c release (Chinta et al., 2010; Devi et al., 
2008; Hsu et al., 2000; Martin et al., 2006; Parihar et al., 2008; Rhinn et al., 2012; Sarafian et al., 
2013; Smith et al., 2005; Stichel et al., 2007). Devi et al. (2008) used ELISA and immuno-EM to 
show that the mitochondria from the SN of PD patients contained significantly more αSyn than 
did the SN from control tissue or the cerebellum from PD brain. These findings were supported 
by another group who recently reported an increase in mitochondrial αSyn in PD patients 
possessing an αSyn mRNA transcript isoform with an elongated 3’ untranslated region 
associated with higher protein levels (Rhinn et al., 2012). Transfection of this isoform in rat 
cortical neurons confirmed a greater redistribution of αSyn to mitochondria from synaptic 
terminals compared to the short isoform, suggesting that αSyn concentration itself may somehow 
contribute to mitochondrial translocation (Rhinn et al., 2012).  
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The precise mitochondrial localization of redistributed αSyn is still controversial. As will 
be addressed further below, αSyn has a well-documented tendency to bind acidic phospholipids. 
The mitochondrial membranes, particularly the inner mitochondrial membrane, are enriched in 
cardiolipin (Daum, 1985), and fluorescence resonance energy transfer studies suggest that αSyn 
preferentially interacts with mitochondrial membranes in vitro (Nakamura et al., 2008). Several 
reports have described an outer mitochondrial membrane association for αSyn (Cole et al., 2008; 
Nakamura et al., 2008; 2011), but others indicate that, under conditions favorable for ATP 
production, it can be localize to the inner membrane as determined by immuno-EM and 
proteinase K digestion experiments (Devi et al., 2008; Liu et al., 2009; Zhang et al., 2008). 
Discrepancies in submitochondrial localization may be due to differences in the cell types 
examined or the degree or form of αSyn expressed within the cell. Though αSyn lacks a classical 
mitochondrial recognition sequence, truncation of the N-terminal 32 residues did abolish the 
mitochondrial import of αSyn in one system (Devi et al., 2008); however, since the N terminus is 
responsible for lipid-induced folding of αSyn, it is conceivable that this could be disruptive to the 
general structure and function of the protein (Bartels et al., 2010; Vamvaca et al., 2009).  
Over the last 8 years there have been a multitude of reports that demonstrating that αSyn 
accumulation, and its subsequent association with mitochondria, is correlated with mitochondrial 
dysfunction. In the aforementioned study by Devi and colleagues (2008), the amount of 
mitochondrial αSyn in PD tissue was inversely correlated to the activity of complex I, but not 
other respiratory complexes. Overexpression of wild type and PD mutant αSyn in mice or cell 
lines also results in reduced complex I activity (Chinta et al., 2010; Devi et al., 2008; Stichel et 
al., 2007). These effects are not observed upon overexpression of an N-terminally truncated 
variant that fails to target to mitochondria (Devi et al., 2008). Further implying a direct role for 
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αSyn in complex I dysfunction, purified αSyn has been shown to dose-dependently reduce 
complex I activity in mitoplasts and freeze-fractured mitochondria (Devi et al., 2008; Liu et al., 
2009). As may be expected by these reported effects on complex I function, overexpression of 
mutant and wild type αSyn is also associated with decreased ∆Ψm and elevated ROS levels and in 
a variety of cell types (Devi et al., 2008; Hsu et al., 2000; Li et al., 2013; Parihar et al., 2009; 
Smith et al., 2005). An increase in mitochondrially-generated ROS could be particularly 
problematic since, aside from its roles in oxidizing macromolecules and facilitating 
mitochondrial permeability transition, ROS have also been reported to promote the 
oligomerization of αSyn (Näsström et al., 2011), perhaps leading to a vicious cycle of 
oligomerization and mitochondrial dysfunction. 
Recent studies suggest that apoptosis observed in αSyn transgenic organisms might be 
related to the activity of the mPTP. Genetic modulation of mPTP components rescued 
cytotoxicity in mice, Drosophila, and C. elegans models of αSyn overexpression (Büttner et al., 
2013; Martin et al., 2013). Interestingly, the pro-apoptotic nuclease Endo-G, which is released 
from mitochondria upon mPTP opening, was observed within the nuclei of cells in PD, but not 
control brain sections (Büttner et al., 2013). These data in agreement with earlier reports that 
αSyn overexpression in cell lines promotes a redistribution of cytochrome c from the 
mitochondria into the cytosol (Parihar et al., 2008; Smith et al., 2005) that can be partially 
rescued by the mPTP inhibitor cyclosporin A (Smith et al., 2005), but not all αSyn transgenic 
mouse models with mitochondrial abnormalities show evidence of mPTP activation (Stichel et 
al., 2007).  
There have been very few investigations into the effect of different forms of αSyn on 
intact mitochondrial function. Parihar and colleagues (2008) reported that aggregated, but not 
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monomeric αSyn, can increase markers of oxidative stress upon incubation with isolated 
mitochondria, but the aggregation state (fibrillar or oligomeric) was not characterized. Overall, 
the overexpression of αSyn is associated with a variety of mitochondrial phenotypes including 
complex I dysfunction, elevated ROS, reduced membrane potential, altered Ca2+ homeostasis, 
and enhanced cytochrome c release. That said, the direct effects of defined αSyn of aggregation 
states on mitochondria in the context of elevated Ca2+, as experienced by the mitochondria of 
neurons vulnerable in PD, has not been investigated. 
 
Physiological Function of α-Synuclein 
Interest in alpha-synuclein intensified when it was identified as the main protein 
component in Lewy bodies associated with synucleinopathies (Spillantini et al., 1997), and 
appropriately, much research has been devoted to the role of its aggregation in disease 
pathogenesis. Studies linking αSyn to disease also spurred research into its physiological 
function. Independent of its recognition as a component of plaques in AD (Culvenor et al., 1999; 
Uéda et al., 1993), αSyn was first discovered in 1988 as a presynaptic protein by virtue of its 
identification in a cDNA library using an antisera to purified cholinergic synaptic vesicles from 
the electric ray Torpedo californica (Maroteaux et al., 1988). This report, and others (McLean et 
al., 2000) also detected αSyn in the nucleus in addition to its synaptic localization, leading to the 
name “synuclein”. Its small size of ~14 kDa is below the molecular weight cutoff for the nuclear 
pore, so it is conceivable that its presence in the nucleus is a result of diffusion rather than a 
specific functional role (Bendor et al., 2013). 
α-, β-, and γ-synuclein (γSyn) comprise the synuclein family of proteins, which is present 
only in vertebrates. There are no identified orthologs in other organisms. All synuclein family 
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members are mainly expressed in the nervous system, with α- and βSyn localized centrally, and 
γSyn present in peripheral nerves. Within species, the proteins share a highly conserved N 
terminus with considerable variability in the C-terminal ~40 amino acids (George, 2002). It is 
also noteworthy that βSyn lacks the residues corresponding to amino acids 53-63 in αSyn, a 
region that partially overlaps with the hydrophobic NAC domain that is required for the 
aggregation of αSyn into fibrils (Giasson et al., 2001). The N terminus of αSyn is also highly 
conserved across taxa; for example the human and mouse sequences are identical through the 
intial 42 amino acids and 95.3% identical overall (Lavedan, 1998). This suggests that N-terminal 
residues are ciritical for the proper structure and function of the protein. 
The exact nature of αSyn’s physiological function is not completely understood. There 
have been reports that αSyn functions as an inhibitor of phospholipase D-2, an enzyme 
responsible for generating the intracellular signaling molecule phosphatidic acid (Jenco et al., 
1998); however, recent evidence argues against this (Rappley et al., 2009). Studies of synelfin, 
an avian homolog of αSyn, revealed abundant presynaptic expression that correlates spatially and 
temporally with zebra finch song learning, thus proposing a role for αSyn in synaptic plasticity 
(George et al., 1995).  The imperfect repeats found in αSyn are similar to lipid binding domains 
of apolipoproteins (Weinreb et al., 1996) suggesting a role in the binding of lipids and vesicles.  
That being said, interaction with lipids may only be transient since over 90% of αSyn is found 
within the cytosol following fractionation (Dettmer et al., 2013; George et al., 1995; Kahle et al., 
2000). Investigations in which the level of αSyn within cells or organisms has been modulated 
support predictions based on protein domain similarity and the presynaptic localization of αSyn. 
Low-level overexpression of aSyn in pheochromocytoma cells resulted in an increase in docked 
dense core vesicles and a corresponding reduction in vesicle fusion events (Larsen et al., 2006).  
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Inhibition of vesicle exocytosis was also observed upon mild overexpression in cultured neurons 
(Nemani et al., 2010), though effects on vesicle endocytosis may be dependent on the cell type 
examined (Ben Gedalya et al., 2009; Nemani et al., 2010). Along these lines, experiments using 
αSyn knockout mice revealed a mild increase in dopamine transmission upon repetitive 
stimulation, consistent with the idea that αSyn functions as a negative regulator of activity-
dependent dopamine release. A more mild effect was seen in glutamatergic neurons (Abeliovich 
et al., 2000). Animals in which multiple synuclein family members have been genetically ablated 
have been reported to display elevated basal neurotransmitter release (Anwar et al., 2011), but 
this may be dependent on which synapses are analyzed (Burré et al., 2010). αSyn has also been 
proposed to act as a chaperone for the activity dependent assembly of neuronal SNARE (SNAP 
(soluble NSF attachment protein) receptor) complexes (Burré et al., 2010), though biochemical 
interaction with SNARE proteins remains controversial (Chandra et al., 2005; DeWitt and 
Rhoades, 2013). 
In vitro examination of αSyn further supports a role for αSyn in lipid binding and 
membrane dynamics. Recombinant αSyn adopts stable, helical secondary structure upon lipid 
binding (Davidson et al., 1998), a process that is dependent on critical N-terminal amino acids 
(Bartels et al., 2010; Vamvaca et al., 2009). Fluorescence correlation spectroscopy indicates that 
αSyn has preference for a high degree of membrane curvature, as found in small diameter 
vesicles like synaptic vesicles (Middleton and Rhoades, 2010). Aside from this type of 
curvature-sensing, there are also reports of curvature-generation by high concentrations of 
recombinant αSyn (Varkey et al., 2010), and it has been proposed that these abilities may be 
related (Jensen et al., 2011). This preference for highly curved membranes and evidence that 
αSyn inhibits the in vitro fusion of small unilamellar vesicles, potentially by relieving stress 
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caused by curvature-induced lipid packing defects (Kamp et al., 2010), provide a degree of 
mechanistic insight into αSyn-induced alterations in exocytosis observed in vivo. 
There is still much to be learned about how and with what molecular partners αSyn is 
acting within cells. Due to the strong connection between αSyn and neurodegenerative disease, 
research has focused on the role of αSyn in the brain; however, high expression of aSyn in 
erythrocytes (Barbour et al., 2008) suggests a broader role for the protein in vesicle/membrane 
dynamics rather than one specific to synaptic vesicles. Future examinations of possible 
erythrocyte phenotypes in knockout animals, for example, could provide insight into previously 
unobserved or underappreciated cellular roles for αSyn. Importantly, the vast majority of in vitro 
efforts to study physiological αSyn and its interaction with various lipid and protein molecules 
have relied on bacterially expressed recombinant protein. Recent work from our lab suggests that 
future investigations into the precise physiological function of αSyn would benefit from the 
availability of protein isolated under non-denaturing conditions from endogenously expressing 
sources (Bartels et al., 2011).  
 
Rethinking the Native State of α-Synuclein 
Original characterizations of bacterially expressed αSyn purified either under native or 
denaturing conditions indicated that the recombinant protein is unfolded and monomeric (Kim, 
1997; Weinreb et al., 1996).  Because of these experiments, the field has generally believed that 
αSyn is similarly unfolded and monomeric under endogenous expression conditions,and has 
therefore routinely used denaturing protocols to prepare αSyn for in vitro studies due to their 
simplicity.  
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A recent report from our laboratory challenged this assumption by using αSyn purified 
under non-denaturing conditions from human erythrocytes, an abundant endogenous source of 
αSyn (Barbour et al., 2008), and from human neuroblastoma cells (Bartels et al., 2011). This 
report demonstrated that native, human αSyn exists in large part as a helically folded oligomer 
that sized as a tetramer by scanning transmission electron microscopy and analytical 
ultracentrifugation. While it is well established that αSyn adopts a helical structure when 
associated with lipid vesicles, the inability of phosphate analysis to detect lipid content in the 
purified samples indicated that helicity of the oligomer observed by Bartels et al. is maintained in 
the absence of phospholipids. Importantly, incubation with the β-sheet-binding dye thioflavin T 
revealed that human cell-derived helical oligomers did not undergo amyloid-type aggregation, 
unlike bacterially expressed recombinant monomers (Bartels et al., 2011). This strongly suggests 
that these helical oligomers are physiological and not pathological species.  
Understandably, these findings have inspired considerable debate in the field.  Since this 
publication, the purification of helical oligomeric αSyn from human erythrocytes has been 
reproduced by one group (Westphal and Chandra, 2013), though not by another (Fauvet et al., 
2012). A third group has recently published that mouse brain contains αSyn that is 
predominantly unfolded and monomeric, though the contribution of helical αSyn was 
downplayed (Burré et al., 2013). Still others have achieved helical oligomeric aSyn from 
bacterial expression protocols under certain conditions (Trexler and Rhoades, 2012; Wang et al., 
2011), most notably those that allow for the N-terminal acetylation of the protein (Trexler and 
Rhoades, 2012). Mammalian αSyn appears to be exclusively N-acetylated (Anderson et al., 
2006; Bartels et al., 2011; Ohrfelt et al., 2011), unlike the protein normally expressed in bacteria, 
and recent studies suggest that this post-translational modification is important for stabilizing 
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helical content (Maltsev et al., 2012; Trexler and Rhoades, 2012). The detection of oligomeric 
protein within intact, but not lysed cells (Dettmer et al., 2013; Klucken et al., 2006) and the 
difficulty in consistently purifying helical oligomers across labs speaks to their labile nature; 
however, it is presently unclear what conditions favor the destabilization of aggregation-resistant 
oligomers into aggregation-prone monomers. 
It should be noted that studies of recombinant protein are appropriate and necessary for 
two reasons. First, unfolded monomeric αSyn clearly represents meaningful pool of total αSyn 
that no doubt plays a role within the cell. And second, investigations into the pathologic role of 
αSyn should focus on a form of the protein that undergoes spontaneous aggregation. As 
discussed above, helical oligomers are aggregation-resistant while unfolded monomers are 
aggregation-prone. Though it is unclear whether monomers on their own are toxic to cells, there 
is overwhelming evidence that toxicity is related to the aggregation of αSyn. That being said, a 
complete understanding of physiological αSyn and its function within neurons and other cells 
will require extensive examination of non-pathologic, helical oligomers. 
 
Overview of Thesis 
This goal of this thesis is to characterize oligomeric forms of αSyn in order to better 
understand their physiological and pathological relevance. αSyn has been heavily studied since it 
was discovered that this normally soluble protein undergoes a conversion into insoluble amyloid 
fibrils that accumulate as cytoplasmic aggregates termed Lewy bodies and Lewy neurites, the 
main cytopathological hallmarks of PD. A growing body of evidence from our lab and others 
suggests that αSyn does not exist purely as an unfolded monomer, as the field has long believed, 
but in an equilibrium between helical oligomers and unfolded monomers. Helical, oligomeric 
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αSyn is aggregation-resistant in vitro while the unfolded monomer readily aggregates into 
insoluble, β-sheet-rich amyloid-type fibrils through prefibrillar, oligomeric intermediates. 
Soluble, prefibrillar oligomers, not their fibrillar end products, have been reported to be 
neurotoxic in vitro and in disease models. My aim was twofold: to characterize toxic αSyn 
species in the context of mitochondrial dysfunction, a central phenotypic feature of PD; and to 
purify helical αSyn from human brain to enable further characterization of physiological αSyn.  
 
Part 1: Soluble, Prefibrillar α-Synuclein Oligomers Promote Complex I-Dependent, Ca2+-
Induced Mitochondrial Dysfunction 
The 1st part of this thesis is focused on exploring the direct relationship between two 
features of PD: αSyn aggregation and mitochondrial dysfunction. I modeled mitochondrial Ca2+ 
stress in a reductionist system composed of isolated mitochondria and recombinant human αSyn 
in various carefully characterized aggregation states. I observed that soluble, prefibrillar αSyn 
oligomers, but neither fibrillar nor monomeric αSyn, decreased the retention of exogenously 
added Ca2+, promoted Ca2+-induced mitochondrial swelling, and accelerated cytochrome c 
release, but only when mitochondria were energized with complex I substrates. αSyn-induced 
changes in mitochondrial parameters were prevented by cyclosporin A, implicating the 
involvement of the mitochondrial permeability transition pore. My results indicate that soluble, 
prefibrillar αSyn oligomers sensitize mitochondria to Ca2+-induced permeability transition and 
reveal that the association of oligomeric αSyn with mitochondria can be particularly harmful to 
cells that experience elevated intracellular Ca2+ levels, such as those that are targeted in PD. 
 
Part 2: Purification and Characterization of α-Synuclein from Human Brain 
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The 2nd part of this thesis is centered on understanding the physiological forms of αSyn 
present under normal conditions in the human brain and providing a means of enabling future 
studies of the function of this protein. In light of our recent studies suggesting that αSyn exists 
natively as a helical oligomer, I sought to purify and characterize native αSyn oligomers from the 
tissue most relevant to neurologic disease. Using a combination of ammonium sulfate 
precipitation, gel filtration, ion exchange, and affinity chromatography, I successfully purified 
soluble αSyn from postmortem, non-diseased human brain. Purified, brain-derived αSyn 
contained significantly more helical content than recombinant protein, as determined by CD 
spectroscopy. Application of the lysine-reactive crosslinker DSG to intact neurons and to 
partially purified αSyn samples revealed that abundant αSyn oligomers exist in the human brain 
under physiological conditions, and that they can survive several purification steps. This protocol 
has proved useful in identifying conditions that destabilize helical oligomers into monomers, and 
it will be important for future in vitro studies of the physiological function of native brain αSyn. 
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Chapter 2 
 
Soluble, Prefibrillar α-Synuclein Oligomers Promote Complex I-Dependent, 
Ca2+-Induced Mitochondrial Dysfunction 
 
 
 
 
 
 
 
Contributions: 
Experiments were designed by Eric Luth, Irina Stavrovskaya, and Dennis Selkoe. 
Measurements of mitochondrial parameters were performed by Eric Luth and Irina 
Stavrovskaya. Tim Bartels assisted Eric Luth with biophysical analysis of αSyn.  
All other experiments were performed by Eric Luth. 
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Abstract 
α-Synuclein (αSyn) aggregation and mitochondrial dysfunction both contribute to the 
pathogenesis of Parkinson’s disease (PD). While recent studies have suggested that 
mitochondrial association of αSyn may disrupt mitochondrial function, it is unclear what 
aggregation state of αSyn is most damaging to mitochondria and what conditions promote or 
inhibit the effect of toxic αSyn species. Since the neuronal populations most vulnerable in PD are 
characterized by large cytosolic Ca2+ oscillations that burden mitochondria, we examined 
mitochondrial Ca2+ stress in an in vitro system comprising isolated mitochondria and purified 
recombinant human αSyn in various aggregation states. Using fluorimetry to simultaneously 
measure 4 mitochondrial parameters, we observed that soluble, prefibrillar αSyn oligomers, but 
not monomeric or fibrillar αSyn, decreased the retention time of exogenously added Ca2+, 
promoted Ca2+-induced mitochondrial swelling and depolarization, and accelerated cytochrome c 
release. Inhibition of the permeability transition pore rescued these αSyn-induced changes in 
mitochondrial parameters. Interestingly, the mitotoxic effects of αSyn were specifically 
dependent upon both electron flow through complex I and mitochondrial uptake of exogenous 
Ca2+. Our results suggest that soluble prefibrillar αSyn oligomers recapitulate several 
mitochondrial phenotypes previously observed in animal and cell models of PD: complex I-
mediated dysfunction, altered membrane potential, disrupted Ca2+ homeostasis, and enhanced 
cytochrome c release. These data reveal how the association of oligomeric αSyn with 
mitochondria can be detrimental to the function of cells with high Ca2+-handling requirements. 
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Introduction 
Parkinson’s disease (PD), the second most common neurodegenerative disease, is 
characterized by the conversion of the normally soluble cytoplasmic protein α-Synuclein (αSyn) 
into insoluble amyloid fibrils that accumulate as cytoplasmic aggregates termed Lewy bodies and 
Lewy neurites (Spillantini et al., 1997). Duplication or triplication of the wild-type αSyn locus 
causes gene dose-dependent early onset PD (Chartier-Harlin et al., 2004; Singleton et al., 2003), 
and 5 pathogenic missense mutations have been reported to cause autosomal dominant PD (Kara 
et al., 2013). Moreover, 3’UTR variants and other single nucleotide polymorphisms in the SNCA 
gene that lead to increased αSyn expression are found in a subset of cases of sporadic PD (Kim, 
2013). In addition, mutations in glucocerebrosidase (GBA1), the most common genetic risk 
factor for PD, can elevate αSyn protein levels, perhaps via reduced lysosomal degradation 
(Cullen et al., 2011). Thus, impaired proteostasis of αSyn is likely a key step in the pathogenesis 
of PD and related human synucleinopathies. 
A growing body of evidence suggests that αSyn normally exits in an equilibrium between 
partially helical tetramers and unfolded monomers (Bartels et al., 2011; Dettmer et al., 2013; 
Wang et al., 2011; Westphal and Chandra, 2013). Helical, oligomeric αSyn is aggregation-
resistant in vitro (Bartels et al., 2011) while the unfolded monomer readily aggregates into 
insoluble, β-sheet-rich amyloid-type fibrils through soluble oligomeric intermediates (Conway et 
al., 2000). Recent studies indicate that these abnormal soluble oligomers, in contrast to the 
fibrillar end products, are neurotoxic in vitro and in disease models (Danzer et al., 2007; 
Karpinar et al., 2009; Volles and Lansbury, 2003; Winner et al., 2011). The pathological 
mechanisms of these toxic oligomeric intermediates and the basis for the selective vulnerability 
of certain brain regions to their effects have not been determined. 
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Many observations suggest that mitochondrial dysfunction is associated with PD. Toxins 
targeting complex I of the electron transport chain (ETC) can cause parkinsonism in humans and 
animal models (Betarbet et al., 2000; Burns et al., 1983; Langston and Ballard, 1983), and 
postmortem brain tissue of PD patients shows deficits in mitochondrial complex I activity 
(Janetzky et al., 1994; Parker et al., 1989; Schapira et al., 1989). Markers of mitochondrial 
oxidative stress, including oxidized complex I subunits (Keeney et al., 2006) and mtDNA 
mutations (Bender et al., 2006), are also elevated in PD patients, though it is unclear whether 
these are a cause or consequence of ETC dysfunction. The neuronal populations most impaired 
in PD, including the substantia nigra pars compacta, locus ceruleus, and dorsal motor nucleus of 
the vagus, share an unusual physiological phenotype: they consist primarily of broad-spike 
pacemaking neurons with high transmembrane Ca2+ currents and low Ca2+ buffering capacities 
(Surmeier and Schumacker, 2013). This combination places a great metabolic burden on 
mitochondria to continually re-establish the resting cytosolic Ca2+ concentration.  Mitochondria-
targeted, redox-sensitive GFP reveals a more oxidative mitochondrial environment in these 
neurons relative to those of regions less affected in PD (Goldberg et al., 2012; Guzman et al., 
2010). The basal level of oxidant stress in the mitochondria of vulnerable neurons may put them 
at risk of dysfunction caused by an additional stressor.  
Recent evidence suggests increased association of αSyn with mitochondria in PD patients 
and animal models (Büttner et al., 2013; Devi et al., 2008; Hsu et al., 2000; Martin et al., 2006; 
2013; Rhinn et al., 2012; Stichel et al., 2007). An apparent partial subcellular redistribution of 
αSyn from the cytoplasm to the inner and outer mitochondrial membranes (Devi et al., 2008; G. 
Liu et al., 2009; Nakamura et al., 2011) is correlated with mitochondrial dysfunction, including 
increased oxidative stress, reduced mitochondrial membrane potential (∆Ψm), altered Ca2+ 
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homeostasis, and cytochrome c release (Büttner et al., 2013; Devi et al., 2008; Hsu et al., 2000; 
Martin et al., 2006; Parihar et al., 2008; Shavali et al., 2008; Stichel et al., 2007). Few studies 
have directly investigated the effect of different forms of αSyn on mitochondrial function.  One 
reported that incubation of isolated mitochondria with aggregated αSyn can increase markers of 
oxidative stress, but the aggregation state (fibrillar or oligomeric) was not thoroughly 
characterized (Parihar et al., 2008). No previous studies have tested the role of mitochondrial 
Ca2+ stress or specific respiratory substrates on the ability of diverse αSyn species to induce 
mitochondrial dysfunction. It therefore remains unclear what form of αSyn is most damaging to 
mitochondrial function and which conditions promote or inhibit the effect of toxic αSyn species. 
We sought to investigate the functional consequences of αSyn on Ca2+-challenged 
mitochondria, with a particular focus on the αSyn aggregation state. We modeled mitochondrial 
Ca2+ stress in an in vitro system comprising isolated mitochondria and pure, recombinant, human 
αSyn at various aggregation states. Soluble, oligomeric αSyn aggregates generated by two 
independent methods, but not monomeric αSyn or mature fibrils, sensitized mitochondria to 
Ca2+-induced dysfunction. The effects of oligomeric αSyn were observed only when 
mitochondria were respiring under complex I-dependent conditions and were challenged with 
exogenous Ca2+ addition. Our results demonstrate a specific effect of oligomeric αSyn on 
complex I-dependent function and reveal a mechanism by which the physical association of 
αSyn with mitochondria impairs their function.  
 
Experimental Procedures 
Purification and preparation of αSyn species  
Purification: 
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Recombinant human αSyn was purified essentially as described (Weinreb et al., 1996). 
Briefly, E. coli transformed with human wildtype αSyn were grown to OD600 = 0.5-1, at which 
time isopropyl β-D-1-thiogalactopyranoside was added to 1 mM to induce αSyn expression. At 
OD600 = 1.5-1.8, bacteria were pelleted by centrifugation and boiled in anion exchange buffer (20 
mM Tris, 25 mM NaCl, pH 8.0). Boiled bacterial lysate was purified sequentially by anion 
exchange chromatography (using 2 x 5 ml HiTrap Q HP columns, GE Healthcare) and size 
exclusion chromatography (using a Superdex 200 XK26/00 column, GE Healthcare). Protein not 
used immediately was lyophilized and stored at 4ºC.  Lyophilized protein was reconstituted 
either in PBS or 10 mM ammonium acetate depending on the method used to prepare oligomers 
(see below).  
 
Lag Phase preparation: 
0.6 mg/ml recombinant αSyn in 10 mM ammonium acetate was incubated at 37°C with 
nutation. The aggregation state was monitored using Thioflavin T (ThT) fluorescence (see 
below). “Unaged” αSyn was sampled at time 0 (prior to 37°C incubation or nutation). αSyn aged 
3 to 9 d without ThT fluorescence above background was considered “ThTneg”. αSyn that had 
plateaued in ThT fluorescence was considered “ThTpos”. 
 
Sonicated preparation: 
2 mg/ml recombinant αSyn in PBS was aggregated for 5 d at 37°C with nutation to form 
ThTpos fibrils. To generate oligomers, αSyn fibrils were diluted to 1 mg/ml and sonicated at 
power level 50 for 5 x 10 strokes using a Sonic Dismembrator Model 300 (Fisher Scientific). 
Aliquots of the resultant material were frozen in liquid nitrogen and stored at -80°C. Fractions of 
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this material were prepared by serial differential centrifugation, first at 16,000 g for 5 min. The 
supernatant was transferred to a new tube and the pellet was resuspended in an equal volume of 
PBS. The 16,000 g supernatant was then spun at 100,000 g for 30 min at 4ºC. The supernatant 
was transferred to a new tube and the pellet was resuspended in an equal volume of PBS. The use 
of a programmable Ultrasonic Liquid Processor (Misonix) equipped with a microtip (settings: 
amplitude of 20, sonication for 1 s on and 1 s off for a total of 60 s) also produced αSyn 
oligomers with comparable bioactivity on mitochondria as those produced via our standard 
manual sonication technique. For both sonicated and lag phase preparations, concentrations of 
fibrillar and oligomeric αSyn listed are estimated based on the monomer concentration before 
aggregation as determined by A280 using a NanoDrop spectrophotometer (Thermo Scientific). 
 
Electron microscopy: 
αSyn fibrils, total sonicated αSyn, and 100,000 g soluble sonicated αSyn were each 
diluted 1:10 in PBS. 5 µl of these αSyn samples were adsorbed for 1 minute to a carbon coated 
grid that had been made hydrophilic by a 30 second exposure to a glow discharge.  Excess liquid 
was removed with filter paper (Whatman) and the samples were stained with 0.75% uranyl 
formate for 30 seconds. After removing the excess uranyl formate with filter paper, the grids 
were examined using a TecnaiG² Spirit BioTWIN transmission electron microscope. Images 
were acquired with an AMT 2k CCD camera. 
 
Dynamic light scattering: 
Experiments were performed using a DynaPro (Wyatt Technology) instrument equipped 
with a 20°C temperature-controlled microsampler. αSyn samples in PBS were placed in a 1.5 
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mm path length quartz cuvette and light scattering was measured in 10 s intervals for 20 cycles. 
Data were analyzed using the Dynamic v.5 software. 
 
Thioflavin T assays: 
2.5 µM αSyn at various aggregation states (i.e. unaged/monomer, fibrils, sonicated 
oligomers and fractions thereof, and lag phase samples) was added in triplicate to 10 µM ThT in 
10 mM glycine buffer, pH 9 to a total of 200 µl. Fluorescence at ex/em of 447/485 nm was 
measured in a black 96-well plate using the Synergy H1 Hybrid Reader (BioTek). Background 
fluorescence of buffer (PBS or 10 mM ammonium acetate) was subtracted from αSyn-containing 
samples. For aggregation seeding assays, 100 µl of 7-20 µM monomeric αSyn in PBS plus 1 
mol% of αSyn “seeds” at various aggregation states and 10 µM ThT were added in triplicate to a 
black 96-well plate. Plates were incubated at 37°C under constant agitation at 300 RPM using a 
titer plate shaker (Lab Line Instruments). ThT fluorescence at ex/em of 447/485 nm was 
measured periodically as above. 
 
Mitochondrial isolation: 
All chemicals were purchased from Sigma-Aldrich unless stated otherwise. All 
procedures for animal use and euthanasia were approved by the institutional animal care and use 
committee. Liver mitochondria were isolated from ~11-13 weeks old mice by the standard 
differential centrifugation method in sucrose-based buffers as described previously (Baranov et 
al., 2008; Stavrovskaya et al., 2010) with some modifications. Briefly, the liver was 
homogenized in a buffer containing 240 mM sucrose, 10 mM K+-HEPES, pH 7.4, 1 mM K+-
EGTA, and 0.5% fatty acid free bovine serum albumin (BSA), and centrifuged at 1,000 g for 10 
 ! 46 
min. The supernatant was then centrifuged for 8 min at 8,000 g. The resulting pellet was 
resuspended in the same buffer and centrifuged for 8 min at 8,000 g. The pellet from this spin 
was resuspended in 240 mM sucrose, 10mM K+-HEPES, pH 7.4 and centrifuged again for 8 min 
at 8,000 g. The final mitochondrial pellet was resuspended in 0.2 ml of 240 mM sucrose, 10 mM 
K+-HEPES, pH 7.4. All centrifugation steps were performed at 4ºC. Mitochondrial protein 
concentration was determined by the DC protein assay (BioRad) using BSA as a standard. The 
quality of isolated mitochondria was assessed by the respiratory control ratio (RCR), calculated 
as the ratio between the rates of respiration in state 3 (ADP-stimulated) and 4 (ADP-exhausted) 
(Chance and Williams, 1955). The RCR for mitochondria used in this study measured to be 4.9 ± 
0.18 under the following conditions: 10 mM succinate, 1 µM rotenone, and 200 µM ADP. 
 
Measurement of mitochondrial Ca2+ uptake capacity, membrane potential, NAD(P)H oxidation 
and swelling: 
All chemicals were purchased from Sigma-Aldrich unless stated otherwise. The 
measurement of these parameters was performed simultaneously on a multichannel dye 
fluorimeter (C&L Instruments, Inc.) as described previously (Baranov et al., 2008; Stavrovskaya 
et al., 2010).  Liver mitochondria were incubated in buffer containing 240 mM sucrose, 10 mM 
HEPES, pH 7.2, 1 mM KH2PO4, 3 µM EDTA, and either 5mM glutamate/malate or 5 mM 
succinate plus 1 µM rotenone and were used at a concentration of 0.25 mg of mitochondrial 
protein/ml.  Changes to mitochondrial membrane potential (∆Ψm) were estimated by measuring 
changes in the fluorescence intensity of tetramethylrhodamine methyl ester (TMRM) (60 nM) 
(Life Technologies) at excitation and emission wavelengths of 543 and 590 nm, respectively. 
Mitochondrial Ca2+ flux was measured as the change in extramitochondrial Ca2+ concentration, 
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measured by fluorescence of CaGreen-5N (125 nM) (Life Technologies) at excitation and 
emission wavelengths of 482 and 535 nm, respectively. The redox state of pyridine nucleotides in 
the mitochondrial suspension was followed by monitoring NAD(P)H autofluorescence at 
excitation and emission wavelengths of 350 and 450 nm, respectively. Mitochondrial swelling 
was measured by light scattering at a wavelength of 587 nm. Mitochondria were challenged by 
single Ca2+ additions of 20-40 nmol Ca2+/mg mitochondrial protein. Mitochondrial Ca2+ retention 
time (CRT) was defined as the time between Ca2+ addition and the plateau in CaGreen-5N 
fluorescence. To induce maximal swelling, the non-specific pore-forming agent alamethicin 
(Ala) was added to a final concentration of 2.5 µM at the conclusion of each run. Fluorimeter 
data were analyzed using Origin v.8.0 (OriginLab) software. The specific conditions of each 
experiment (i.e. substrates, inhibitors, concentration of Ca2+ or other mitochondrial permeability 
transition pore (mPTP) inducers, and αSyn species) are noted in the text. CRT was normalized to 
vehicle control. 
 
Assessment of mitochondrial cytochrome c release: 
30 µl aliquots were removed from vehicle- and αSyn-treated mitochondrial suspensions 
used for fluorescence analysis of mitochondrial parameters (see above) at timepoints 
corresponding approximately to 25, 50, 75, and 100% swelling of vehicle-treated mitochondria. 
Another aliquot was removed following the addition of 2.5 µM Ala, which was used to induce 
maximal swelling and cytochrome c release. Aliquots were centrifuged for 5 min at 14,000 g to 
pellet intact mitochondria.  12 µl of the supernatant were added to LDS sample buffer containing 
5% β -mercaptoethanol and analyzed by SDS-PAGE/Western blot for released, soluble 
cytochrome c. 
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Assessment of mitochondria-associated αSyn: 
Mitochondria were incubated as described for fluorescence measurements of 
mitochondrial parameters. In all cases, glutamate/malate and αSyn were added to the 
mitochondrial suspension. 20 µM Ca2+ or an equivalent volume of water was added 2 min after 
αSyn, and after 5 additional minutes, 200 µl aliquots of the suspension were removed. Aliquots 
were spun at 8,000 g for 10 min to pellet mitochondria, and the supernatant was removed. 
Mitochondrial pellets were washed 4 times in 50 µl assay buffer without substrates after which 
they were lysed with 50 µl of 1% NP40 lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 10 mM 
EDTA, 1% v/v nonidet P-40, complete mini EDTA-free protease inhibitor tablet) for 25 min on 
ice. Lysed mitochondria were spun for 5 min at 6,000 g, and the supernatant was collected. The 
supernatants of the mitochondrial suspension, washes, and lysed mitochondrial pellets were 
analyzed by SDS-PAGE/Western blot for αSyn. To quantify the total αSyn immunoreactivity of 
lysed mitochondrial pellets, densitometric analysis was performed using ImageJ (NIH). 
 
SDS-PAGE/Western blotting: 
Samples for western blotting were electrophoresed on Nu-PAGE 4-12% Bis-Tris gels 
(Life Technologies) with MES-SDS running buffer. Gels were then transferred onto 0.45 µm 
Immobilon-P PVDF membranes (Millipore) for 60 min at 400 mA constant current at 4°C in 
transfer buffer consisting of 25 mM Tris, 192 mM glycine, and 20% methanol. After transfer, 
membranes were blocked in 5% non-fat milk in PBS with 0.1% v/v Tween-20 (PBS-T) for 30 
min at room temperature and then incubated in primary antibody either overnight at 4 °C or for 
60 min at room temperature. Membranes were then washed 3 times for 5 min in PBS-T, 
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incubated with secondary antibody, washed 3 more times for 5 min in PBS-T, and then 
developed with ECL Plus or ECL Prime (GE-Amersham) according to the manufacturer’s 
directions. 
 
Antibodies: 
2F12, an in-house generated mouse monoclonal antibody against αSyn (Dettmer et al., 
2013) was used at 0.18 µg/ml in PBS-T plus 5% milk. The mouse monoclonal anti-cytochrome c 
antibody 7H8 (Santa Cruz) was used at 200 ng/ml in PBS-T plus 1% milk. Horseradish 
peroxidase-conjugated mouse secondary antibody (GE Healthcare) was diluted 1:10,000 in PBS-
T plus 1% milk. 
 
Statistical analysis: 
Data are presented as the mean ± standard deviation (SD) unless otherwise specified. 
Comparisons across 2 groups were made using an unpaired t-test. When 3 or more groups were 
compared, a one-way ANOVA followed by a Tukey’s multiple comparison’s test were used. 
Data are considered significant at a p-value ≤ 0.05. 
 
Results 
Prefibrillar thioflavin T-negative αSyn promotes complex I-dependent, Ca2+-mediated 
mitochondrial dysfunction: 
To assess whether αSyn can directly compromise mitochondrial function, we prepared 
recombinant human αSyn for application to isolated mitochondria. To this end, we monitored the 
aggregation state of αSyn solutions incubated at 37°C under nutation. Assaying αSyn at different 
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time-points in this in vitro “aging” process using the amyloid binding dye thioflavin-T (ThT) 
produced a sigmoidal curve of ThT fluorescence (Figure 2.1A). We compared unaged monomer, 
aged ThT-negative (ThTneg) αSyn sampled during the aggregation lag phase, and ThT-positive 
(ThTpos) aggregates (Figure 2.1A, blue, red, and green, respectively) for their ability to alter the 
function of mitochondria. We hypothesized that ThTneg αSyn from the aggregation lag phase 
would be bioactive when applied to the isolated mitochondria, because this phase is 
characterized by the presence of soluble oligomers (Cremades et al., 2012; Fink, 2006; Volles et 
al., 2001) that are believed to be more toxic than ThTpos fibrils that are abundant at the end stage 
of aggregation.  
Mitochondrial stress was modeled by exposing isolated mitochondria to a single bolus of 
Ca2+ to induce eventual membrane permeabilization associated with a collapse of ∆Ψm, release 
of endogenous and exogenously-administered Ca2+, oxidation of pyridine nucleotides, and 
mitochondrial swelling. We used a fluorimeter-based assay to simultaneously measure these 4 
parameters (∆Ψm, Ca2+ uptake/release, redox state of NAD(P)H, and swelling) in isolated mouse 
liver mitochondria. Figure 2.1B shows a representative record of these 4 mitochondrial 
parameters for mitochondria respiring with the complex I substrates glutamate and malate 
(complex I conditions) and exposed to a single Ca2+ addition in the absence (black traces) or the 
presence of 1 µM monomeric (blue traces) or aged, ThTneg αSyn (red traces). Addition of 
mitochondria into the incubation buffer, as indicated by the labeled arrow, induced the sharp 
decline of the TMRM signal (i.e., TMRM concentration in the buffer) due to the accumulation 
and quenching of the dye by polarized mitochondria. The addition of Ca2+ at 180 s induced a 
transient depolarization (and therefore increase of TMRM signal) as well as a spike in 
extramitochondrial Ca2+ concentration before rapid uptake into mitochondria.  Alamethicin  
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Figure 2.1: Prefibrillar, ThTneg αSyn sensitizes mitochondria to Ca2+-induced dysfunction 
in a substrate-dependent manner.  
A. Sample aggregation timecourse of recombinant αSyn as measured by thioflavin T (ThT) 
fluorescence. 0.6 mg/ml αSyn was aged at 37°C under nutation and ThT fluorescence was 
monitored periodically. Unaged monomeric protein was obtained prior 37°C incubation, ThT-
negative (ThTneg) aged protein was sampled from the aggregation lag phase, and ThT-positive 
(ThTpos) aged protein was collected once ThT fluorescence had plateaued. B. Representative 
traces of basic parameters of isolated liver mitochondria simultaneously measured by a 
multichannel fluorimeter in the presence of 5mM glutamate and 5 mM malate as substrates, 
either PBS vehicle (black traces), 1 µM monomeric αSyn (blue traces), or 1 µM ThTneg αSyn 
(red traces), and a single 20 µM Ca2+ addition. Mitochondrial membrane potential (∆Ψm) was 
measured via TMRM fluorescence. Higher intensity corresponds to depolarized mitochondria. 
Ca2+ concentration in the suspension was measured as Ca-Green 5N fluorescence signal. The 
redox status of pyridine nucleotides was measured by NAD(P)H autofluorescence. Lower 
intensity corresponds to a more oxidized state of NAD(P)H. Mitochondrial swelling was 
measured the change in light scattering of the suspension. A decrease in scattering indicates a 
dilution of mitochondrial solutes due to swelling.  Spikes result from additions of Ca2+, αSyn or 
vehicle, and alamethicin (Ala), which was used at the conclusion of the measurement to induce 
maximal swelling. C. Quantification of the ability of aged, ThTneg but not monomeric αSyn to 
reduce the mitochondrial retention time of 20 µM Ca2+ under complex I (glutamate and malate as 
substrates) but not complex II conditions (succinate as a substrate plus rotenone to inhibit 
complex I). Ca2+ retention time (CRT) was defined as time from Ca2+ addition to ultimate 
plateau of Ca-Green 5N fluorescence. Error bars represent the SD from at least 5 independent 
 ! 52 
 
 
Figure 2.1 (Continued): Prefibrillar, ThTneg αSyn sensitizes mitochondria to Ca2+-induced 
dysfunction in a substrate-dependent manner.  
experiments * = p < 0.05 ANOVA followed by Tukey’s multiple comparisons test. D. The 
relative CRT of ThTpos αSyn taken from end-stage plateau of fluorescence was compared to 
vehicle control. Error bars represent the SD of 4 independent experiments. 
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(Ala), a non-specific pore-forming agent, was added as a positive control to observe maximal 
mitochondrial swelling at the end of these measurements (note the rapid reduction in absorbance 
at 587 nm). Unaged, monomeric αSyn had no effect on mitochondrial Ca2+ retention time (CRT) 
while 1 µM ThTneg αSyn significantly reduced mitochondrial CRT by 27% vs. control (Figure 
2.1C). We found that αSyn sampled from the end-stage plateau of aggregation (ThTpos) failed to 
reduce mitochondrial CRT (Figure 2.1D). Taken together, these data suggest that partially aged, 
ThTneg αSyn, but not monomeric or highly aggregated, ThTpos αSyn, sensitizes mitochondria to 
Ca2+-mediated mitochondrial dysfunction. 
Since the level of mitochondria-localized αSyn has been inversely correlated with 
complex I activity in the substantia nigra of PD patients (Devi et al., 2008), we investigated 
whether the effect of prefibrillar αSyn was restricted to complex I conditions. Therefore, instead 
of the complex I substrates glutamate and malate, we added the complex II substrate succinate 
and complex I inhibitor rotenone (complex II conditions). Interestingly, under complex II 
conditions, neither ThTneg nor monomeric αSyn significantly affected CRT (Figure 2.1C) or the 
other mitochondrial parameters tested (data not shown). This result suggests that the ability of 
aged ThTneg αSyn to sensitize mitochondria to Ca2+ is specifically dependent on electron flow 
through complex I and also serves as an important specificity control for our analytical method. 
 
Duration of the aggregation lag phase is variable: 
The data presented in Figure 1 highlight the fact that obtaining bioactive αSyn is 
critically dependent on predicting the timing of the aggregation lag phase and “catching” αSyn at 
the optimal oligomerization state. While the effects of aged, ThTneg αSyn occurred consistently, 
the duration of the aggregation lag phase leading to activity varied considerably and was thus  
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Figure 2.2: Variation in αSyn aggregation kinetics.  
Aggregation state of 5 different 0.6 mg/ml αSyn samples incubated on different days under 
nutation at 37°C were monitored over time by ThT fluorescence. Note the broken abscissa and 
variation in duration of the aggregation lag phase prior to ThT positivity. Raw fluorescence 
values were normalized to the maximal fluorescence signal for each sample. Error bars were 
omitted to highlight differences among, rather than within samples. 
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difficult to predict a priori. Five examples of αSyn incubated under identical conditions on 
different days are displayed in Figure 2.2. In some cases the lag phase extended over several 
days, while in others the samples already contained ThT-binding species at early timepoints after 
the start of incubation (Fig. 2.2, note the broken abscissa). The kinetics of αSyn aggregation are 
known to be altered by many factors, including pH, temperature, sample volume, degree of 
agitation, protein concentration, and the presence of even a small amount of oligomeric “seeds”. 
We therefore sought a more reproducible way of generating bioactive oligomers.  
 
Characterization of αSyn fibrils before and after sonication: 
Sonicated αSyn fibrils have recently been used to seed the aggregation of endogenous 
αSyn in cells and mice (Luk et al., 2012; 2009). Since mature αSyn fibrils can be prepared easily 
and reproducibly, we asked whether the mechanical disruption of fibrils into small species can 
produce oligomers that are functionally similar to the prefibrillar oligomers present during the 
aggregation lag phase (above). We first generated recombinant human αSyn fibrils (see 
Experimental Procedures) and characterized them by several techniques before and after 
sonication. Electron microscopy of non-sonicated fibrils revealed long, relatively uniform fibers 
hundreds of nm in length with diameters between 10 and 15 nm (Figure 2.3A). In contrast, 
sonicated fibril samples were more heterogeneous and included short fibril fragments as well as 
spherical αSyn aggregates (Figure 2.3B) Dynamic light scattering analysis revealed the average 
hydrodynamic radius of non-sonicated fibrils and sonicated fibrils to differ markedly at ~950.5 
nm and ~40.0 nm, respectively (Figure 2.3C, note log scale). We examined the ensemble 
aggregation state of sonicated αSyn by incubating samples with the β-sheet-binding dye ThT. 
Sonicated αSyn was only 10% as fluorescent as non-sonicated fibrils (Figure 2.3D) illustrating a  
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Figure 2.3: Characterization of sonicated and non-sonicated αSyn fibrils.  
A,B. Representative electron micrographs of αSyn aggregated at 2 mg/ml for 5 d under nutation 
before (A) and after (B) sonication. Sonicated fibrils contained a heterogeneous mixture of 
species including spherical oligomers and short fibril fragments. Scale bars = 100 nm. C. 
Hydrodynamic radii (Rh) of fibrils and sonicated fibrils as measured by dynamic light scattering. 
Error bars represent SEM of 3 and 7 replicates for fibrils and sonicated fibrils, respectively. D. 
Background-subtracted fluorescence values of 2.5 µM (based on starting monomer 
concentration) fibrillar, and sonicated αSyn fibrils in the presence of 10 µM ThT expressed as a 
percentage of signal obtained for fibrillar αSyn. Sonicated fibrils fluoresced with approximately 
10% of the intensity of fibrils. Error bars represent SD of 3 independent experiments. E. An 
example aggregation timecourse of 7 µM monomeric αSyn seeded with 1 mol % of fibrillar, 
sonicated, or additional monomeric αSyn is shown. Sonicated and non-sonicated fibrils 
accelerated the aggregation of monomeric αSyn compared to additional monomeric αSyn. In this 
experiment, monomer-seeded αSyn was observed to acquire ThT positivity after 40 h of aging. 
100,000 AFU represents the upper limit of detection of our instrument. Error bars represent the 
SD of 3-4 replicates. Similar data were obtained in 3 other independent experiments. 
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Figure 2.3 (Continued): Characterization of sonicated and non-sonicated αSyn fibrils.  
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substantial loss of β-sheet content. Despite this loss of β-sheet content, we observed that 
sonicated αSyn fibrils were able to seed the aggregation of monomeric αSyn (Figure 2.3E), 
confirming that they still contained species that they can serve as a template for further 
aggregation.  
 
Sonicated αSyn fibrils recapitulate the mitochondrial effects of prefibrillar ThTneg αSyn: 
We compared sonicated and non-sonicated fibrils for their ability to alter the biochemical 
function of mitochondria. Under complex I conditions, sonicated αSyn reduced mitochondrial 
CRT in a dose-dependent manner, with the 1 µM and 2 µM doses causing significant 14% and 
21% reductions, respectively (Figure 2.4A, B). This CRT reduction was again associated with 
commensurate acceleration in membrane depolarization, oxidation of endogenous pyridine 
nucleotides, and swelling of the mitochondria (Figure 2.4A). In contrast to the sonicated 
material, and in agreement with the ThTpos samples described above (Fig. 1D), non-sonicated 
αSyn fibrils did not significantly alter CRT (Figure 2.4C) or the 3 other mitochondrial 
parameters we measured. Under complex II conditions, neither 1 µM nor 2 µM sonicated αSyn 
led to a reduction in CRT when incubated with mitochondria (Figure 2.4D, E). Together, these 
data confirm that oligomeric, but not ThTpos fibrillar αSyn, promotes Ca2+-induced mitochondrial 
dysfunction specifically under complex I conditions. 
In general, the reduction of CRT by sonicated αSyn (1 µM) under complex I conditions 
was highly reproducible, but in 4 of 23 samples tested, no effect of the αSyn preparation could be 
detected. In the detailed characterization of the effects of αSyn on mitochondria that follows, we 
analyzed data from all those sonicated preparations that were found to be bioactive (i.e., 19 out 
of 23).  
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Figure 2.4: Sonicated αSyn fibrils promote Ca2+-mediated mitochondrial dysfunction in a 
substrate-dependent manner. 
A. Representative traces of basic parameters of isolated liver mitochondria (∆Ψm, 
extramitochondrial Ca2+fluorescence, NAD(P)H autofluorescence, and mitochondrial swelling) 
simultaneously measured by a multichannel fluorimeter and recorded in the presence of a single 
20 µM Ca2+ addition, 5 mM glutamate and 5 mM malate as substrates, and either PBS vehicle 
(black traces), 1 µM (red traces) or 2 µM (pink traces) sonicated αSyn fibrils. Spikes result from 
addition of mitochondria; arrows are used to indicate the time of Ca2+ addition. B. The CRT of 
mitochondria treated with 1 and 2 µM sonicated αSyn fibrils under complex I conditions 
(glutamate/malate-dependent respiration) were normalized to vehicle-treated mitochondria. 
Sonicated αSyn dose-dependently reduced CRT under these conditions. Error bars represent SD 
from at least 9 independent experiments * = p < 0.05 ANOVA followed by Tukey’s multiple 
comparison’s test. C. The relative CRT of isolated mitochondria respiring under complex I 
conditions and treated with non-sonicated αSyn fibrils was determined. Error bars represent SD 
from 5 independent experiments. D: Representative traces of parameters measured in isolated 
mitochondria under complex I conditions with either vehicle (black) or 1 µM sonicated αSyn 
fibrils (red). E: The CRT of mitochondria respiring under complex II conditions 
(succinate/rotenone-dependent respiration) and treated with 1 and 2 µM sonicated αSyn was 
compared to vehicle-treated mitochondria under identical conditions. Error bars represent SD 
from at least 4 independent experiments. 
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Figure 2.4 (Continued): Sonicated αSyn fibrils promote Ca2+-mediated mitochondrial 
dysfunction in a substrate-dependent manner. 
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Bioactivity of sonicated αSyn is contained within a 100,000 g supernatant: 
We sought to further define the bioactive component of the sonicated αSyn fibril 
preparation. Analysis of the CRT-reduction capability of the 16,000 g supernatant revealed that it 
contained equivalent bioactivity compared to the total sonicated material (Figure 2.5). To 
determine whether the active component was retained in a high speed supernatant, we 
fractionated the total sonicated material via ultracentrifugation at 100,000 g. Electron 
microscopy of the 100,000 g-soluble and -insoluble fractions showed a near complete separation 
of small, rounded oligomers and large amyloid fibril fragments into the supernatant and pellet, 
respectively (Figure 2.6A, B). Further analysis using dynamic light scattering revealed that the 
100,000 g supernatant contained oligomers with a mean hydrodynamic radius of 20.3 nm 
compared to monomeric αSyn and the 100,000 g pellet which had mean hydrodynamic radii of 
3.8 nm and 42.8 nm, respectively (Figure 2.6C). Moreover, the 100,000 g supernatant was able 
to seed the aggregation of monomeric αSyn much faster than did additional monomer (Figure 
2.6D), suggesting that it contains misfolded species that can promote the conversion of unfolded 
protein into β-sheet-rich aggregates. When applied to mitochondria, the 100,000 g supernatant 
significantly reduced CRT to a degree equivalent to the total sonicated sample, while the 
volume-normalized pellet failed to reduce CRT (Figure 2.6E). Though the pellet contained 
considerably less material than the supernatant as determined by total protein assays, subsequent 
experiments showed that the protein in the pellet had no capability to decrease CRT when 
protein normalized (data not shown). Together, these data demonstrate that sonication of αSyn 
fibrils produces entirely soluble oligomers that can disrupt mitochondrial Ca2+ homeostasis, 
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Figure 2.5: 16,000 g soluble fraction of sonicated αSyn fibrils contains bioactive protein. 
A. Ca2+ flux measurements of mitochondria treated with total sonicated material (red), the 
soluble (orange) and insoluble (blue) fractions from a 16,000 g centrifugation step, or vehicle 
(black) were compared. B. CRT reduction upon treatment with the 16,000 g supernatant and 
pellet of the total sonicated material were compared. Data are represented as percent CRT 
reduction compared to total sonicated material from the same αSyn preparation. Error bars 
represent the SD from 3 independent experiments. * = p < 0.05 using student’s T-test.  
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Figure 2.6: 100,000 g soluble fraction of sonicated αSyn fibrils contains bioactive oligomers. 
A,B. Representative electron micrographs of sonicated αSyn fibrils fractionated into a 100,000 g 
supernatant (A) and pellet (B). Large fibril fragments pellet at this speed while smaller, rounded 
oligomers remain soluble. Scale bars = 100 nm. C. Comparison of the hydrodynamic radii (Rh) 
of αSyn monomer and the 100,000 g supernatant and pellet of sonicated αSyn fibrils as measured 
by dynamic light scattering. Error bars represent SEM of 3, 5, and 3 replicates for fibrils, 
100,000 g supernatant, and 100,000 g pellet, respectively. D. Soluble oligomers present in the 
100,000 g supernatant can seed the aggregation of monomeric αSyn. Monomeric αSyn at 20 µM 
was seeded with 1 mol % of additional monomeric αSyn or the 100,000 g supernatant of 
sonicated fibrils. An aggregation timecourse representative of 3 independent experiments is 
shown. Error bars represent the SD of 3-4 replicates. E. CRT reduction upon treatment with the 
100,000 g supernatant and pellet of the total sonicated material were compared. Data are 
represented as percent CRT reduction compared to total sonicated material from the same αSyn 
preparation. Error bars represent the SD from 3 independent experiments. * = p < 0.05 using 
student’s T-test.  
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Figure 2.6 (Continued): 100,000 g soluble fraction of sonicated αSyn fibrils contains 
bioactive oligomers. 
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while larger αSyn species that pellet under these conditions (intact fibrils and larger fragments 
thereof) have no significant effect on mitochondrial function. 
 
Sonicated fibrils promote Ca2+-mediated mitochondrial dysfunction and associated cytochrome c 
release via permeability transition pore induction: 
There is mounting evidence that under pathophysiological conditions within a cell, the 
exposure of mitochondria to elevated cytosolic Ca2+ can result in mitochondrial damage via a 
permeability transition mechanism (Di Lisa et al., 2001; Lemasters et al., 1998; Scorrano et al., 
1999). The induction of opening of the mitochondrial permeability transition pore (mPTP) is 
associated with membrane depolarization and release of intra-mitochondrial Ca2+. These changes 
are followed closely by the rupture of the outer mitochondrial membrane and subsequent release 
of cytochrome c, which in an intact cell could lead to the downstream initiation of apoptosis 
(Petit et al., 1998).  
To ascertain whether the opening of the mPTP was responsible for the αSyn-induced and 
Ca2+-mediated changes in mitochondrial parameters documented above, we examined the effect 
of the specific mPTP inhibitor cyclosporin A (CsA). As expected, preincubation of the 
mitochondria with 1 µM CsA prevented the CRT reduction by sonicated αSyn fibrils (Figure 
2.7A, left panel, purple trace) and the associated decrease in the time to complete mitochondrial 
swelling (Figure 2.7A, right panel, purple trace).  We next determined whether the earlier onsets 
of mitochondrial Ca2+ release and swelling caused by incubation with sonicated αSyn oligomers 
were accompanied by premature cytochrome c release. We removed aliquots of the vehicle- and 
αSyn-treated mitochondrial suspensions at timepoints corresponding to approximately 25, 50, 75, 
and 100% swelling of vehicle-treated mitochondria. Another aliquot was removed following the 
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Figure 2.7: αSyn-induced changes in Ca2+ flux and swelling are due to activity of mPTP 
and are accompanied by cytochrome c release.  
A. Comparison of extramitochondrial Ca2+ fluorescence (left) and swelling (right) of 
mitochondria incubated with vehicle (black), 1 µM sonicated αSyn (red) and 1 µM sonicated 
fibrils plus 1 µM cyclosporin A (CsA; purple). Experiments were conducted with the addition of 
20 µM Ca2+ under complex I conditions. 30 µl aliquots were removed at the indicated times (1-4, 
Ala) and further processed for analysis in B. * = addition of Ala. Traces are representative of 4 
independent experiments. B. Aliquots removed from the suspensions shown in A were 
centrifuged at 14,000 g for 5 min. The supernatants were run on SDS-PAGE, Western blotted, 
and probed with an antibody against cytochrome c to detect cytochrome c released from 
damaged mitochondria. Western blots are representative of 4 independent experiments.  
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addition of Ala, which was used to induce maximal swelling and cytochrome c release. Western 
blots of the supernatants from all these aliquots indicated that the detection of released 
cytochrome c correlated with the degree of swelling (change in light scattering) in the 
mitochondrial suspension as a whole (Figure 2.7B). Importantly, CsA preincubation also 
prevented αSyn-induced cytochrome c release (Figure 2.7B) suggesting that, in our system, this 
swelling occurs as a consequence of mPTP opening rather than via direct membrane 
permeabilization by αSyn oligomers. 
 
Activity of sonicated αSyn is dependent on exogenous Ca2+ uptake: 
Thus far, we had only investigated whether αSyn can alter mitochondrial function in the 
presence of exogenously added Ca2+.  We therefore asked whether the ability of sonicated αSyn 
to alter mitochondrial function under complex I conditions was dependent on added Ca2+. For 
this purpose, we incubated the isolated mitochondria with sonicated αSyn but without addition of 
exogenous Ca2+. No changes in all 4 measured mitochondrial parameters (∆Ψm, Ca2+ flux, 
NAD(P)H oxidation state and swelling) were detected for incubation times up to one hour 
(Figure 2.8A). To confirm that effects of sonicated αSyn are mediated by exogenous Ca2+, we 
asked whether sonicated αSyn fibrils sensitized mitochondria to a non-Ca2+ inducer of mPTP 
opening, the bifunctional hydrophobic thiol-cross linking agent phenylarsine oxide (PhAsO) 
(Bernardi et al., 1992).  As in the absence of exogenous Ca2+, we observed no sensitizing effect 
of αSyn in the presence of 10 µM PhAsO (Figure 2.8B). We then specifically tested whether 
Ca2+ uptake into mitochondria, rather than simply its presence in the mitochondrial suspension, 
was required to observe αSyn–induced changes to mitochondrial parameters. Preincubation with 
the specific inhibitor of the mitochondrial Ca2+ uniporter Ru360 (10 µM) was sufficient to  
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Figure 2.8: αSyn does not affect mitochondrial parameters in the absence of added Ca2+.  
Comparison of mitochondrial suspensions incubated with vehicle control (black) or 1 µM 
sonicated αSyn fibrils (red) under complex I conditions in the absence of exogenous Ca2+. 
Addition of sonicated αSyn resulted in no change in steady state ∆Ψm, Ca2+ flux, oxidation state 
of pyridine nucleotides, or membrane swelling. Ala was added to induce swelling after 1 hour. 
Arrows = addition of mitochondria. Traces are representative of 4 independent experiments. B: 
Mitochondria treated with 10 uM PhAsO in the presence of vehicle control (black) or 1 µM 
sonicated αSyn fibrils (red) and in the absence of added Ca2+. The normalized time to swelling 
was quantified. Error bars represent the SD from 4 independent experiments. 
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Figure 2.9: Mitochondrial Ca2+ cycling is necessary for αSyn-induced mPTP induction, but 
not binding. 
A. Extramitochondrial Ca2+ (as determined by Ca-Green 5N fluorescence) of mitochondrial 
suspensions incubated with vehicle (black) or sonicated αSyn (red) and challenged with 20 µM 
Ca2+ in the absence (top) or presence of 10 µM Ru360, an inhibitor of the mitochondrial Ca2+ 
uniporter (bottom). Note that Ru360 prevents uptake of exogenous Ca2+. Traces are 
representative of 4 independent experiments. B. Measurements of mitochondrial swelling 
(decrease in absorbance at 587 nm) obtained from incubations of the same αSyn and 
mitochondrial preparations shown in A. 20 µM Ca2+ was added to mitochondrial suspensions in 
the absence (top) or presence of 10 µM Ru360 (bottom). There is no Ca2+-induced swelling in 
the presence of Ru360 whether αSyn is present or not. Traces are representative of 4 independent 
experiments. C. SDS-PAGE/western blot of the supernatant (S), washed pellets (W1-W4), and 
lysed pellets (L) of mitochondrial suspensions after brief incubation with sonicated αSyn in the 
presence or absence of 20 µM Ca2+. Membranes were probed for αSyn (top panel) and 
cytochrome c (bottom panel). The majority of the incubated αSyn remains in the supernatant, but 
a fraction resists 4 washes in assay buffer and is specifically associated with the mitochondrial 
pellet. As expected, cytochrome c is only detectable in the lysed mitochondrial pellets suggesting 
mitochondria remain intact after these washes. Blots are representative of 4 independent 
experiments. D. Quantification of total αSyn immunoreactivity of lysed mitochondrial pellets (L) 
after incubation with sonicated αSyn in the presence or absence of Ca2+and extensive washing. 
Total lane immunoreactivity was normalized to samples in which 20 µM Ca2+ was added to the 
αSyn/mitochondria suspension. Error bars represent the SD of 4 independent experiments. 
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Figure 2.9 (Continued): Mitochondrial Ca2+ cycling is necessary for αSyn-induced mPTP 
induction, but not binding. !
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completely block uptake of exogenous Ca2+  (Figure 2.9A, compare bottom and top panels) and 
prevent the mPTP-inducing effects of sonicated αSyn, as exemplified by the swelling traces 
shown in Figure 2.9B. We observed no reduction in absorbance over time, indicating that αSyn 
did not promote mitochondrial swelling in the presence of Ru360 (compare top and bottom 
panels of Figure 2.9B). To determine whether exogenous Ca2+ enhanced the physical association 
of αSyn with mitochondria, we incubated mitochondria with sonicated αSyn in the presence or 
absence of 20 µM Ca2+, ran the lysate of extensively washed mitochondrial pellets on SDS-
PAGE, and blotted for αSyn. We observed no differences in the intensity or pattern of αSyn 
immunoreactivity in the lysed mitochondrial pellet (Figure 2.9C lanes “L”, and Fig. 8D). This 
indicates that, while Ca2+ uptake is necessary for the downstream functional consequences of the 
αSyn/mitochondria association (i.e., CRT reduction and sensitization to mPTP opening), the 
association itself is not regulated by Ca2+ under our conditions. These data suggest that the 
addition of Ca2+ and the concomitant metabolic changes that accompany its uptake into 
mitochondria make the mitochondria vulnerable to the effects of bound αSyn.  
 
Discussion 
Evidence from many labs makes it increasingly clear that mitochondria are a principal 
target for aberrant accumulation of αSyn within the cell (Chinta et al., 2010; Choubey et al., 
2011; Devi et al., 2008; Hsu et al., 2000; Martin et al., 2013; 2006; Parihar et al., 2008; Shavali 
et al., 2008; Stichel et al., 2007); however few studies have investigated the effects of different 
assembly forms of αSyn directly on the function of mitochondria. Here, we used a reductionist 
model system comprising isolated mitochondria and different, well-characterized forms of pure 
human αSyn to discover that highly soluble, prefibrillar αSyn oligomers, but not monomers or 
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ThTpos fibrils, impair mitochondrial function. Further, we show that the toxicity of oligomeric 
αSyn is specifically dependent on both mitochondrial uptake of exogenous Ca2+ and electron 
flow through complex I.  
The literature is replete with protocols for preparing αSyn oligomers (e.g., by incubation 
with supraphysiological levels of metal ions, lipids, detergents or oxidizing agents) that are either 
not further characterized or vary in their morphological, biochemical, and/or functional 
characteristics (Danzer et al., 2007; De Franceschi et al., 2011; Drescher et al., 2010; Giehm et 
al., 2011; Natalello et al., 2011; Näsström et al., 2011; Volles and Lansbury, 2002).  In this 
study, we report highly complementary results using two independent methods for generating 
soluble prefibrillar αSyn oligomers in the absence of any additives: sonication of fully formed 
amyloid fibrils (sonicated prep) and collection of oligomers during the lag phase of initial 
aggregation (lag phase prep). Though oligomers obtained with the sonicated prep are formed by 
the sonication of fibrils and could therefore be considered “postfibrillar”, they are capable of 
seeding the aggregation of monomeric protein into ThTpos fibrils. Thus, for simplicity and to 
distinguish them from physiological, aggregation-resistant helical oligomers (Bartels et al., 2011; 
Dettmer et al., 2013), we refer herein to oligomers from the sonicated and lag phase preps as 
“prefibrillar oligomers”. Both of these preparations produce closely similar effects on 
mitochondrial function, which argues against the likelihood of artifactual effects caused by a 
specific preparation of oligomers. Under the specific conditions discussed further below, αSyn 
generated using either of our protocols recapitulated several mitochondrial phenotypes 
previously reported in animal and cell models of PD, namely, complex I-mediated dysfunction, 
altered ∆Ψm, disrupted Ca2+ homeostasis, and enhanced cytochrome c release.  
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Collectively, our data indicate that highly soluble prefibrillar oligomers, rather than 
larger, 100,000 g-pelletable oligomers or fibril fragments, can disrupt proper mitochondrial 
function. ThT assays suggest that our bioactive material is not β-sheet-rich; however, we cannot 
exclude the possibility that a small percentage of β-sheet-containing oligomers that do not avidly 
bind ThT contribute to our observed effects, especially in light of a propensity of the active 
material to act as a template for the formation of β-sheet-containing amyloid fibrils. Our 
sonicated prep was modeled in part after the sonicated preformed fibrils used by Lee and 
colleagues (Luk et al., 2012; 2009) who demonstrated the neuronal internalization of 
extracellularly applied sonicated fibrils and their ability to promote the aggregation of 
endogenous αSyn. To date, the colocalization, if any, of the seeded protein with mitochondria 
and the possible functional consequences for these organelles have not been assessed, but in light 
of our findings, they should be.  
The mitochondria of neurons of the substantia nigra pars compacta and other brain 
regions vulnerable to PD are subjected to high Ca2+ concentrations due to regular influx through 
pacemaking L-type channels and low expression of cytosolic Ca2+ buffering proteins (Foehring 
et al., 2009; Goldberg et al., 2012; Guzman et al., 2010). We therefore studied the effects of 
αSyn on mitochondrial function in the context of elevated Ca2+ levels. We observed that 
bioactive prefibrillar αSyn disrupted basic mitochondrial parameters (∆Ψm, Ca2+ uptake/release, 
redox state of pyridine nucleotides, and swelling) only in the presence of exogenously added 
Ca2+. Since Ru360 abolished this effect, we can conclude that the downstream effects of 
mitochondria-associated αSyn were dependent on the uptake of Ca2+ into the mitochondrial 
matrix.  
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The protective effects of CsA on our αSyn-induced changes in mitochondrial parameters 
demonstrated that addition of prefibrillar αSyn sensitized mitochondria to mPTP activation in 
our experiments. The acceleration of cytochrome c release in αSyn-treated mitochondria was 
likewise rescued by preincubation with CsA. This result suggests that cytochrome c release was 
also regulated by the mPTP in our system rather than by channels formed via direct 
permeabilization of the outer membrane by oligomeric αSyn, as had been suggested (Camilleri et 
al., 2013).  
Ca2+-induced mPTP opening can be broadly split into three main phases that could be 
accelerated by αSyn based on our new work: the “initiation phase”, during which Ca2+ is taken 
up into the matrix through the mitochondrial Ca2+ uniporter; the “lag phase”, during which 
mPTP components are recruited and assembled; and the and the “propagation phase”, during 
which mPTP induction spreads through the population (Baranov et al., 2008). Our data showing 
the lack of direct effect of αSyn on ∆Ψm and the unimpaired initial uptake of Ca2+ both suggest 
that the first phase is not significantly affected by αSyn. There is also no apparent shift in the 
slope of the final propagation phase, suggesting no significant effect on that aspect of mPTP 
induction.   This suggests that αSyn primarily acts during the lag phase, and accordingly, the lag 
phase is significantly shortened in our αSyn-treated mitochondria.!
Alteration of the lag phase by prefibrillar oligomers is also consistent with our observing 
a clear-cut respiratory substrate-dependent effect. Our results show that prefibrillar αSyn 
oligomers sensitize mitochondria to Ca2+-induced permeability transition under complex I, but 
not complex II conditions. Even mild inhibition of complex I function could be detrimental to 
mitochondria depolarized by Ca2+ uptake. Restoration and maintenance of the ∆Ψm, a primary 
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defense against mPTP opening, would require increased electron flow into a compromised 
complex I. 
Flux into and/or through, an impaired complex I would be expected to lead to initiation of 
a feed-forward cycle of increasing reactive oxygen species (ROS) generation (which occurs only 
minimally at complex II) and worsening complex I function. Our working hypothesis is that 
increased ROS may result, at least locally, from interactions between αSyn and complex I, one of 
the primary sites of mitochondrial ROS generation (Y. Liu et al., 2002). ROS are a principal 
sensitizer to Ca2+-induced permeability transition active during the second/lag phase. ROS can 
act by oxidizing thiol groups of protein components of the mPTP and by promoting oxidation of 
membrane lipids (Kowaltowski et al., 2001), a process that itself creates secondary mPTP 
inducers (Kristal et al., 1996; Stavrovskaya et al., 2010).  
In summary, we demonstrate for the first time a direct link between a particular form of 
αSyn assembly and mitochondrial dysfunction in a system that models the Ca2+ phenotype of 
cells affected in PD. Our data suggest that, in the context of PD, alterations in αSyn proteostasis 
that destabilize physiological α-helical oligomers or otherwise shift the equilibrium toward 
aggregation-prone monomeric αSyn may drive the generation of mitotoxic prefibrillar oligomers 
that then contribute to complex I-dependent dysfunction and the resultant degeneration of Ca2+-
challenged neuronal populations.
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Abstract 
Despite decades of research, the physiological function of the Parkinson’s disease-related 
protein α-synuclein (αSyn) is not well understood. Almost all of the in vitro studies aimed at 
addressing this question have utilized bacterially-expressed recombinant protein with the 
assumption that αSyn exists in the human brain under non-pathological conditions in a similarly 
unfolded and monomeric state. Over the past few years, we have published multiple reports 
demonstrating that αSyn exits in neurons and other cell types a metastable oligomer that 
principally sizes as a tetramer. In contrast to recombinant αSyn, physiological oligomers purified 
from human erythrocytes and neuroblastoma cells are α-helical and aggregation resistant. In light 
of these studies, we sought to purify and characterize native αSyn from the tissue most relevant 
to neurologic disease, human brain. We successfully purified soluble αSyn from postmortem 
non-diseased human cortex using a combination of ammonium sulfate precipitation, gel 
filtration, ion exchange, and affinity chromatography. Crosslinking of the starting material and 
partially purified samples indicated that there are abundant αSyn oligomers in the human brain 
but that they can be destabilized under certain conditions. CD spectroscopy showed that purified, 
brain-derived αSyn contained significantly more helical content than recombinant protein. We 
envision that a slightly modified version of this protocol will be useful for obtaining helical αSyn 
for testing in functional assays and for identifying conditions that lead to the stabilization of 
these oligomers. 
 
Introduction 
α-Synuclein (αSyn) was first discovered in the Torpedo electric organ (Maroteaux, 1991), 
and subsequent studies have shown that it is highly expressed throughout the nervous system of 
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vertebrates, particularly in the brain (Iwai et al., 1995). Interest in the protein intensified after it 
was discovered that missense mutations in and genomic multiplications of SNCA, the gene that 
encodes αSyn, are sufficient to cause autosomal dominant forms of Parkinson’s disease (PD) 
(Chartier-Harlin et al., 2004; Kara et al., 2013; Singleton et al., 2003). Moreover, αSyn was 
identified as the main component of Lewy bodies and Lewy neurites, insoluble protein 
aggregates that form the main cytopathological hallmark of PD and other synucleinopathies 
(Spillantini et al., 1997). Due to its prominent role in neurodegenerative diseases, there have 
been extensive investigations into possible pathological activities of αSyn with particular 
emphasis on the ability of this normally soluble protein to aggregate (Breydo et al., 2012; 
Cookson and van der Brug, 2008; Volles and Lansbury, 2003). 
The precise physiological function of αSyn is still unclear. Though αSyn is primarily 
localized to the presynaptic terminal (George et al., 1995; Iwai et al., 1995), the vast majority of 
the protein appears cytosolic after cellular fractionation (Dettmer et al., 2013; George et al., 
1995; Kahle et al., 2000). This indicates that associations with synaptic membranes are likely 
weak and/or transient. Animals lacking αSyn display relatively subtle deficits in synaptic 
function. Studies of knockout mice point to αSyn as a negative regulator of synaptic vesicle 
release under conditions of elevated neuronal activity (Abeliovich et al., 2000; Yavich et al., 
2006; 2004). Consistent with this idea, mild overexpression of WT αSyn has been shown to 
interfere with synaptic vesicle exocytosis (Larsen et al., 2006; Nemani et al., 2010), though some 
other reported synaptic vesicle phenotypes may be related to the formation of toxic species 
(Boassa et al., 2013; Scott et al., 2010). It has also been proposed that αSyn acts to modulate 
membrane remodeling (Kamp et al., 2010; Varkey et al., 2010; Westphal and Chandra, 2013), 
perhaps as a chaperone for the SNARE complex (Burré et al., 2010), though biochemical 
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interaction with SNARE proteins remains controversial (Chandra et al., 2005; Dettmer et al., 
2013; DeWitt and Rhoades, 2013). Well-controlled in vitro studies of pure αSyn with various 
membrane lipid and protein compositions could help elucidate a more defined role for the protein 
and aid in differentiating between physiological and pathological activities. 
Due to initial studies characterizing the bacterially expressed recombinant protein as a 
natively unfolded monomer (Kim, 1997; Weinreb et al., 1996), the field has operated under the 
assumption that αSyn exists exclusively in this form under physiological conditions. As such, in 
vitro investigations into the function of αSyn have continued to employ unfolded recombinant 
protein. We recently demonstrated that αSyn also exists physiologically as an aggregation-
resistant, helically folded tetramer based on a characterization of αSyn purified under non-
denaturing conditions from human erythrocytes and neuroblastoma cells (Bartels et al., 2011). In 
follow-up studies using an intact cell crosslinking protocol that I helped develop (see Appendix 
3), we showed that abundant non-pathological oligomers of αSyn, as well as the aggregation-
resistant β-synuclein (βSyn), could be trapped in a variety of cells including primary neurons 
(Dettmer et al., 2013; Newman et al., 2013).  A thorough understanding of how neuronal αSyn 
functions under non-pathological conditions will require in vitro examination of this emerging 
form of the protein. 
While the biophysical and functional properties of monomeric αSyn have been 
extensively studied in vitro, and we have previously characterized α-helical tetramers isolated 
from human red blood cells, nothing is known about the properties of the helical αSyn oligomers 
found in the brain. A recent study described a purification of αSyn from mouse brain, albeit with 
limited details on the purification procedure (Burré et al., 2013). The amino acid sequence of 
mouse αSyn differs from that of human αSyn, most notably at residue 53 where rodents possess 
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a threonine (Hsu et al., 1998), reminiscent of the PD-causing A53T missense mutation in humans 
(Polymeropoulos et al., 1997). We therefore sought to develop a protocol to purify soluble αSyn 
from human brain, with the hope that characterizing isolated helical αSyn will aid in the study of 
the function of physiological oligomers and serve as a comparison to pathological conformations 
present in synucleinopathies. Here we describe a method for the purification of αSyn from 
postmortem human cortex. We show that this protocol yields pure αSyn with greater helical 
content than recombinant protein but that the degree of helicity is variable. Crosslinking of the 
starting material and partially purified samples followed by SDS-PAGE/WB revealed that αSyn 
oligomers are abundant in intact human neurons and are readily detectible at intermediate stages 
of purification; however, chromatography steps designed to purify αSyn to homogeneity may 
lead to the destabilization of native oligomers. 
 
Experimental Procedures 
Purification of Synucleins from Human Brain 
Homogenization and ultracentrifugation: 
Frozen cortices with no evidence of αSyn pathology were provided by Dr. M. Frosch 
(Massachusetts General Hospital/Harvard NeuroDiscovery Center) under an institutional review 
board (IRB)-approved protocol. Approximately 20 g of white and gray matter from frozen 
cortical slices was cut into ~1 cm3 pieces and placed in a glass homogenizer 3.5 volumes 
phosphate buffered saline (PBS) with protease inhibitor cocktail (0.5 mg/ml leupeptin, aprotinin, 
and 0.2 mg/ml pepstatin-A). Homogenization was performed with 24 strokes of a Teflon-coated 
pestle in an Overhead Stirrer (Wheaton) at power level 2.4. Total homogenates were centrifuged 
at 230,000 g for 50 min at 4°C to collect the truly soluble protein.  
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Ammonium sulfate precipitation (ASP): 
Ammonium sulfate was added to the supernatant of the ultracentrifugation step to a final 
concentration of 55%, after which samples were incubated at 4°C for 60 min under nutation, and 
then centrifuged for 20 min at 20,000 g at 4°C to pellet precipitated αSyn. At this stage, αSyn-
containing pellets were either dried and stored at -80°C or immediately processed for size 
exclusion chromatography.  
 
Size exclusion chromatography (SEC): 
Pellets were resuspended in 5-8 ml of anion exchange buffer A (20 mM HEPES pH 8, 25 
mM NaCl, 1 mM EDTA) and injected onto a Superdex 200 XK26/100 gel filtration column (GE 
Healthcare) that had been equilibrated in anion exchange buffer A. The column was washed with 
anion exchange buffer A at 1 ml/min, and 1.5 ml fractions were collected. SDS-PAGE/Western 
blotting (WB) was performed (see below) to identify αSyn-containing fractions.  
 
Anion exchange chromatography (AEC): 
SEC fractions that contained αSyn but minimal amounts of key contaminating proteins 
were pooled and loaded onto an equilibrated MonoQ anion exchange column (GE Healthcare) at 
a rate of 0.5 ml/min. αSyn was eluted using a gradient from 100% anion exchange buffer A to 
50% anion exchange buffer A and 50% anion exchange buffer B (20 mM HEPES pH 8, 1,000 
mM NaCl, 1 mM EDTA). αSyn eluted at approximately 300 mM NaCl. As before, fractions 
were probed for the presence of αSyn by SDS-PAGE/WB and for purity by SDS-
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PAGE/Coomassie staining. AEC fractions that contained αSyn, but not βSyn were used for 
thiopropyl Sepharose 6b incubation.  
 
Thiopropyl Sepharose 6b (TS6b) incubation: 
TS6b resin (GE Healthcare) was prepared by washing dried beads with 200 ml MilliQ 
water/0.25 g of dried beads over filter paper. Hydrated beads were then made into slurry by 
adding MilliQ water to adjust the volume to 1 ml slurry/0.25 g dried beads. αSyn-containing 
AEC fractions were incubated with TS6b resin at a ratio of 1.5:1 overnight at 4°C with circular 
rotation. The αSyn-containing supernatant was collected by centrifugation for 5 min at 1,500 g at 
4°C. 
 
β-synuclein: 
Purification of βSyn was performed identically to αSyn purification except that TS6b was 
incubated with AEC fractions that contained βSyn, but not αSyn.  
 
Circular Dichroism (CD) Spectroscopy: 
Following purification, αSyn was exchanged into 10 mM ammonium acetate using Zeba 
spin desalting columns (Thermo Fisher), lyophilized, and resuspended in 10 mM ammonium 
acetate at a concentration of approximately 10 uM. αSyn samples were added to a 1 mm path 
length quartz cuvette and analyzed using a J-815 CD spectrometer (Jasco). Spectra from at least 
7 recordings were averaged. A background spectrum of 10 mM ammonium acetate was 
subtracted from all αSyn spectra. Calculations of helicity were performed using the following 
formula, as in (Scholtz et al., 1991): ƒhelix = ([Θ]222 – [Θ]coil)/([Θ]helix – [Θ]coil) where % helicity = 
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(100)( ƒhelix). The mean-residue ellipticities at 222 nm for completely helical and 
unfolded/random coil peptides were obtained from [Θ]helix = -40,000(1-2.5/n) + 100T/°C and 
[Θ]coil = 640 -45T/°C. n = 140, the number of amino acids in the αSyn polypeptide, and T = 20°C 
 
Mass Spectrometry (MS): 
 Gel samples submitted for digestion by trypsin were digested using method described 
previously (Shevchenko et al., 1996). Samples were analyzed on an ABI model 4800 TOF/TOF 
Matrix Assisted Laser Desorption (MALDI) mass spectrometer Applied Biosystems, Foster City, 
CA).  It is a research grade time of flight instrument equipped with delayed extraction 
technology and a reflectron for resolution of up to 20,000 (FWHH) with MSMS capability by 
way of tandem TOF/TOF technology. Samples previously digested were prepared by mixing 0.5 
µl of sample with 0.5 µl of alpha cyano-4-hydroxy-trans-cinnamic acid (10mg/ml in 70% 
acetonitrile 0.1%TFA).  The sample is rinsed after drying with 0.1%TFA.  Intact mass analysis is 
also performed on the 4800 but run in linear mode, and spotted using 3,5-Dimethoxy-4-
hydroxycinnamic acid!(10mg/ml in 70% acetonitrile 0.1%TFA) and calibrated using an external 
calibration. Data was analyzed using the Mascot algorithm by searching against the updated non-
redundant database from NCBI.   
 
Determination of protein concentrations: 
Total protein concentrations were determined by BCA assay (Thermo Scientific) 
according to the manufacturer’s instructions. αSyn concentrations were determined using an in-
house developed sandwich ELISA for total αSyn. 96-well Multi-Array High Bind plates (MSD, 
Meso Scale Discovery) were coated with the capture antibody 2F12 diluted (6.7 ng/µl) in Tris-
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buffered saline with 0.1% Tween-20 (TBS-T) in 30 µl volumes/well and incubated at 4°C 
overnight. Following emptying of the wells, plates were blocked for 1 h at RT in blocking buffer 
(5% MSD Blocker A; TBS-T). After 3 washes with TBS-T, samples diluted in TBS-T with 1% 
MSD Blocker A and 0.5% nonidet P-40 were loaded and incubated at 4°C overnight. Sulfo-
tagged SOY1 mAb (detection Ab) was generated using Sulfo-Tag-NHS-Ester (MSD), diluted in 
blocking buffer (6.7 ng/µl), added to the plate (30 µl volumes/well) and shaken for 1 h at RT. 
Following 3 washes, MSD Reader buffer was added and the plates were immediately measured 
using a MSD Sector 2400 imager.  
 
Crosslinking: 
For crosslinking of purified or partially purified samples, 1 µl Dithiobis[succinimidyl 
propionate] (DSP) or disuccinimidyl glutarate (DSG) dissolved in dimethyl sulfoxide was added 
to 50 µl of sample to a variety of concentrations noted in the text and figure legends. Typically, 
and to adjust for changes in total protein concentration, a starting concentration of 0.5 mM 
DSG/DSP was used for total homogenates, total soluble protein fractions (supernatants from the 
ultracentrifugation step), and ammonium sulfate precipitated samples; and 0.25 mM was used for 
SEC and AEC fractions. Upon addition of DSP or DSG, samples were incubated quiescently at 
37°C for 30 min, after which 2.5 µl of 1 M Tris pH 7.6 was added and samples were incubated at 
room temperature for 15 min under nutation to quench crosslinking reactions.  
For intact-cell crosslinking of human brain tissue, samples (human cortical biopsy) were 
finely minced by two rounds on a McIlwain Tissue Chopper (model MTC/2E, Mickle 
Laboratory Engineering Co., blade distance set to 100 µm); the sample was turned by 90° for the 
second round of mincing. Human cerebral cortex biopsies were obtained fresh from middle-aged 
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subjects undergoing focal ablative surgery for epilepsy who were otherwise healthy and had no 
evidence of synucleinopathy or other neurodegenerative disease; the sample was obtained from 
unaffected, discarded tissue and analyzed fresh (storage on ice <1hr). The minced brain samples 
were transferred to 15 ml tubes containing ~5 ml PBS/PI, and the solution containing the intact 
brain pieces was resuspended by gentle shaking without homogenization. From this suspension, 
aliquots were transferred to 1.5 mL tubes, which were spun at 1,500 g for 5 min at RT. 
Supernatants were discarded, and pellets (bits of intact tissue) underwent crosslinking, routinely 
at a ratio of 1000 µl of 1 mM DSG in PBS/PI per 100 mg tissue or else 1000 µl of 2 mM 
DSP/100 mg tissue. The suspensions were incubated at 37°C for 30 min while shaking, followed 
by spinning at 1,500 g for 5 min at RT. After crosslinking, the supernatant was discarded, and 
the pellet was resuspended in PBS/PI (in 25-50% of the volume of the crosslinking solution), 
followed by sonication (Sonic Dismembrator model 300, Fisher Scientific; microtip setting = 40; 
2 x 15 sec). Spinning at 800 g for 5 min at 4°C yielded the postnuclear supernatant. A second 
spin at 100,000 g for 60 min at 4°C yielded the cytosolic material in the supernatant. Crosslinked 
samples were stored on ice (for immediate use) or at -20°C. 
 
SDS-PAGE for Western blotting (WB) or Coomassie staining: 
Samples were prepared using MilliQ water and 4x sample buffer containing LDS plus 
20% β-mercaptoethanol (βME) (for crosslinked samples), or without βME (for non-crosslinked 
samples). Samples were electrophoresed on Nu-PAGE 4-12% Bis-Tris gels (Life Technologies) 
with MES-SDS running buffer.  
 
Western blotting (WB) and Coomassie Staining: 
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Gels were then transferred onto 0.45 µm Immobilon-P PVDF membranes (Millipore) for 
60 min at 400 mA constant current at 4°C in transfer buffer consisting of 25 mM Tris, 192 mM 
glycine, and 20% methanol. After transfer, membranes were blocked in 5% non-fat milk in PBS 
with 0.1% v/v Tween-20 (PBS-T) for 30 min at room temperature and then incubated in primary 
antibody either overnight at 4 °C or for 60 min at room temperature. Membranes were then 
washed 3 times for 5 min in PBS-T, incubated with secondary antibody, washed 3 more times for 
5 min in PBS-T, and then developed with ECL Plus or ECL Prime (GE-Amersham) according to 
the manufacturer’s directions. For Coomassie staining, gels were incubated in MilliQ water for 
10 min and then stained using Gel Code Blue for 45 min at room temperature. Gels were 
destained by washing with MilliQ water. 
 
Storage Condition Testing: 
SEC fractions containing αSyn were aliquoted into either standard or low-binding 
centrifuge tubes and stored at room temperature (RT), 4°C, -20°C, or -80°C. Aliquots were 
periodically probed for αSyn using SDS-PAGE/WB with the 2F12 antibody. Aliquots stored at 
RT and 4°C were sampled at day 0, and then once a day for 5 additional days. Aliquots stored at 
-20°C and -80°C were sampled prior to freezing and then following each of 5 freeze/thaw cycles.  
 
Antibodies: 
2F12 and SOY1, monoclonal mouse antibodies (mAb) against αSyn were generated by 
immunizing αSyn -/- (KO) mice with αSyn purified from human erythrocytes. Hybridoma cell 
lines were generated by fusion of mouse splenocytic B lymphocytes with X63-Ag8.653 
myeloma cells. Antibodies were generated and purified from hybridoma supernatant by Cell 
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Essentials (Boston, MA). For WB, 2F12 was used at 0.18 µg/ml in 5% milk. Another mouse 
monoclonal AB, 15G7, was generously provided by the Haass lab (Kahle et al., 2000), and the 
rabbit polyclonal αSyn antibody C20 was purchased from Santa Cruz. The following 
commercially available antibodies were also used: mAb EP1537Y to β-synuclein (Novus 
Biologicals) and mAb NSE-P1 to γ-enolase (Santa Cruz). 
 
Results 
Purification of αSyn from human brain: 
We designed and carried out a 5-step protocol for the purification of soluble αSyn from 
the cerebral cortex of humans with no evidence of αSyn pathology (Figure 3.1A). We detected 
abundant αSyn in cortical white matter in addition to gray matter (Figure 3.2A) and therefore 
included both in our preparations. To minimize the possibility disrupting intermolecular 
interactions within αSyn oligomers we avoided the use of detergents during our purification. As 
such, total cortical matter was homogenized in PBS plus protease inhibitors. Though this method 
does not extract membrane-associated αSyn, we and others have previously shown that 
the protein is predominantly (≥90%) localized to the cytosol (Dettmer et al., 2013; George et al., 
1995; Kahle et al., 2000). Using an αSyn-specific, in-house developed ELISA coupled with total 
protein assays, we estimated that αSyn comprised ~0.3% of total cytosolic protein (Figure 3.2B), 
in line with published findings (Iwai et al., 1995). PBS homogenates were spun at 240,000g to 
pellet all membrane components and insoluble protein. Since we were interested only in 
physiological forms of αSyn, we wanted to avoid all possible contribution from αSyn found in 
insoluble Lewy bodies should they exist in this non-diseased tissue. Ammonium  
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Figure 3.1: Purification of αSyn from human cortex.  
A. Schematic of the strategy used to purify αSyn from human cortex. B. 400 ng of samples from 
after each stage of the purification were run on SDS-PAGE and stained with Coomassie blue. C. 
30 ng of samples from after each purification step were run on SDS-PAGE and probed for αSyn 
using the antibody 2F12. All samples were taken after the chromatography step listed at the top 
of their respective lanes. Ultra = ultracentrifugation, ASP = ammonium sulfate precipitation, 
SEC = size exclusion chromatography, AEC = anion exchange chromatography, TS6b = 
thiopropyl Sepharose 6b incubation. !
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Figure 3.2: Abundant αSyn is present in cortical gray and white matter.  
A. Cortical gray and white matter both contain αSyn. Gray matter (G) and white matter (W) were 
separated prior to homogenization and processed through the ammonium sulfate purification 
(ASP) step. Protein normalized samples of gray and white matter from after the 
ultracentrifugation (ultra.) and ASP steps were run on SDS-PAGE and probed for αSyn. B. The 
total protein concentration as determined by BCA assay and αSyn content as measured by 
ELISA were used to calculate the percentage of αSyn in crude cortical homogenates and the 
supernatant following ultracentrifugation. Error bars represent the standard deviation from 4 
independent experiments.  
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sulfate was added to the supernatant to a final concentration of 55% in order to precipitate aSyn 
quantitatively. The resuspended pellet was applied to a Superdex 200 column for size exclusion 
chromatography (SEC), and fractions containing aSyn were pooled and further purified using 
anion exchange chromatography (AEC). αSyn-containing fractions were collected, and 
purification was completed using thiopropyl Sepharose 6b  (TS6b) resin in batch mode. Since 
aSyn lacks cysteines, it remained in the supernatant, while the few remaining contaminants 
bound to this resin and were pelleted by centrifugation.  
Samples from each stage of the purification were protein normalized and run on SDS-
PAGE (Figure 3.1B,C). Coomassie blue staining of ~400 ng of total protein first revealed a 14 
kDa band (the molecular weight of the αSyn monomer) corresponding to αSyn after SEC. This 
band was greatly enriched following AEC, and was the only band remaining following the final 
TS6b pull-down of contaminating proteins (Figure 3.1B). Western blotting of 30 ng of protein 
with the mouse monoclonal aSyn antibody 2F12 matched what was observed with Coomassie 
blue staining: the 14 kDa αSyn band was strongly enhanced after AEC and was retained by 
incubation with thiopropyl Sepharose 6b (Figure 3.1C).  Importantly, we tested a panel of three 
aSyn antibodies and detected the purified protein with each of them (Figure 3.3A), but not with 
an antibody directed against its homologue, β-synuclein (βSyn) (Figure 3.3B). Next we 
confirmed the purity of αSyn using mass spectrometry.   Enzymatic digestion and LC-MS/MS of 
the final supernatant following thiopropyl Sepharose incubation identified aSyn as the only 
human protein present in the sample. Analysis of the digested fragments revealed 65% coverage 
of the amino acid sequence and the presence of an N-terminal acetylation (Figure 3.3C), as we 
had previously observed for aSyn purified from human erythrocytes (Bartels et al., 2011). No 
additional post-translational modifications were detected. Intact mass spectrometry (which is   
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Figure 3.3: Enrichment of αSyn during purification. 
A. Increasing concentrations of purified αSyn were run on SDS-PAGE and probed with 3 
different monoclonal αSyn antibodies, 2F12, 15G7, and C20 which all detect the final purified 
sample. B. βSyn could not be detected in the AEC fraction and subsequent supernatant from 
TS6b incubation but was observed in the AEC start and all previous steps. C. Mass spectrometry 
was performed on the final purified sample. Following TS6b incubation, the sample was loaded 
for SDS-PAGE and the gel was stopped as soon as the sample entered the gel. The entire sample 
was excised, digested, and analyzed by mass spectrometry. The αSyn sequence covered by 
observed peptide fragments is shown in red. D. The fold enrichment of αSyn after each 
purification step was calculated by dividing the percentage of total protein that is αSyn at each 
step by the percentage of αSyn in the starting homogenate. E. The percent of soluble αSyn 
remaining after each chromatography step was plotted. On average, approximately 7.5% of the 
total soluble αSyn was ultimately collected. Error bars represent the standard deviation from 4 
independent experiments. 
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Figure 3.3 (Continued): Enrichment of αSyn during purification. 
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performed under conditions that do not maintain intermolecular interactions) revealed a  
molecular mass of 14,527 Da, consistent with an  N acetylated protein without additional post-
translational modifications.  
Total protein and aSyn content were measured after each stage of purification by a BCA 
assay and an in-house developed, αSyn-specific sandwich ELISA, respectively. From these 
results, we calculated the progressive degrees of enrichment of αSyn during the purification 
(Figure 3.3D). SEC and AEC were particularly effective, with each enriching for αSyn by 
approximately one order of magnitude. Ultimately, this protocol provided a > 3,500 fold 
enrichment of αSyn from the starting total homogenate of cortical tissue and yielded 5-10% of  
the total cytosolic αSyn (Figure 3.3E). We typically obtained approximately 100-200 µg of pure 
αSyn starting from 20-25 g of cortex. 
As a matter of best practice, we tried to avoid storing the protein solutions until the 
purification was completed; however, we occasionally did need to store the partially purified 
samples. We therefore investigated whether different storage conditions affected the stability of 
partially purified (following SEC), brain-derived αSyn (Figure 3.4). For samples stored in either 
standard or low-binding tubes at room temperature or 4°C, the αSyn levels appeared consistent 
over the course of 5 days. For samples frozen at -20°C, the amount of detectable αSyn appeared 
to decrease with each successive freeze/thaw cycle regardless of whether standard or low-
binding tubes were used for storage, though this effect was greater in standard tubes.  Flash 
freezing in liquid nitrogen and storing at -80°C did not lead to αSyn loss even after 5 freeze/thaw 
cycles. Based on these findings, we used low-binding tubes for all possible αSyn-containing 
fractions and stored these samples at 4°C (for short-term storage) or -80°C (for longer-term 
storage). 
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Figure 3.4: Testing of storage conditions for partially purified samples. 
SEC fractions were stored either in standard tubes (control) or low-protein-binding tubes at room 
temperature (RT), 4°C, -20°C, or -80°C and monitored periodically for detectable levels of full-
length αSyn. Samples were run fresh (F) or after storing in the indicated conditions. Number 1-5 
correspond either to days in storage (for RT and 4°C samples) or number of freeze-thaw cycles 
(for samples stored at -20°C and -80°C). Storage at -20°C led to a loss of protein upon multiple 
freeze thaw cycles that was partially prevented with the use of low-binding tubes. 
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Key contaminants and their removal: 
Overall, the procedure described above reproducibly led to pure αSyn; however, four 
noteworthy proteins occasionally hindered purification due to their abundance and apparently 
similar biochemical properties. These contaminating proteins were initially revealed by 
Coomassie stain. Bands at ~50, 45, and 40 kDa were excised and analyzed by in-gel digestion 
and tandem LC-MS/MS, which revealed their identity to be ATP-synthase beta subunit 
(ATP5B), gamma-enolase (NSE), creatine kinase B-type (CKB), respectively. These results were 
later confirmed by Western blotting with specific antibodies (Figure 3.5A). A single incubation 
with TS6b resin was usually enough to completely purify αSyn (Figure 3.1B); however, in some 
cases, these contaminating proteins were so abundant that a second incubation with the resin was 
needed to achieve sufficient purity for further analysis (Figure 3.5B). In later preparations, before 
pooling αSyn-containing SEC fractions for AEC, we routinely probed a range of SEC fractions 
with specific antibodies that recognize the principal contaminating proteins in addition to an 
antibody that detects αSyn (Figure 3.5C). This approach allowed for the strategic reduction in the 
amount of these contaminants that would reach the thiopropyl Sepharose step. 
 The other common contaminant that was present through the early stages of the 
purification was βSyn, which co-purified with αSyn through the SEC step (Figure 3.5C). βSyn 
was generally separated from αSyn using the AEC step, during which it eluted later (i.e. at a 
slightly higher salt concentration) than αSyn (Figure 3.5D) - as anticipated due to its lower 
predicted isoelectric point (pI αSyn = 4.67, pI βSyn = 4.41) (UniProt Consortium, 2014). Only 
αSyn-containing AEC fractions that lacked βSyn (when AEC sufficiently resolved these two  
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Figure 3.5: Principal contaminating proteins. 
A. WB for γ-enolase (NSE) and αSyn in the AEC fractions shows an overlap in the elution 
profiles of these two proteins. Start refers to pooled SEC fractions that were used for AEC. B. 
Coomassie staining of an αSyn-rich AEC fraction prior to and after 1x and 2x TS6b incubation 
steps. In some cases, two incubation steps were necessary to remove contaminants such as 
ATP5b and produce αSyn of >90% purity. C. WB for NSE, βSyn, and αSyn in the SEC fractions 
shows considerable overlap in the elution profiles of these three proteins; however the peak of 
αSyn immunoreactivity is shifted relative to these two contaminants. D. Some αSyn-rich AEC 
fractions also contained abundant βSyn (as confirmed by mass spectroscopy) that was not 
separated from αSyn by the TS6b incubation step.   
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proteins) were incubated with thiopropyl Sepharose since βSyn also lacks cysteines and was not 
be separated from αSyn by this technique (Figure 3.5D). 
 
Brain-derived αSyn contains variable helical content: 
We and others have recently provided evidence that endogenous aSyn in intact cells 
exists in substantial part as a tetramer and related oligomers (Bartels et al., 2011; Dettmer et al., 
2013; Klucken et al., 2006; Newman et al., 2013; Westphal and Chandra, 2013) that, unlike 
monomeric αSyn, display α-helical structure when purified (Bartels et al., 2011; Trexler and 
Rhoades, 2012; Wang et al., 2011; Westphal and Chandra, 2013). We therefore performed 
circular dichroism (CD) spectroscopy to determine the secondary structure of αSyn purified from 
human brain. In contrast to recombinant αSyn, which consistently showed the expected random 
coil secondary structure (with a predictable minimum of ellipticity at 196 nm), the CD spectra of 
human brain αSyn purified using this protocol was more variable. In some cases, the spectra 
contained significant α-helical content (Figure 3.6A, red trace), while in others, the protein 
appeared almost completely unfolded (Figure 3.6A, blue trace). We quantified the helical content 
of brain-derived and recombinantly-expressed αSyn by comparing the ellipticity values at 222 
nm to those of completely helical and unfolded peptides (Scholtz et al., 1991). Recombinant 
αSyn, as expected, displayed little helical content with a mean of 4%. On average, brain-derived 
αSyn possessed significantly more helical content, ranging from 7-21%, with a mean of  ~12% 
(Fig. 6B). As a point of comparison, vesicle-folded recombinant αSyn, an accepted helical form 
of αSyn (Davidson et al., 1998), contains ~43% helicity by these calculations. We did, on 
occasion, observe a spontaneous increase in α-helical content of brain-derived αSyn samples that  
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Figure 3.6: Purified human brain αSyn is partially helically folded.  
Circular dichroism (CD) spectroscopy was used to estimate the secondary structure of purified 
αSyn samples. A. CD spectra obtained from two samples of αSyn purified from human brain 
highlighting the variability in helical content. A partially helical sample is shown in red and 
largely unfolded sample is shown in blue. CD spectroscopy of monomeric recombinant αSyn in 
the absence (unfolded - solid black trace) and presence of POPC/POPS small unilamellar vesicle 
(α-helical – solid gray trace) are shown for reference. B. The helicity of αSyn samples purified 
from human brain are compared to recombinant monomer and are expressed as the percentage of 
vesicle-folded recombinant αSyn. Relative helicity was determined using the ellipticity value at 
222 nm. * = p < 0.01 using an unpaired t-test. Error bars represent the standard deviation of 6 or 
8 independent experiments for recombinant and brain-derived αSyn, respectively. C. CD spectra 
of human brain αSyn before (blue trace) and after room temperature (RT) incubation (green 
traces) were compared to unfolded and vesicle-folded recombinant αSyn (black and gray traces, 
respectively). The raw data obtained after room temperature incubation (light green trace) was 
scaled to adjust for changes in protein concentration (dark green trace). 
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Figure 3.6 (Continued): Purified human brain αSyn is partially helically folded.  
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initially were determined to be of a random coil conformation (Figure 3.6C). In these cases, 
reanalysis after 4-5 d at RT showed a relative loss of unfolded character and gain in helicity 
(Figure 3.6B). When the spectra were scaled so that they passed through the isosbestic point at 
approximately 204 nm (i.e. adjusted for soluble protein concentration), the spectra appeared 
quite similar to the samples that were partially folded immediately following purification 
(compare red trace in Figure 3.6A to dark green trace in Figure 3.6C). Together, these data 
suggest that the human cortex contains helical αSyn but that there are factors that can influence 
its stability over the purification procedure. 
 
Abundant αSyn oligomers occur in human brain:  
We examined the oligomerization state of the aSyn purified from human brain with the 
expectation, based on the partially α-helical CD spectra in Figure 3.6A, that these samples would 
contain both oligomeric and monomeric protein. Crosslinking using the homo-bifunctional, 
lysine-reactive crosslinker disuccinimidyl glutarate (DSG) revealed a pattern of αSyn-
immunoreactive bands that is similar to what was obtained from the diffusion-controlled, 
stochastic crosslinking of recombinant monomeric αSyn (a ladder of monomers, dimers, trimers, 
tetramers etc.) (Figure 3.7A). Preliminary quantification indicated that the oligomeric content of 
partially α-helical cortical αSyn is greater than that of the bacterially expressed protein, but the 
presence of unfolded, monomeric αSyn in the brain samples precludes a meaningful comparison.  
Because our previous work indicated that rat neurons and other cells contain abundant, 
physiological αSyn oligomers (Bartels et al., 2011; Dettmer et al., 2013; Newman et al., 2013), 
we crosslinked intact human brain cells (in vivo crosslinking) using DSG to determine whether 
mid-molecular weight oligomers could similarly be trapped in human cortical cells. SDS-PAGE/ 
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Figure 3.7: Pattern of immunoreactivity for pure crosslinked αSyn differs from αSyn 
trapped within cells. 
A. Recombinant αSyn purified from bacteria and partially helical αSyn purified from human 
brain were suspended at 10 µg/ml and crosslinked with 0.25, 0.5, or 1 mM DSG. Recombinant 
αSyn shows a ladder of oligomers whose abundance decreases as their size increases. A similar 
pattern is seen for brain-derived αSyn. Smearing of the immunoreactivity in the mid-to-high 
molecular weight region precludes a meaningful quantitative comparison of the oligomer to 
monomer ratio. B. Crosslinking of intact cells from human cortex using a range of DSG from 0.5 
mM to 1.5 mM revealed abundant oligomers of distinct apparent sizes (60 kDa, 80 kDa, and a 
doublet at 100 kDa). The sample run in the lane marked “R” was crosslinked with 1 mM of the 
cleavable crosslinker DSP and then reduced (cleaved) by boiling in sample buffer containing 
βME, and served as a non-crosslinked control. 
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Western blotting of the 100,000 soluble lysate of cells crosslinked with DSG revealed a major 60 
kDa species (as well as 80 and 100 kDa αSyn-immunoreactive bands that may be conformers or 
oligomers composed of additional αSyn monomers (Dettmer et al., 2013; Gould et al., 2014) in 
addition to a minor 14 kDa monomer (Figure 3.7B). This suggests that soluble oligomers 
constitute a major pool of physiological αSyn in non-diseased  human neurons. Taken together 
with the crosslinking of purified, brain-derived αSyn, this suggests that cortical neurons possess 
abundant αSyn oligomers but either the purification protocol is biased toward monomeric αSyn 
or the majority of these oligomers are destabilized at some point in the purification. 
To further address this issue, we crosslinked αSyn-containing fractions at all intermediate 
stages of purification. Crosslinking of the total brain homogenate, the 230,000 g-soluble 
homogenate, and the re-solubilized ammonium sulfate precipitated material revealed an 
abundant ~80 kDa oligomeric band that comigrated with the ~80 kDa oligomer trapped by 
crosslinking of lysed cells that we reported recently (Dettmer et al., 2013; Newman et al., 2013) 
(Figure 3.8). Note that the crosslinking efficiency of the DSG in the ammonium sulfate 
precipitated material is dramatically reduced due to the presence of residual free amines that act 
to quench this lysine-reactive crosslinker. Crosslinking of this material following SEC (with no 
ammonium sulfate present) again revealed abundant mid molecular weight oligomers (Figure 
3.9). By crosslinking a wide range of SEC fractions and probing with a panel of αSyn antibodies, 
we were able to observe a consistent elution profile for a variety of αSyn species. Moreover, the 
species themselves (~14, 60, 80, 100 kDa bands) were in accord with our previous observations 
of crosslinked αSyn, though the 100 kDa band was often seen as a doublet in these experiments. 
Oligomers were still readily detectable in the peak αSyn-containing fractions following AEC, but 
their relative abundance was less than at earlier stages of purification (Figure 3.9A). This  
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Figure 3.8: Abundant αSyn oligomers are detected after initial chromatography steps. 
Total brain homogenate, soluble protein (ultra. supernatant), and ammonium sulfate precipitated 
protein (ASP) samples were protein normalized and crosslinked with a range of DSG 
concentrations from 0.5-1 mM. A clear 80 kDa band was visible in crosslinked samples from 
each of these three stages of purification. Residual ammonium sulfate present in the re-
solubilized ASP samples led to a reduced DSG crosslinking efficiency in those samples. “R” 
lanes were crosslinked with 1 mM of the cleavable crosslinker DSP and then reduced (cleaved) 
by boiling in sample buffer containing βME. They served as non-crosslinked controls. 
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Figure 3.9: TS6b incubation precludes the detection of oligomeric αSyn. 
A. A range of SEC fractions, a sample taken from SEC fractions pooled for AEC (i.e. AEC start 
(St.), and a range of AEC fractions were crosslinked with either DSG or DSP at 250 µM. DSP-
crosslinked samples were cleaved by boiling in βME-containing sample buffer prior to loading 
and are labeled “R”. All samples were probed with an antibody for αSyn. Oligomeric species, 
especially the 60 kDa and 100 kDa doublet bands, are predominant in SEC fractions. These 
oligomeric species are also readily detectable following AEC, though the relative abundance of 
monomer in the main αSyn-containing fractions is higher compared to after SEC. B. An 
oligomer-rich AEC fraction was crosslinked with a range of DSG from 50-250 µM of before and 
after TS6b incubation. The 60 kDa band seen before TS6b incubation was only faintly visible 
afterwards and the strongly immunoreactive 100 kDa band was completely undetectable. Higher 
crosslinker concentration did not result in the trapping of oligomers, but rather resulted in “over-
crosslinking” and a loss of protein able to enter the gel. 
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Figure 3.9 (Continued): TS6b incubation precludes the detection of oligomeric αSyn  
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indicates that the AEC step may contribute to a destabilization of αSyn oligomers during our 
purification. Interestingly, oligomers were prevailing in later AEC fractions (suggesting that they 
have a greater negative charge than monomer); however these fractions were not pooled for 
thiopropyl Sepharose incubation due to the presence of βSyn (see above).  
 
TS6b incubation destabilizes αSyn oligomers: 
Crosslinking of oligomer-rich fractions before and after TS6b incubation revealed a 
striking loss of crosslinker-stabilized oligomers following this chromatography step (Figure 
3.9B, compare lanes 1 and 2). Because there is substantial loss of total protein, the DSG 
concentration used to trap oligomers before the TS6b incubation may result in an “over-
crosslinking” of the material and a reduction in the ability of αSyn to enter the gel. To overcome 
this, we titrated DSG at lower concentrations (Figure 3.9B, lanes 3 and 4); however, we were 
unable to trap more than relatively small amounts of oligomeric αSyn compared to monomer, 
and not in the ratios predicted by the crosslinked pre-TS6b sample (Figure 3.9B dark exposure). 
The difference in crosslinking pattern seen here compared to what was observed in Figure 3.7A 
is likely the result of the ammonium acetate buffer used for CD spectroscopy; ammonium ions 
reduce the crosslinking efficiency of DSG and prevent over-crosslinking until higher 
concentrations are used. 
We then asked whether our inability to detect αSyn oligomers was due to their 
depolymerization or a reduction in crosslinking efficiency. To answer this we took advantage of 
samples that were contaminated with NSE after TS6b incubation. Western blotting for NSE after 
DSG crosslinking revealed that residual NSE could still be efficiently crosslinked into its  
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Figure 3.10: αSyn oligomers are destabilized by TS6b resin and a related chemical. 
A. AEC fraction containing αSyn and NSE oligomers was incubated with TS6b resin for 1 hour 
and then crosslinked with a range of DSG concentrations. Samples were blotted for αSyn (top) 
and NSE (bottom). B. AEC fraction from A was incubated with TS6b resin or dithiopyridine 
(DTP) for 10 min and then crosslinked with the indicated DSG concentrations. Samples were 
blotted for αSyn (top) and NSE (bottom). A light and dark exposure are shown for DTP-
incubated samples. C. AEC fraction containing αSyn oligomers was left undiluted (lane 1) or 
diluted 1:2 (lane 2) or 1:3 (lane 3). Samples were then crosslinked with DSG that was diluted to 
keep the crosslinker : protein ratio the same across samples and then blotted for αSyn. 
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physiological, dimeric form (Chai et al., 2004) (Figure 3.10A). This suggests that αSyn 
oligomers are preferentially destabilized by this step. Potential mechanisms of destabilization 
include reduction of the total protein content and depletion or disruption of a specific stabilizing 
factor by the resin, To exclude these possibilities, we incubated αSyn oligomer-containing AEC 
fractions with 2,2’-dithiopyridine (DTP) at a concentration equivalent to that of the active groups 
on the TS6b resin.   DTP is the disulfide of 2-thiopyridine, the compound released from TS6b 
resin upon protein binding. Its addition creates an environment similar to that resulting from the 
TS6b resin incubation without removing cysteine-containing proteins from solution, thereby also 
avoiding a reduction in protein concentration. As we had observed upon TS6b incubation, 
addition of DTP reduced our ability to trap oligomeric αSyn, but not NSE dimers (Figure 3.10B). 
Higher DSG concentrations did not lead to the recovery of these oligomers (as would be 
expected if crosslinking inefficiency were to blame), but instead to a greater amount of gel-
excluded material - mostly at the expense of monomer (Figure 3.10B dark exposure). This 
implies that mid molecular weight αSyn assemblies have been greatly depolymerized but that 
residual oligomers are somewhat resistant to over-crosslinking. To confirm that dilution 
specifically did not affect our ability to detect αSyn oligomers, we diluted oligomer-containing 
AEC fractions 1:2 and 1:3 - in the range of total protein reduction caused by TS6b incubation (as 
determined by BCA assay). Diluted samples were effectively crosslinked by the DSG when the 
ratio of DSG : protein was adjusted accordingly to avoid over-crosslinking (Figure 3.10C). As 
shown earlier, similarly reducing the DSG concentration used in samples incubated with TS6b 
resin did not lead to the recovery of αSyn oligomers (Figure 3.9B). These data suggest that the 
depolymerizing effect of TS6b resin is due, at least in part, to a chemical interaction induced by 
its leaving group. Our results demonstrate that physiological αSyn oligomers are carried through 
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our purification protocol until the final step at which point incubation with TS6b destabilizes 
oligomers and selectively enriches for monomeric αSyn. Though the specific reasons for this 
have yet to be elucidated, this finding is a potential explanation for our inability to consistently 
purify helical αSyn. 
 
Purification of β-synuclein: 
While optimizing our protocol to purify αSyn, we serendipitously discovered that we 
could simultaneously purify βsyn. As mentioned above, βSyn co-purified with αSyn until the 
AEC step, at which point βSyn eluted at a higher concentration of NaCl than aSyn, as predicted 
by its lower isoelectric point (Figure 3.5D). βsyn-containing AEC fractions occasionally also 
contained αSyn, but in the event that αSyn was not detectable, we were able to completely purify 
βSyn using the TS6B resin. Like αSyn, βSyn lacks cysteines, and thus it can also be separated 
from remaining contaminating proteins using this step (Figure 3.11A). Following TS6b 
incubation, the identity of βSyn was confirmed by LC-MS/MS (Figure 3.11B). Crosslinking of 
βSyn-containing fractions following SEC and AEC demonstrated that human neurons contain 
βSyn oligomers (Figure 3.11C) that migrate and elute in a patter similar to what was observed 
for αSyn (Figure 3.9A). This finding is in agreement with of crosslinked βSyn oligomers trapped 
within rat primary neurons (Dettmer et al., 2013). 
 
Discussion 
αSyn is an intensely studied protein, and it is extremely abundant in the human nervous 
system, with estimates that it accounts for up to 1% of total brain protein (Iwai et al., 1995).  
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Figure 3.11: Purification of βSyn. A. Coomassie stain of AEC fractions illustrating that βSyn 
elutes later (at a higher salt concentration) than αSyn and is also able to be purified away from 
contaminating proteins using TS6b incubation. B. Mass spectroscopy was performed on the final 
purified sample. The βSyn sequence covered by observed peptide fragments is shown in red. C. 
DSG crosslinking of SEC and AX fractions, as well as the AEC start (St.), shows that abundant 
oligomers of βSyn can also be trapped after these intermediate purification steps.  
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Anderson and colleagues (2006) isolated insoluble αSyn from the brains of synucleinopathy 
patients, but studies of non-pathologic αSyn isolated from human brain are lacking. This report is 
the first to describe the purification of soluble human brain αSyn. βSyn was similarly purified 
from the same starting material with only slight modifications to the penultimate step of the 
protocol. This set of protocols will be useful in further studies of the physiological function of 
these two members of the synuclein family. 
In recent years, the secondary structure and oligomerization state of native αSyn have 
been vigorously debated. Our lab and others have provided evidence that the endogenous protein 
can exist, in large part, as a helical oligomer (Bartels et al., 2011; Dettmer et al., 2013; Westphal 
and Chandra, 2013) while other groups maintain that it exists exclusively (or almost exclusively) 
as an unfolded monomer (Burré et al., 2013; Fauvet et al., 2012). We show here that we can 
purify αSyn with significant helical content from human brain, but that the degree of helicity is 
variable. We also observed instances in which αSyn that had initially appeared unfolded by CD 
spectroscopy later showed a partially helical spectrum after room temperature incubation. This 
phenomenon could be interpreted as an initial induction of helicity in the purified samples, a re-
folding of protein that had become unfolded at some point in the purification, or an apparent 
folding due to an increase in relative abundance of folded protein. Based on other observations in 
this report and in previously published work (Burré et al., 2013), we favor the third 
interpretation. We have previously reported that, unlike the unfolded monomer, helical αSyn 
oligomers are resistant to aggregation (Bartels et al., 2011). Based on this finding, one would 
predict that in a mixed sample containing both unfolded and helical αSyn and under conditions 
that favor aggregation, helical αSyn would remain soluble while unfolded αSyn will aggregate 
and become insoluble. Since insoluble protein does not contribute to the CD spectrum, the 
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sample will appear to have undergone a random coil-to-α-helical transition when, simply, a 
larger percentage of the measureable αSyn is helical. In line with this interpretation, we observed 
a reduction in the amplitude of the CD signal following the apparent increase in helicity 
suggesting that there is less soluble protein. A similar phenomenon was reported by Burré and 
colleagues (2013) in their recent characterization of αSyn purified from mouse brain. They 
detected a degree of helical content in their purified αSyn that is in line with our partially folded 
samples. Moreover, they also observed an increase in helical content and an accompanying 
reduction in protein concentration after room temperature incubation, as inferred by a reduction 
in CD amplitude. Our findings, as well as those of Burré et al., are consistent with the idea that 
cortical tissue contains a pool of helical αSyn that is aggregation resistant. Furthermore, they 
reinforce the idea that therapeutics designed to stabilize helical conformations of αSyn may 
reduce the relative abundance of aggregation prone monomer, thereby interfering with 
pathological processes in PD and related synucleinopathies. 
Our purified brain-derived αSyn did not consistently contain as much helical character as 
αSyn isolated from RBCs and neuroblastoma cells (Bartels et al., 2011). A simple explanation 
for this could be related to the tissue from which these samples originate. The source material 
dictates the nature and array of contaminating proteins, which, in turn, determine what 
chromatographic techniques are best for isolating αSyn. We optimized the protocol presented 
here to remove contaminants that are highly expressed in brain but may not be abundant in these 
other cell types, for example, CKBB and βSyn (Su et al., 2004; Thompson et al., 1980). As 
discussed further below, overnight TS6b incubation as a polishing step is not favorable for the 
recovery of helical αSyn. This step will, accordingly, be the subject of further investigation. To 
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better directly compare brain- and RBC-derived αSyn, we are currently testing the ability of our 
previously published RBC protocol to yield helical αSyn from brain tissue. 
The variation in helical content of our final purified samples can likely be attributed to 
differences in the retention of oligomeric material during the purification. By its very nature, 
protein isolation involves sacrificing yield for purity. It is possible that, in the case of our 
protocol and the one used by Burré et al. (2013) to isolate αSyn from mouse brain, the most 
straightforward way to achieve pure samples (choosing αSyn-containing fractions that have the 
least amount of key contaminants) may have resulted in the loss of a pool of αSyn enriched in 
oligomers. In agreement with our published in vivo crosslinking studies (Dettmer et al., 2013), 
the crosslinking data presented here consistently showed that cortical homogenates contain 
oligomers of αSyn (and the non-aggregation-prone βSyn) (Hashimoto et al., 2001) at early and 
intermediate steps of the purification. In fact, until the final chromatography step (the TS6b 
incubation) we observed abundant oligomeric material that co-migrated with oligomeric αSyn 
trapped using in vivo crosslinking, suggesting that they are representative of species that can be 
trapped within intact cells. Coomassie blue staining coupled with Western blotting of crosslinked 
αSyn-containing AEC fractions revealed that oligomer-enriched fractions elute later and are 
often less pure then monomer-rich fractions. In particular, oligomer-enriched fractions often 
contained high levels of βSyn, from which αSyn cannot be separated with our current polishing 
step. Even when AEC resulted in a complete resolution of αSyn and βSyn by Coomassie 
staining, other contaminants, such as NSE or CKB, were more plentiful in later fractions, making 
complete purification of αSyn from these oligomer-rich fractions more difficult. Differences in 
the degree of contamination by these proteins across preparations can influence what fractions 
are used for successive steps and therefore the amount of purified oligomeric αSyn. 
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While we cannot presently explain the apparent destabilizing effect of incubation with 
TS6b resin, the effect of DTP on its own supports the idea that destabilization is not due to the 
dilution of αSyn nor the pull-down of a stabilizing factor. DTP is an oxidant but its high 
specificity for thiols makes it unlikely that αSyn itself is a target. Reaction of DTP with a 
cysteine-containing protein would create 2-thiopyridine, a mild reducing agent. Whatever the 
biochemical mechanism behind this depolymerization, our data suggest that the stability of 
physiological oligomers is particularly vulnerable to changes in the chemical environment 
caused by this leaving group. We therefore suggest that laboratories attempting to purify native 
αSyn from brain be aware of potential changes in chemical conditions, especially in the later 
stages of purification when there will be less endogenous redox buffering capacity. We are 
currently investigating alternative polishing steps for our protocol to better preserve the 
oligomeric content present after AEC. Though the current protocol will require said optimization 
before high quantities of oligomeric protein can be isolated, the purification strategy presented 
here can still be useful in studying the function of brain-derived αSyn (and βSyn) oligomers. We 
are currently able to obtain ~50% pure samples that contain abundant αSyn oligomers. These 
samples can be examined in functional studies (for example, assays of vesicle fusion) and 
compared to samples from which αSyn has been immunodepleted. 
Our findings support the existence of helical αSyn oligomers in human cortical neurons. 
They also highlight the difficulty of purifying such labile species unless great care is taken 
throughout the purification process to avoid any conditions that destabilize native protein-protein 
interactions. The apparent ease in which crosslinkable oligomers can be lost during purification 
provides an explanation for why some groups have difficulty obtaining fully helical material 
even from established sources of folded protein (Fauvet et al., 2012). Once fully optimized, this 
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protocol could be used to analyze qualitative and quantitative differences in the pool of soluble 
αSyn between control and diseased brain tissue. It will also be a key tool in identifying other 
conditions that destabilize oligomeric αSyn and promote the relative abundance of aggregation 
prone monomer.   
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Chapter 4 
 
Discussion 
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Altered proteostasis of αSyn is an important factor in the pathogenesis of familial and 
sporadic PD. In this thesis, I addressed two central questions pertaining to the role of this 
abundant, soluble protein in health and disease: 1) what is the assembly state of αSyn within and 
upon purification from non-diseased neurons? and 2) how does the aberrant accumulation of 
misfolded αSyn contribute to the vulnerability of select neuronal populations? Since the 
discovery of it association with PD, the field has focused largely on the pathological properties 
of the protein and on debating the various potentially toxic species. Originally, Lewy bodies and 
their amyloid fibril components were thought to be toxic (Goedert et al., 2013), but more 
recently, there has been renewed emphasis on soluble oligomers as the culprit in 
neurodegeneration (Haass and Selkoe, 2007).  On the other hand, initial characterization of 
recombinant αSyn as an unfolded monomer (Weinreb et al., 1996) was immediately accepted as 
representative of the physiological state of this protein within mammalian cells. Recent data from 
our lab, to which I contributed, challenged this assumption and proposed a model in which two 
fundamentally different types of soluble oligomers exist: misfolded oligomers associated with 
pathology, and helical oligomers that play a physiological role. Purified helical oligomers are 
aggregation resistant in vitro and may require depolymerization before proceeding down an 
aggregation pathway in vivo. Accumulation of aggregated αSyn is associated with, among other 
things, mitochondrial dysfunction and eventual cell death. Figure 4.1 illustrates the proposed 
relationship of αSyn species with each other and with mitochondria, a principal target of their 
toxic effects. There is much to be learned about the biochemical and cellular mechanisms linking 
all of these players. This thesis work provides a platform for the discussion of several of these 
processes. 
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Figure 4.1: The proposed relationship of αSyn species with each other and of prefibrillar 
oligomers with mitochondria. 
Under physiological conditions, αSyn is localized presynaptically and exists in an equilibrium 
between helical oligomers and unfolded monomers. Monomeric αSyn adopts a helical 
conformation when biding highly curved membranes composed of acidic phospholipids, like 
synaptic vesicles, where it can negatively regulate vesicle fusion with the plasma membrane. 
Membrane-induced folding may promote the formation of helical oligomers prior to or upon 
membrane detachment. Helical oligomers may become depolymerized later to yield unfolded 
monomers under conditions that favor membrane localization. Under pathological conditions, 
unfolded monomers, but not helical oligomers, aggregate into soluble, prefibrillar oligomers and 
then insoluble amyloid fibrils. Pathology is also associated with increased αSyn in proximal 
compartments such as neurites and the soma. Genomic multiplication of SNCA, reduced 
clearance of αSyn due to mutations in glucocerebrosidase (GBA1 gene), or other conditions that 
elevate αSyn expression increase the amount of both helical oligomers and unfolded monomers 
without necessarily altering the ratio. Higher absolute levels of unfolded monomer favor 
aggregation. PD-linked mutations in αSyn skew this ratio toward the monomer, thereby 
promoting aggregation, and can also speed up pathological oligomerization. Prefibrillar 
oligomers serve as a template for additional aggregation of monomer and can interact with 
mitochondria to inhibit complex I-dependent function, possibly by reducing its enzymatic 
activity. When complex I dysfunction coincides with mitochondrial Ca2+ uptake, complex I may 
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Figure 4.1 (Continued): The proposed relationship of αSyn species with each other and of 
prefibrillar oligomers with mitochondria. 
generate excessive ROS that further promotes aggregation and the opening of the mPTP, leading 
to cell death. Prefibrillar oligomers further aggregate into insoluble fibrils that coalesce to form 
Lewy bodies. Formation of these fibrils is a pathological phenomenon, but it may sequester 
mitotoxic species into a form that does not directly disrupt mitochondrial function.  
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Destabilization and Formation of Physiological Oligomers 
During purification 
We have shown that, in addition to an unstructured monomer, αSyn exists 
physiologically in cells as an oligomer that is helically folded and sizes as a tetramer upon 
purification (Bartels et al., 2011; Dettmer et al., 2013). Because our data indicate that tetrameric 
αSyn is aggregation resistant (Bartels et al., 2011), the identification of factors that promote the 
formation of physiological oligomers (or their depolymerization back into monomers) could 
have profound functional and pathological consequences. While our previous studies both 
support the existence of oligomers within cells under normal conditions, we observed in the 
latter report (and in Appendix 3) that these oligomers are largely lysis sensitive; crosslinking of 
cells immediately after lysis revealed little oligomeric content (Dettmer et al., 2013). And yet, 
helical oligomers can be purified (Bartels et al., 2011; Westphal and Chandra, 2013). How does 
one reconcile these findings?  
In this thesis we used crosslinking to probe the array of oligomeric αSyn species present 
in brain tissue, in crude homogenates, and at various states of purification. DSG crosslinking of 
intact brain cells trapped species that migrate at approximately 60, 80, and 100 kDa, as we have 
previously reported with rodent neurons(Dettmer et al., 2013), but we are only able to trap an 80 
kDa species immediately following cell lysis. Though we are presently unable to identify the 
precise relationship of the oligomers represented by these bands, our published data argue 
against the likelihood of hetero-oligomers with other proteins (Dettmer et al., 2013). It is 
possible that they represent discrete αSyn oligomers made up of a distinct number of monomeric 
subunits or that they are conformational variants that are differentially crosslinked by DSG. We 
are currently distinguishing between these possibilities using intact mass spectrometry of 
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purified, crosslinked species.  Crosslinking of brain homogenates after our first two purification 
steps (ultracentrifugation and ammonium sulfate precipitation) similarly trapped only the 80 kDa 
band (in addition to monomer). To further complicate matters, we observed here that 60 and 100 
kDa species could be “recovered”, apparently at the expense of 80 kDa αSyn, by crosslinking 
with DSG after size exclusion chromatography, and that they persisted until the final step of 
purification. The depolymerizing effect of this last step is further discussed below. 
Our previous findings suggest that that 80 kDa band may be fundamentally different from 
the 60 and 100 kDa bands: as mentioned above, the 60 and 100 kDa bands, but not the 80 kDa 
band, are lysis sensitive, and the addition of recombinant monomer to cell lysate prior to 
crosslinking led to the enhancement of the 80 kDa, but not 60 or 100 kDa bands (Dettmer et al., 
2013). One hypothesis is that the 80 kDa band observed after crosslinking may represent an 
assembly composed of unfolded αSyn – whether it originates from recombinant protein or 
endogenous oligomers that have been destabilized – while the 60 and 100 kDa bands (to which 
recombinant protein does not contribute) consist of helical oligomers. The inability to crosslink 
60 and 100 kDa bands after cell lysis could be explained by the presence of a factor (or factors) 
in the lysate that actively destabilizes helical oligomers. In the context of an intact cell, this 
destabilization may be regulated by other proteins or by spatial separation of αSyn and this 
factor. Cell lysis may interfere with this regulation, allowing greater access to oligomers, thereby 
resulting in their depolymerization. Based on the data presented here, this potential destabilizing 
agent shares similar solubility properties with αSyn, since the only the 80 kDa band can be 
trapped by DSG after both the ultracentrifugation and ASP steps. Upon further purification by 
SEC, after which αSyn exists in solution only with proteins of similar hydrodynamic radii, the 60 
and 100 kDa bands are again observed upon crosslinking. Because buffer conditions were 
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otherwise unchanged, their reappearance after this chromatography step suggests that the 
removal of a contaminating factor allows for oligomerization. Macromolecular dilution that 
occurs upon membrane rupture may be partly responsible for the loss of detectable oligomers 
after cell lysis, but this phenomenon cannot explain the reappearance of these species after SEC 
– especially because the SEC step further dilutes the sample by over 10 fold. If such an 
oligomer-destabilizing factor exists, it may be associated with a membranous compartment in 
intact cells since the Triton X-100-soluble fraction contain exclusively monomeric αSyn (with 
oligomeric bands detectable only in the PBS-soluble fractions) (Dettmer et al., 2013). Cytosolic 
αSyn can be efficiently crosslinked as oligomers in intact cells but not in the PBS-soluble phase 
of lysed cells. This would suggest that cell lysis acts to increase the interaction of this factor with 
cytosolic αSyn and would imply a weak membrane association. The existence of such a factor 
would be supported by experiments in which the spiking in of brain homogenate (or the soluble 
fraction thereof) can prevent the crosslinking of 60 and 100 kDa oligomers in samples that would 
otherwise show αSyn immunoreactivity at these positions (for example, in SEC or AEC 
fractions). 
 
Oligomer to monomer ratio in PD and disease models 
 The data presented here and in our previous publication (Bartels et al., 2011) suggest that 
helical αSyn oligomers are aggregation resistant and unfolded monomers are aggregation prone. 
The presence of αSyn-rich Lewy bodies in patient brains (Spillantini et al., 1997) and reports of 
the pathological effects of prefibrillar αSyn oligomers described here and elsewhere strongly 
implicate αSyn aggregation in the pathogenesis of PD (Chen et al., 2009; Volles and Lansbury, 
2003; Winner et al., 2011). Therefore, if physiological oligomers are indeed non-toxic, one might 
! 136 
predict that manipulations that lead to disease-associated αSyn aggregation may act by altering 
the ratio of crosslinked oligomer to monomer ratio in favor of the monomer. In support of this 
hypothesis, recent data from our lab demonstrate that all 5 familial PD-linked mutations in αSyn 
do indeed lead to an increase in the relative abundance of monomeric αSyn as revealed by 
crosslinking and fluorescence complementation studies (unpublished data). These data make 
sense in light of the fact that there is no clear connection between all PD mutant variants and the 
in vitro aggregation propensity of their recombinantly expressed unfolded monomer. In vivo, 
these mutations could indirectly promote aggregation by either preventing the formation or 
decreasing the stability of aggregation resistant physiological oligomers. It should be noted that 
we also observe that changes in αSyn expression levels (up to an order of magnitude) do not 
appear to alter the ratio of 60 to 14 kDa bands trapped by multiple crosslinking reagents. 
Increasing the absolute abundance of aggregation-prone monomer without necessarily altering 
this ratio, for example with a genomic multiplication of the αSyn-encoding SNCA gene 
(Chartier-Harlin et al., 2004; Singleton et al., 2003), is also sufficient to cause PD. The same 
could be true for mutations in glucocerebrosidase (GBA1), the most common genetic risk factor 
for PD, which can elevate αSyn protein levels, perhaps via reduced lysosomal degradation 
(Cullen et al., 2011). 
αSyn-induced toxicity in in vitro and Drosophila models can be rescued by the 
expression of human Hsp70 (Auluck et al., 2002; Klucken et al., 2006). Based on the 
accompanying reduction in αSyn aggregation in these systems, it was suggested that this 
chaperone prevented the misfolding of αSyn into toxic species; subsequent work by Danzer et 
al.(2011) supports this interpretation. Complementarily, Hsp70 could also be acting to preserve 
the folding of helical oligomers, thereby reducing the proportion of unfolded, aggregation prone 
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monomers. Additional crosslinking studies following the knockdown or overexpression of 
chaperones in cells with endogenous αSyn expression levels or in those overexpressing low 
levels of oligomer-destabilizing PD mutants would help address this possibility. 
 Other models of PD implicate ROS production in the aggregation of αSyn (Betarbet et 
al., 2000; Sherer et al., 2002). While ROS-induced damage to protein degradation systems will 
almost certainly lead to an accumulation of αSyn (and other proteins), oxidative stress may also 
promote αSyn aggregation more specifically. In our purification of αSyn from human brain, we 
observed an apparent conversion of soluble 60 and 100 kDa αSyn oligomers into monomers by 
addition of the oxidant DTP. This implies that changes to environmental redox conditions can 
promote the depolymerization of aggregation-resistant oligomers and suggests an interesting 
potential feedback mechanism between αSyn-induced mitochondrial dysfunction (Chapter 2) and 
further aggregation. 
 
The αSyn functional unit 
The aforementioned possibility of a membrane-associated factor that promotes the 
depolymerization of physiological oligomers could be relevant to the function of αSyn. Such 
regulation could ensure that oligomeric αSyn remains cytosolic while monomers are permitted 
access to membranes. It is widely believed that the function of αSyn lies at membranes; in vitro 
and in vivo studies reviewed by Bendor et al. (2013) suggest that αSyn plays a role in 
membrane/vesicle dynamics. Though we observed that purified helical tetramers derived from 
human cells avidly bound artificial membranes, in vitro membrane binding assays do not reflect 
the complexity of the neuronal environment and do not take into consideration possible 
regulatory mechanisms at play. Using crosslinking agents, we have shown that the majority of 
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αSyn in normal cells is oligomeric and that these oligomers can be trapped exclusively in the 
cytosol. Compared to oligomers, the monomeric pool of αSyn is enriched in the membrane 
fraction (Dettmer et al., 2013). It is possible that the N-terminal conserved repeats in αSyn that 
are responsible for membrane binding (Bussell and Eliezer, 2003) also participate in 
physiological self-association (Wang et al., 2011), though not simultaneously. Emerging data 
from our lab indicate that in-register mutations in these repeat regions completely abolish the 
ability to crosslink mid-molecular weight oligomers and instead promote the association of αSyn 
with the Triton-X soluble fraction. This supports the idea that monomeric αSyn associates with 
membranes where it is in the position to carry out the purported functions for αSyn and suggests 
that oligomerization may have a greater sensitivity to point mutations in these regions than does 
membrane binding. Physiological oligomers present in the cytosol may be equally as important 
in that they may act as a storage form, not only to prevent the aggregation of unfolded monomers 
as has been proposed (Gurry et al., 2013), but also to modulate the size of the active pool of 
αSyn.  
A recent publication analyzed 26 αSyn variants, including three familial PD mutants 
(A53T, A30P, E46K) in different model systems and across several assays relevant to proposed 
physiological and pathological activities (Burré et al., 2012). The authors observed that these 
mutants (and others) enhanced toxic effects of αSyn, such as neuronal death and impaired 
motility in mice, without significantly compromising its ability to carry out putative 
physiological functions, including enhancement of SNARE complex assembly (Burré et al., 
2012). Combining this with our crosslinking data, it seems that mutations that lower the tetramer 
to monomer ratio can increase pathology without losing “functional” effects. This is consistent 
with the idea that monomeric αSyn is capable of carrying out reported physiological functions.  
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It would be interesting to examine whether even stronger mutations, for example our engineered 
mutant that cannot be crosslinked into mid-molecular weight oligomers, can still rescue αSyn-
dependent functions in knockout neurons, though low-level expression may be required to avoid 
aggregation-related phenotypes. 
 
Release from the membrane 
In vitro experiments with purified αSyn and artificial membranes demonstrate a high 
affinity of αSyn for membranes (Beyer, 2007). In vivo, however, only a small percentage of 
αSyn is present at the membrane at any given time (Dettmer et al., 2013; Kahle et al., 2000). It 
has been proposed that neuronal activity stimulates the release of αSyn from synaptic vesicles 
(with which is it believed to associate) either by the dilution of specific acidic phospholipids 
upon vesicle fusion with the presynaptic membrane or by the lessening of membrane curvature 
that occurs concomitantly (Rhoades et al., 2006; Tao-Cheng, 2006). Based on our unpublished 
observations, αSyn adheres more tightly to vesicles in vitro. Thus, there are also likely to be 
factors that regulate the release of αSyn from the membrane back into the cytosol where it can 
assemble into physiological oligomers. Other cytosolic regulators of vesicle trafficking are 
subject to regulation by soluble factors; for example, rab3 is extracted off of fusing synaptic 
vesicles by the protein GDP-dissociation inhibitor (Ignatev et al., 2008).  
There is evidence that such a factor also exists for αSyn. Using permeabilized 
synaptosomes, Wislet-Gendebien et al. (2006) demonstrated that addition of brain cytosol 
promoted the release of αSyn from vesicles. The activity of the added cytosol was sensitive to 
heat and protease treatment, suggesting the requirement for functional proteins (Wislet-
Gendebien et al., 2006). One could investigate the ability of αSyn knockout brain cytosol to 
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promote αSyn release using in vitro assays in which N-acetylated recombinant αSyn (which is 
more likely to form helical oligomers (Trexler and Rhoades, 2012)) is induced to adopt helical 
folding in the presence of lipids. After separating the soluble from lipid-bound αSyn via 
centrifugation, one could examine the oligomerization state soluble αSyn using chemical 
crosslinking, with cytosol-treated recombinant protein incubated in the absence of lipid as a 
control. Due to the possibility of a competing factor that may lead to oligomer destabilization (as 
discussed above) but that would not necessarily be expected to affect release, it would be prudent 
to test further fractionated cytosol as well. 
 
Mitotoxicity of Prefibrillar αSyn Oligomers 
Possible mechanisms of action 
We observed that soluble, ThTneg, prefibrillar oligomers, but not monomers or ThTpos 
fibrils promoted complex I-dependent, Ca2+-induced mitochondrial dysfunction. These results 
provide a potential subcellular target of prefibrillar αSyn oligomers recently reported to be 
cytotoxic in cellular and animal models. Karpinar and colleagues (2009) reported greater 
oligomerization propensity but reduced fibrilization and β-sheet content of recombinant αSyn 
engineered to contain various proline substitutions. Overexpression of these mutants in rat 
primary neurons, C. elegans, and Drosophila was associated with neurotoxicity that was 
inversely proportional to the β-sheet content of in vitro oligomers of the same αSyn proteins 
(Karpinar et al., 2009), but mitochondrial dysfunction was not specifically addressed. Recent 
work by Winner et al. (2011) is also in line with our findings: αSyn mutants that preferentially 
form β-sheet-poor oligomers rather than β-sheet-rich fibrils in vitro were associated with more 
neurotoxicity in lentiviral-infected human mesencephalic cells and rat brain. Moreover, 
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interaction of these oligomers with cellular membranes was suggested as a potential mediator of 
toxicity (Winner et al., 2011), but again mitotoxicity was not examined.  
It remains unclear whether the prefibrillar αSyn used in our system directly reduces 
complex I activity, though in light of existing literature, this is a likely explanation for our 
findings. A specific deficit in complex I activity has been reported in dopaminergic neurons 
overexpressing mutant αSyn (Chinta et al., 2010), and Devi et al. (2008) observed an inverse 
correlation between mitochondrial αSyn and complex I activity in the substantia nigra of PD 
patients. Furthermore, spectrophotometric analyses of complex I enzymatic activity from αSyn-
treated mitochondria and mitoplasts has revealed a dose-dependent inhibition by αSyn (Devi et 
al., 2008; Liu et al., 2009). We are currently performing these experiments with our bioactive, 
prefibrillar oligomers.  
In our reductionist system, we did not observe αSyn-induced reduction of basal ∆Ψm. 
This would imply a mild reduction in complex I activity that is exacerbated by Ca2+ influx. 
Previous reports suggest that overexpressing αSyn in cells or animals can lead to alterations in 
mitochondrial function in the absence of overt Ca2+ stress (Chinta et al., 2010; Choubey et al., 
2011; Devi et al., 2008; Hsu et al., 2000; Lee et al., 2001; Parihar et al., 2008; Shavali et al., 
2008). These results could be explained by one or more of the following possibilities. First, toxic 
αSyn species could affect the function of other organelles or cellular pathways leading to 
intracellular Ca2+ dyshomeostasis. Second, when overexpressed in cell lines or animals (vs. 
briefly incubated with mitochondria in vitro as here), there may be greater opportunity for αSyn 
to exert its effects, such that mild alterations of mitochondrial function (which could be 
exacerbated by our acute Ca2+ challenge) can accumulate chronically. In this context, 
physiological Ca2+ transients in neurons could be a sufficient stress in the presence of 
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prefibrillar, oligomeric αSyn (Loew et al., 1994). Furthermore, endogenous toxins such as the 
monoamine oxidase product of dopamine, 3,4-dihydroxyphenylacetaldehyde, have also been 
shown to facilitate mitochondrial permeability transition (Kristal et al., 2001) and may act 
synergistically with pathological αSyn in dopaminergic neurons. And third, the ability of Ca2+ to 
exacerbate the mitochondrial effects of αSyn may not be due to Ca2+ uptake per se but rather the 
associated increase in ETC activity. Mitochondrial Ca2+ influx comes at the expense of ∆Ψm, 
which must be re-established in order to generate ATP and buffer further Ca2+ loads. One 
possibility is the increased electron transport through a compromised complex I could increase 
the generation of ROS, thereby accelerating mPTP opening.  
Prefibrillar αSyn oligomers could act to inhibit complex I function either by directly 
associating with protein subunits or indirectly via perturbations of mitochondrial membrane 
lipids. A recent paper described reduced ∆Ψm and increased ROS in mitochondria of αSyn 
transgenic mice; however co-immunoprecipitation revealed no specific association of αSyn with 
complex I protein subunits (Sarafian et al., 2013), although a thorough investigation into the 
biochemical interaction between αSyn and complex I, an integral membrane protein with its 45 
subunits, would require extensive optimization and analysis. αSyn’s well-demonstrated tendency 
to bind negatively charged phospholipids, especially cardiolipin (Nakamura et al., 2008), which 
is critical for proper electron transfer by complexes I and III (Fry and Green, 1981; Zhang et al., 
2002), suggests that membrane association of pathological αSyn oligomers could impair 
complex I activity. Consistent with this idea and the nature of the toxic αSyn species we 
identified, Smith and colleagues (Smith et al., 2008) observed that soluble, prefibrillar αSyn 
oligomers populated during the aggregation lag phase bind to negatively charged membranes 
with an affinity approximately two orders of magnitude higher than unaged protein and 
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significantly higher than ThTpos species. Moreover, electron microscopy of these oligomers 
revealed a striking similarity to our bioactive αSyn. 
 
Mitoxicity in the context of PD 
In PD associated with an established alteration of αSyn homeostasis, such as in familial 
PD caused by mutations in or genomic multiplications of αSyn or in sporadic PD linked to other 
risk factors known to increase αSyn levels, it is reasonable to assume that aberrant αSyn 
accumulation is an initial pathogenic stimulus.  Furthermore, the presence of Lewy pathology in 
sporadic PD underscores the relevance of dysfunctional αSyn proteostasis in the vast majority of 
PD cases. That said, the precise sequence of specific pathological events is not known. Under 
physiological conditions, αSyn is localized primarily at the presynaptic terminals of mature 
neurons (Kahle et al., 2000). The insoluble αSyn inclusions characteristic of PD are found in the 
soma and neurites. Thus, there is an apparent subcellular redistribution of αSyn in the disease 
state. Does this precede mitochondrial dysfunction or does it occur as a result? Accumulation of 
αSyn in proximal compartments is likely the result of either impaired axonal transport of αSyn 
destined for the presynaptic terminal or an inability to clear αSyn that is normally degraded from 
these areas (Cuervo et al., 2004). Both of these processes are highly dependent on ATP.  
Because of their prominent transmembrane Ca2+ currents associated with pacemaking 
activity and their low expression of Ca2+ buffering proteins, the neurons vulnerable in PD 
continuously require ATP to pump large amounts of Ca2+ out of the cytosol. This high basal 
demand for ATP translates to a modest bioenergetic reserve (the difference between the 
maximum capacity for ATP generation and basal ATP consumption) and puts these neurons at 
risk of being unable to meet additional bioenergetic demands (Surmeier and Schumacker, 2013). 
Therefore, they may be less able to energetically handle the proteostatic challenge brought on by 
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elevated αSyn. This may be particularly true of nigral dopaminergic neurons in which normal 
aging leads to progressive energy impairment due to accumulated mtDNA mutations (Kraytsberg 
et al., 2006). A shortage of ATP could compromise transport and degradation machinery, thereby 
leading to an accumulation and mislocalization of αSyn, which subsequently misfolds and 
aggregates. Prefibrillar αSyn may then associate with mitochondria, resulting in complex I 
dysfunction and perhaps increased ROS generation. Elevated ROS levels would further 
compromise mitochondrial function and promote αSyn aggregation (Hashimoto et al., 1999). 
Therefore neuronal populations operating near their respiratory capacity may be more likely to 
accumulate αSyn and more vulnerable to its toxic effects. Our results suggest that excessive Ca2+ 
uptake under these circumstances could more easily lead to the formation of the mPTP. Pore 
opening could result in apoptosis or necrosis depending on the number of mitochondria having 
undergone permeability transition and, therefore, the supply of ATP required to form the 
apoptosome from components released by damaged mitochondria (Rasola and Bernardi, 2011). 
It is believed that apoptosis is more prevalent in PD (Kostrzewa, 2000), so it is likely that only a 
subset of mitochondria are terminally affected. 
We used a reductionist system in order to directly test the effect of defined αSyn species 
on Ca2+-induced mitochondrial permeability transition. Though the role of mitochondrial 
permeability transition in PD-related cell death requires further study, two recent reports support 
the in vivo relevance of our data. Findings from Martin et al. (2013) indicate that the genetic 
ablation of cyclophilin D, the mPTP modulator and target of CsA, delayed the onset of 
mitochondrial abnormalities and neuronal apoptosis in Thy1-αSyn A53T transgenic mice. Also, 
Büttner et al. (2013) showed that overexpression of αSyn in yeast led to cell death and a 
redistribution of the pro-apoptotic nuclease EndoG from mitochondria to the nucleus. These 
! 145 
effects could both be rescued by genetic modulation of the mPTP components. Moreover, 
nuclear translocalization of EndoG was preferentially detected in the brain sections of PD 
patients compared to age-matched controls (Büttner et al., 2013). 
 
Temporal Spreading of PD Pathology 
The potential spreading of αSyn pathology to synaptically-connected neurons has 
emerged as a popular hypothesis and possible alternative to the idea of selective vulnerability. 
Based on an ever-expanding literature, there can be no doubt that this occurs in cell and animal 
models with high amounts of αSyn introduced exogenously (Hansen and Li, 2012). In controlled 
models like this, it is possible to establish a temporal spread of pathology. Defining such a 
chronological progression from the brains of disparate individuals at different ages is much more 
challenging. Even if one were to accept the premise of a pathogenic spread model, synaptic 
connectivity is not enough to explain which neurons display αSyn pathology; areas that exhibit 
αSyn pathology are invariably connected to others that do not (Surmeier et al., 2010). Ultimately, 
this reinforces the idea that, at some level, there must be certain populations of neurons that are 
predisposed to develop αSyn aggregates or are more vulnerable to their effects. 
 
Implications for PD Diagnosis and Treatment 
Classical treatment strategies for PD are focused on enhancing dopaminergic 
transmission in the nigrostriatal pathway, either by augmenting the production of dopamine by 
presynaptic nigral neurons or stimulating postsynaptic striatal neurons directly (Olanow and 
Schapira, 2013). These are purely symptomatic treatments that do not address the underlying 
cause of neurodegeneration and eventually lose their efficacy. This highlights the need for 
disease modifying, neuroprotective therapeutics that can be effective over the long term. 
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 As discussed earlier, my working hypothesis is that αSyn sensitizes mitochondria to Ca2+-
induced permeability transition by increasing ROS generation at complex I. Based on this and 
other reports of oxidative stress in PD, one would expect that antioxidant therapies, such as 
Coenzyme Q10 could be effective neuroprotective agents. Data from a number of clinical trials, 
however, do not provide strong evidence of protection. Studies indicate that some antioxidants, 
like monoamine oxidase-B inhibitors, do provide some benefit to patients, but it is possible that 
these are due to symptomatic effects resulting from an increase in synaptic dopamine. Analysis 
of these clinical trials points to problems of dosing and bioavailability in the brain (Schapira and 
Olanow, 2004). If these hurdles can be surmounted and appropriate doses can reach at-risk 
neurons, then I would expect some degree of neuroprotection – especially if these treatments 
were coupled with drugs like dihydropyridines (DHPs) that may target a source of oxidative 
stress. 
Epidemiological studies have shown that use of DHPs, antagonists of the L-type Ca2+ 
channels that are the source of much of the Ca2+ influx in vulnerable pacemaking neurons, to 
treat hypertension are associated with a reduced risk of PD (Pasternak et al., 2012; Ritz et al., 
2010). Though L-type Cav1.3 channels contribute to pacemaking in mature nigral dopaminergic 
neurons, earlier in development they do not. It was recently shown that, upon blockade of Cav1.3 
channels in adult nigral neurons, mitochondrial oxidant stress is reduced and pacemaking persists 
due to the compensatory activity of Na+-permeable hyperpolarization activated cyclic nucleotide 
channels that are normally used in immature neurons (Chan et al., 2007; Guzman et al., 2010). 
This suggests that targeting these channels would not significantly impair dopaminergic 
transmission. It should be noted that it is unknown whether the physiology of other vulnerable 
populations that exhibit high transmembrane Ca2+ flux can be similarly manipulated without 
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dramatic functional consequences. Of course by the time symptoms appear, nigral neurons may 
already be significantly compromised by cycles of energetic stress and mitochondrial 
dysfunction. This could potentially be overcome by prospective treatment, but predictive 
biomarkers are lacking. 
 
Biomarkers 
The best way to protect neurons from disease related loss is to target the source of the 
problem, and to do it as early as possible. By the time patients present with PD, most of their SN 
dopaminergic neurons have been lost forever (Bernheimer et al., 1973; Riederer and Wuketich, 
1976), and in order to better treat these individuals, we need a means to detect the disease earlier. 
One possibility would be to examine the ratio of physiological oligomers to monomers. Based on 
our unpublished analysis of familial PD variants, pathogenic mutations in αSyn alter the ratio of 
specific oligomeric bands to the 14 kDa monomer.  Based on the presence of Lewy pathology 
and other factors implicating altered αSyn proteostasis, it is likely that a portion of sporadic PD 
also arises from a shift toward aggregation prone monomers. Though analysis of brain tissue 
would not be recommended (especially for such diagnostic purposes), we and others have shown 
that αSyn is highly expressed in erythrocytes, a renewable and easily accessible source (Barbour 
et al., 2008; Bartels et al., 2011). Live cell crosslinking of erythrocytes for analysis by Western 
blotting is unlikely to be suitable for diagnostic purposes for two reasons. The semiquantitative 
nature of Western blotting may reduce diagnostic accuracy, and the abundance of hemoglobin in 
erythrocytes can interfere with specific αSyn-αSyn crosslinking, thereby confounding 
interpretation. Another possibility is an ELISA using conformation-specific antibodies for 
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monomers and physiological oligomers, and our lab is currently pursuing the development of 
these potentially useful tools.  
 
Neuroprotective therapeutics 
Our observation of mitochondrial dysfunction induced by prefibrillar αSyn oligomers, but 
not monomeric αSyn, is supportive of efforts to inhibit αSyn aggregation as a neuroprotective 
strategy, but they call into question a current approach. ThT, which binds strongly to highly 
aggregated species with a particular amyloid structure (Biancalana and Koide, 2010), is often 
used to screen the ability of compounds to inhibit αSyn aggregation. Our work and the work of 
others suggest that the formation of toxic αSyn species occurs earlier in the timeline of 
aggregation than onset of ThT positivity. Thus, compounds that prevent amyloid aggregation 
will not necessarily inhibit the formation of toxic αSyn species and may, in fact, stabilize them. 
The fact that we observed effects of prefibrillar ThTneg, but not ThTpos aggregates on 
mitochondrial function suggests that our results are in agreement with the concept of Lewy 
pathology as a protective mechanism, at least temporarily (Reeve et al., 2012; Tompkins and 
Hill, 1997). Alternatively, one could attempt to accelerate the fibrilization process to decrease 
levels of potentially toxic oligomers, although it is likely that they are in equilibrium, and fibrils 
could release smaller oligomers that promote aggregation of monomeric protein via a secondary 
nucleation mechanism (Cohen et al., 2013; Cremades et al., 2012). Other well-validated dyes or 
antibodies that detect αSyn at earlier aggregation states would need to be developed so that they 
can be used as a new benchmark for pathological aggregation. 
An alternative therapeutic strategy to developing aggregation inhibitors is to find ways to 
stabilize native, aggregation-resistant, helical oligomers(Bartels et al., 2011; Dettmer et al., 
2013); however, it is still unclear what form of αSyn represents the (or a) functional unit. 
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Stabilizers would be expected to reduce pathological aggregation of unfolded monomers, but it is 
also possible that they could compromise the physiological function of the protein. It is therefore 
crucial to understand specifically how αSyn functions within neurons so that we may undertake 
an extensive functional characterization of purified helical oligomers. Until that can be achieved, 
emphasis should be placed on early diagnosis (as discussed above) and on neutralizing the 
effects of small, soluble, prefibrillar oligomers - either by preventing their formation using 
aggregation inhibitors, or by promoting the clearance of excess unfolded monomer or toxic 
oligomers using immunotherapy with specific antibodies. 
 
Future Work 
One limitation of my work characterizing the assembly state of αSyn in human brain 
homogenates and in intermediate purification steps is that I only looked at oligomerization by 
crosslinking. Unfortunately, there are a limited number of techniques able assess the assembly 
state of a single, endogenously expressed protein in a complex mixture of other proteins. Aside 
from the crosslinking approach used in this work, native gels could theoretically be used to size 
αSyn complexes. Recently, we have been unsuccessful in consistently distinguishing between 
unfolded, monomeric αSyn (recombinant protein) and helical αSyn oligomers on native gels. A 
new paper by the Ischiropoulos group (2014), however, has successfully employed the technique 
to detect multiple conformers of αSyn in human brain extract, and it will be worth examining our 
homogenates and partially purified samples using their optimized conditions. Another 
alternative, an ELISA specific for physiological oligomers, is currently under development in our 
lab. An important short-term goal for this project is to gain a better understanding of the 60, 80, 
and 100 kDa crosslinked bands. As mentioned above, intact mass spectrometry of these purified, 
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crosslinked species may distinguish between conformers or oligomers made up of a different 
number of subunits. 
Additional analysis will provide greater insight into the scope and mechanism of αSyn’s 
effects on mitochondria. Our results indicate that mitochondria treated with prefibrillar αSyn 
exhibit defective complex I-dependent function, and we are now specifically addressing whether 
the activity of complex I in this system is also reduced. Alternatively, it is possible that αSyn is 
limiting complex I substrate availability by impeding transport of glutamate or malate into 
mitochondria. Thus far we have used mitochondria isolated from liver because they provide a 
high yield of stable mitochondria suitable for testing an array of αSyn species and respiratory 
conditions in a single experiment. Now that we have identified a consistent source of bioactive 
αSyn, we are beginning to examine the effects of this material on the activity brain-derived 
mitochondria. Expanding to this more disease-relevant source of mitochondria will also enable 
us to measure ROS production that we hypothesize is behind the αSyn-induced sensitivity to 
mPTP; the amount of catalase present in liver mitochondria preparations precludes accurate 
quantification.   
Ultimately, I think it would be of great interest to further bridge the two parts of my 
thesis, and there are interesting questions at the interface of my two projects. Does mitochondrial 
Ca2+ stress alter the ratio of native oligomers to monomers in situ? From my preliminary results 
with partially purified αSyn samples, I can speculate that ROS produced by mitochondria may 
lead to a destabilization of native oligomers, but this would need to be tested directly in a cellular 
context. Do αSyn mutants that are incapable of forming native oligomers (or are more likely to 
form prefibrillar oligomers (Winner et al., 2011)) show greater evidence of mPTP activation 
compared to wild type αSyn when overexpressed within neurons? How does αSyn extracted 
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from human brain affect the functioning of isolated mitochondria? An initial experiment suggests 
that helical oligomers have no effect on mitochondrial Ca2+ retention, and if confirmed, this 
would further support the non-pathological nature of this species. As illustrated by the ThT 
aggregation data presented here, the behavior of recombinant αSyn can be quite variable. 
Recombinant αSyn can be induced to aggregate in a variety of different ways to produce 
numerous species with different structural and functional properties. The fact that two 
independent preparations resulted in bioactive oligomeric αSyn with similar functional effects on 
mitochondria reduces the likelihood that our observations are due to artifactual effects related to 
specific aggregation conditions. That being said, the most relevant source of potentially toxic, 
prefibrillar αSyn is the brain tissue from synucleinopathy patients, and we aim to purify these 
species for testing on mitochondria. The experiments proposed here would build upon the 
groundwork laid by my thesis and provide even greater understanding of the role of αSyn in 
neurodegenerative disease. 
 
  
! 152 
References 
 
Auluck, P.K., Chan, H.Y.E., Trojanowski, J.Q., Lee, V.M.-Y., Bonini, N.M., 2002. Chaperone 
suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. 
Science 295, 865–868. 
 
 
Barbour, R., Kling, K., Anderson, J.P., Banducci, K., Cole, T., Diep, L., Fox, M., Goldstein, 
J.M., Soriano, F., Seubert, P., Chilcote, T.J., 2008. Red blood cells are the major source of 
alpha-synuclein in blood. Neurodegener Dis 5, 55–59. 
 
 
Bartels, T., Choi, J.G., Selkoe, D.J., 2011. α-Synuclein occurs physiologically as a helically 
folded tetramer that resists aggregation. Nature 477, 107–110. 
 
 
Bendor, J.T., Logan, T.P., Edwards, R.H., 2013. The function of α-synuclein. Neuron 79, 1044–
1066. 
 
 
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seitelberger, F., 1973. Brain 
dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and 
neurochemical correlations. J. Neurol. Sci. 20, 415–455. 
 
 
Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V., Greenamyre, J.T., 
2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. 
Neurosci. 3, 1301–1306. 
 
 
Beyer, K., 2007. Mechanistic aspects of Parkinson's disease: alpha-synuclein and the 
biomembrane. Cell Biochem. Biophys. 47, 285–299. 
 
 
Biancalana, M., Koide, S., 2010. Molecular mechanism of Thioflavin-T binding to amyloid 
fibrils. Biochim. Biophys. Acta 1804, 1405–1412. 
 
 
Burré, J., Sharma, M., Südhof, T.C., 2012. Systematic mutagenesis of α-synuclein reveals 
distinct sequence requirements for physiological and pathological activities. Journal of 
Neuroscience 32, 15227–15242. 
 
 
Bussell, R., Eliezer, D., 2003. A structural and functional role for 11-mer repeats in alpha-
synuclein and other exchangeable lipid binding proteins. Journal of Molecular Biology 329, 
763–778. 
! 153 
 
 
Büttner, S., Habernig, L., Broeskamp, F., Ruli, D., Vögtle, F.N., Vlachos, M., Macchi, F., 
Küttner, V., Carmona-Gutierrez, D., Eisenberg, T., Ring, J., Markaki, M., Taskin, A.A., 
Benke, S., Ruckenstuhl, C., Braun, R., Van den Haute, C., Bammens, T., van der Perren, A., 
Fröhlich, K.-U., Winderickx, J., Kroemer, G., Baekelandt, V., Tavernarakis, N., Kovacs, 
G.G., Dengjel, J., Meisinger, C., Sigrist, S.J., Madeo, F., 2013. Endonuclease G mediates α-
synuclein cytotoxicity during Parkinson's disease. EMBO J 32, 3041–3054. 
 
 
Chan, C.S., Guzman, J.N., Ilijic, E., Mercer, J.N., Rick, C., Tkatch, T., Meredith, G.E., Surmeier, 
D.J., 2007. 'Rejuvenation‘ protects neurons in mouse models of Parkinson’s disease. Nature 
447, 1081–1086. 
 
 
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., 
Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., Waucquier, N., Defebvre, L., Amouyel, 
P., Farrer, M., Destée, A., 2004. Alpha-synuclein locus duplication as a cause of familial 
Parkinson's disease. Lancet 364, 1167–1169. 
 
 
Chen, L., Periquet, M., Wang, X., Negro, A., McLean, P.J., Hyman, B.T., Feany, M.B., 2009. 
Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on 
neurotoxicity and soluble oligomer formation. J. Clin. Invest. 119, 3257–3265. 
 
 
Chinta, S.J., Mallajosyula, J.K., Rane, A., Andersen, J.K., 2010. Mitochondrial α-synuclein 
accumulation impairs complex I function in dopaminergic neurons and results in increased 
mitophagy in vivo. Neurosci. Lett. 486, 235–239. 
 
 
Choubey, V., Safiulina, D., Vaarmann, A., Cagalinec, M., Wareski, P., Kuum, M., Zharkovsky, 
A., Kaasik, A., 2011. Mutant A53T alpha-synuclein induces neuronal death by increasing 
mitochondrial autophagy. J. Biol. Chem. 286, 10814–10824. 
 
 
Cohen, S.I.A., Linse, S., Luheshi, L.M., Hellstrand, E., White, D.A., Rajah, L., Otzen, D.E., 
Vendruscolo, M., Dobson, C.M., Knowles, T.P.J., 2013. Proliferation of amyloid-β42 
aggregates occurs through a secondary nucleation mechanism. Proceedings of the National 
Academy of Sciences 110, 9758–9763. 
 
 
Cremades, N., Cohen, S.I.A., Deas, E., Abramov, A.Y., Chen, A.Y., Orte, A., Sandal, M., 
Clarke, R.W., Dunne, P., Aprile, F.A., Bertoncini, C.W., Wood, N.W., Knowles, T.P.J., 
Dobson, C.M., Klenerman, D., 2012. Direct observation of the interconversion of normal 
and toxic forms of α-synuclein. Cell 149, 1048–1059. 
! 154 
 
 
Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., Sulzer, D., 2004. Impaired 
degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 
1292–1295. 
 
 
Cullen, V., Sardi, S.P., Ng, J., Xu, Y.-H., Sun, Y., Tomlinson, J.J., Kolodziej, P., Kahn, I., 
Saftig, P., Woulfe, J., Rochet, J.-C., Glicksman, M.A., Cheng, S.H., Grabowski, G.A., 
Shihabuddin, L.S., Schlossmacher, M.G., 2011. Acid β-glucosidase mutants linked to 
Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. 
Ann. Neurol. 69, 940–953. 
 
 
Danzer, K.M., Ruf, W.P., Putcha, P., Joyner, D., Hashimoto, T., Glabe, C., Hyman, B.T., 
McLean, P.J., 2011. Heat-shock protein 70 modulates toxic extracellular α-synuclein 
oligomers and rescues trans-synaptic toxicity. The FASEB Journal 25, 326–336. 
 
 
Dettmer, U., Newman, A.J., Luth, E.S., Bartels, T., Selkoe, D., 2013. In vivo cross-linking 
reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-
neural cells. J. Biol. Chem. 288, 6371–6385. 
 
 
Devi, L., Raghavendran, V., Prabhu, B.M., Avadhani, N.G., Anandatheerthavarada, H.K., 2008. 
Mitochondrial import and accumulation of alpha-synuclein impair complex I in human 
dopaminergic neuronal cultures and Parkinson disease brain. Journal of Biological 
Chemistry 283, 9089–9100. 
 
 
Fry, M., Green, D.E., 1981. Cardiolipin requirement for electron transfer in complex I and III of 
the mitochondrial respiratory chain. J. Biol. Chem. 256, 1874–1880. 
 
 
Goedert, M., Spillantini, M.G., Del Tredici, K., Braak, H., 2013. 100 years of Lewy pathology. 
Nat Rev Neurol 9, 13–24. 
 
 
Gould, N., Mor, D., Lightfoot, R., Malkus, K., Giasson, B., Ischiropoulos, H., 2014. Evidence of 
Native α-Synuclein Conformers in the Human Brain. J. Biol. Chem. 
 
 
Gurry, T., Ullman, O., Fisher, C.K., Perovic, I., Pochapsky, T., Stultz, C.M., 2013. The dynamic 
structure of α-synuclein multimers. J. Am. Chem. Soc. 135, 3865–3872. 
 
 
! 155 
Guzman, J.N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P.T., 
Surmeier, D.J., 2010. Oxidant stress evoked by pacemaking in dopaminergic neurons is 
attenuated by DJ-1. Nature 468, 696–700. 
 
 
Haass, C., Selkoe, D.J., 2007. Soluble protein oligomers in neurodegeneration: lessons from the 
Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101–112. 
 
 
Hansen, C., Li, J.-Y., 2012. Beyond α-synuclein transfer: pathology propagation in Parkinson's 
disease. Trends Mol Med 18, 248–255. 
 
 
Hashimoto, M., Takeda, A., Hsu, L.J., Takenouchi, T., Masliah, E., 1999. Role of cytochrome c 
as a stimulator of alpha-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274, 
28849–28852. 
 
 
Hsu, L.J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., Wong, J., Takenouchi, 
T., Hashimoto, M., Masliah, E., 2000. alpha-synuclein promotes mitochondrial deficit and 
oxidative stress. Am. J. Pathol. 157, 401–410. 
 
 
Ignatev, A., Kravchenko, S., Rak, A., Goody, R.S., Pylypenko, O., 2008. A structural model of 
the GDP dissociation inhibitor rab membrane extraction mechanism. J. Biol. Chem. 283, 
18377–18384. 
 
 
Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., 
Leimer, U., van Der Putten, H., Probst, A., Kremmer, E., Kretzschmar, H.A., Haass, C., 
2000. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -
synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365–6373. 
 
 
Karpinar, D.P., Balija, M.B.G., Kügler, S., Opazo, F., Rezaei-Ghaleh, N., Wender, N., Kim, H.-
Y., Taschenberger, G., Falkenburger, B.H., Heise, H., Kumar, A., Riedel, D., Fichtner, L., 
Voigt, A., Braus, G.H., Giller, K., Becker, S., Herzig, A., Baldus, M., Jäckle, H., Eimer, S., 
Schulz, J.B., Griesinger, C., Zweckstetter, M., 2009. Pre-fibrillar alpha-synuclein variants 
with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J 
28, 3256–3268. 
 
 
Klucken, J., Outeiro, T.F., Nguyen, P., McLean, P.J., Hyman, B.T., 2006. Detection of novel 
intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. The 
FASEB Journal 20, 2050–2057. 
 
! 156 
 
Kostrzewa, R.M., 2000. Review of apoptosis vs. necrosis of substantia nigra pars compacta in 
Parkinson's disease. Neurotox Res 2, 239–250. 
 
 
Kraytsberg, Y., Kudryavtseva, E., McKee, A.C., Geula, C., Kowall, N.W., Khrapko, K., 2006. 
Mitochondrial DNA deletions are abundant and cause functional impairment in aged human 
substantia nigra neurons. Nat Genet 38, 518–520. 
 
 
Kristal, B.S., Conway, A.D., Brown, A.M., Jain, J.C., Ulluci, P.A., Li, S.W., Burke, W.J., 2001. 
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets 
mitochondria. Free Radical Biology and Medicine 30, 924–931. 
 
 
Lee, M., Hyun, D., Halliwell, B., Jenner, P., 2001. Effect of the overexpression of wild-type or 
mutant alpha-synuclein on cell susceptibility to insult. Journal of Neurochemistry 76, 998–
1009. 
 
 
Liu, G., Zhang, C., Yin, J., Li, X., Cheng, F., Li, Y., Yang, H., Uéda, K., Chan, P., Yu, S., 2009. 
α-Synuclein is differentially expressed in mitochondria from different rat brain regions and 
dose-dependently down-regulates complex I activity. Neurosci. Lett. 454, 187–192. 
 
 
Loew, L.M., Carrington, W., Tuft, R.A., Fay, F.S., 1994. Physiological cytosolic Ca2+ transients 
evoke concurrent mitochondrial depolarizations. Proc. Natl. Acad. Sci. U.S.A. 91, 12579–
12583. 
 
 
Martin, L.J., Semenkow, S., Hanaford, A., Wong, M., 2013. The mitochondrial permeability 
transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic 
mice. Neurobiol. Aging 10.1016–j.neurobiolaging.2013.11.008. 
 
 
Nakamura, K., Nemani, V.M., Wallender, E.K., Kaehlcke, K., Ott, M., Edwards, R.H., 2008. 
Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with 
mitochondria. Journal of Neuroscience 28, 12305–12317. 
 
 
Olanow, C.W., Schapira, A.H.V., 2013. Therapeutic prospects for Parkinson disease. Ann. 
Neurol. 74, 337–347. 
 
 
Parihar, M.S., Parihar, A., Fujita, M., Hashimoto, M., Ghafourifar, P., 2008. Mitochondrial 
association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. 65, 1272–1284. 
! 157 
 
 
Pasternak, B., Svanström, H., Nielsen, N.M., Fugger, L., Melbye, M., Hviid, A., 2012. Use of 
calcium channel blockers and Parkinson's disease. Am. J. Epidemiol. 175, 627–635. 
 
 
Rasola, A., Bernardi, P., 2011. Mitochondrial permeability transition in Ca(2+)-dependent 
apoptosis and necrosis. Cell Calcium 50, 222–233. 
 
 
Reeve, A.K., Park, T.-K., Jaros, E., Campbell, G.R., Lax, N.Z., Hepplewhite, P.D., Krishnan, 
K.J., Elson, J.L., Morris, C.M., McKeith, I.G., Turnbull, D.M., 2012. Relationship between 
mitochondria and α-synuclein: a study of single substantia nigra neurons. Arch. Neurol. 69, 
385–393. 
 
 
Rhoades, E., Ramlall, T.F., Webb, W.W., Eliezer, D., 2006. Quantification of alpha-synuclein 
binding to lipid vesicles using fluorescence correlation spectroscopy. Biophysj 90, 4692–
4700. 
 
 
Riederer, P., Wuketich, S., 1976. Time course of nigrostriatal degeneration in parkinson's 
disease. A detailed study of influential factors in human brain amine analysis. J. Neural 
Transm. 38, 277–301. 
 
 
Ritz, B., Rhodes, S.L., Qian, L., Schernhammer, E., Olsen, J.H., Friis, S., 2010. L-type calcium 
channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67, 600–606. 
 
 
Sarafian, T.A., Ryan, C.M., Souda, P., Masliah, E., Kar, U.K., Vinters, H.V., Mathern, G.W., 
Faull, K.F., Whitelegge, J.P., Watson, J.B., 2013. Impairment of mitochondria in adult 
mouse brain overexpressing predominantly full-length, N-terminally acetylated human α-
synuclein. PLoS ONE 8, e63557. 
 
 
Schapira, A.H.V., Olanow, C.W., 2004. Neuroprotection in Parkinson disease: mysteries, myths, 
and misconceptions. JAMA 291, 358–364. 
 
 
Shavali, S., Brown-Borg, H.M., Ebadi, M., Porter, J., 2008. Mitochondrial localization of alpha-
synuclein protein in alpha-synuclein overexpressing cells. Neuroscience Letters 439, 125–
128. 
 
 
Sherer, T.B., Betarbet, R., Stout, A.K., Lund, S., Baptista, M., Panov, A.V., Cookson, M.R., 
! 158 
Greenamyre, J.T., 2002. An in vitro model of Parkinson's disease: linking mitochondrial 
impairment to altered alpha-synuclein metabolism and oxidative damage. Journal of 
Neuroscience 22, 7006–7015. 
 
 
Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., 
Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, 
D., Adler, C., Cookson, M.R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., 
Gwinn-Hardy, K., 2003. alpha-Synuclein locus triplication causes Parkinson's disease. 
Science 302, 841. 
 
 
Smith, D.P., Tew, D.J., Hill, A.F., Bottomley, S.P., Masters, C.L., Barnham, K.J., Cappai, R., 
2008. Formation of a high affinity lipid-binding intermediate during the early aggregation 
phase of alpha-synuclein. Biochemistry 47, 1425–1434. 
 
 
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., 1997. 
Alpha-synuclein in Lewy bodies. Nature 388, 839–840. 
 
 
Surmeier, D.J., Guzman, J.N., Sanchez-Padilla, J., Goldberg, J.A., 2010. What causes the death 
of dopaminergic neurons in Parkinson's disease? Prog. Brain Res. 183, 59–77. 
 
 
Surmeier, D.J., Schumacker, P.T., 2013. Calcium, bioenergetics, and neuronal vulnerability in 
Parkinson's disease. J. Biol. Chem. 288, 10736–10741. 
 
 
Tao-Cheng, J.-H., 2006. Activity-related redistribution of presynaptic proteins at the active zone. 
Neuroscience 141, 1217–1224. 
 
 
Tompkins, M.M., Hill, W.D., 1997. Contribution of somal Lewy bodies to neuronal death. Brain 
Research 775, 24–29. 
 
 
Trexler, A.J., Rhoades, E., 2012. N-Terminal acetylation is critical for forming α-helical 
oligomer of α-synuclein. Protein Sci. 21, 601–605. 
 
 
Volles, M.J., Lansbury, P.T., 2003. Zeroing in on the pathogenic form of alpha-synuclein and its 
mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42, 7871–7878. 
 
 
Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L.T.T., Liao, J., Auclair, J.R., 
! 159 
Johnson, D., Landeru, A., Simorellis, A.K., Ju, S., Cookson, M.R., Asturias, F.J., Agar, J.N., 
Webb, B.N., Kang, C., Ringe, D., Petsko, G.A., Pochapsky, T.C., Hoang, Q.Q., 2011. A 
soluble α-synuclein construct forms a dynamic tetramer. Proceedings of the National 
Academy of Sciences 108, 17797–17802. 
 
 
Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A., Lansbury, P.T., 1996. NACP, a protein 
implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 
13709–13715. 
 
 
Westphal, C.H., Chandra, S.S., 2013. Monomeric synucleins generate membrane curvature. J. 
Biol. Chem. 288, 1829–1840. 
 
 
Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., 
Vilar, M., Campioni, S., Tzitzilonis, C., Soragni, A., Jessberger, S., Mira, H., Consiglio, A., 
Pham, E., Masliah, E., Gage, F.H., Riek, R., 2011. In vivo demonstration that alpha-
synuclein oligomers are toxic. Proceedings of the National Academy of Sciences 108, 4194–
4199. 
 
 
Wislet-Gendebien, S., D'Souza, C., Kawarai, T., St George-Hyslop, P., Westaway, D., Fraser, P., 
Tandon, A., 2006. Cytosolic proteins regulate alpha-synuclein dissociation from presynaptic 
membranes. J. Biol. Chem. 281, 32148–32155. 
 
 
Zhang, M., Mileykovskaya, E., Dowhan, W., 2002. Gluing the respiratory chain together. 
Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. J. 
Biol. Chem. 277, 43553–43556. 
 
!!
 
 
 
 
 
 
Appendix 1 
 
Investigating the Ability of α-Synuclein to Sensitize Cells to Ca2+-Induced Toxicity 
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Introduction 
In addition to its role in familial forms of PD, αSyn contributes to the pathogenesis of the 
more common sporadic forms of the disease. Intracellular aggregates of αSyn are the main 
component of Lewy bodies and Lewy neurites, the pathological hallmarks of PD (Spillantini et 
al., 1997). It is becoming increasingly clear that soluble αSyn oligomers, rather than insoluble 
fibrils, are the main neurotoxic species in PD and other such synucleinopathies (Volles and 
Lansbury, 2003). PD selectively targets neurons of the SNc, DMV, LC, and other brain regions 
that are characterized by intracellular Ca2+ oscillations and low expression of cytosolic Ca2+ 
buffering proteins (Surmeier and Schumacker, 2013). Proper regulation of cytosolic Ca2+ levels 
by ATP-dependent plasma membrane pumps and uptake by Ca2+-buffering organelles is 
necessary to prevent Ca2+-associated apoptotic or necrotic cell death. Elevated cytosolic Ca2+ can 
therefore burden mitochondria in two ways: mitochondrial generation of ATP is required to 
actively pump Ca2+ into the extracellular space or internal stores such as the endoplasmic 
reticulum, and mitochondria themselves act as Ca2+ buffering organelles.  Mitochondrial Ca2+ 
uptake also presents a potential risk to the cell. Physiological Ca2+ uptake is favorable for ATP 
production because Ca2+ stimulates the activity of the tricarboxylic acid cycle; however, 
excessive Ca2+ uptake can compromise ATP production by reducing the mitochondrial 
membrane potential that is used to drive oxidative phosphorylation or by leading to the formation 
of the mPTP (Brookes et al., 2004). Despite the physiological phenotype of cells at risk in PD 
and the important role of αSyn accumulation in most forms of the disease, there has been little 
investigation into the ability of αSyn to sensitize cells to Ca2+-induced toxicity. 
To investigate αSyn-induced changes to Ca2+ homeostasis, we used a neuroblastoma cell 
line that can be induced to overexpress αSyn. Our results suggest that regulated overexpression 
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of αSyn results in higher levels of mitochondrial matrix Ca2+ ([Ca2+]m) as measured by Rhod2 
fluorescence, and sensitizes neuroblastoma cells to toxicity resulting from exposure to the Ca2+ 
ionophore A23187.  Preliminary experiments indicate that αSyn overexpression also renders 
cells more susceptible to toxicity caused by a more targeted elevation of [Ca2+]m induced by 
exposing cells to NMDA.  
 
Results and Discussion 
Inducible overexpression of αSyn:  
We used 3D5 cells, a human dopaminergic neuroblastoma cell line that can be induced to 
overexpress α-synuclein in a tetracycline-off system (Ko et al., 2008). 3D5 cells were cultured in 
the presence of tetracycline, which acts to repress αSyn overexpression. We induced αSyn 
overexpression by culturing the cells in tetracycline-free conditions and harvested them after 
different durations of induction. A protein normalized (see actin loading control) Western blot 
for αSyn confirms this overexpression beginning at, in this case, 4 d of induction (Figure 
A1.1A). In this example, the minimal increase in αSyn overexpression earlier could result from 
residual tetracycline in the media that acts to keep the cells in a relatively repressed state. 
Inducing αSyn overexpression for longer in this system leads to the presence of a small amount 
SDS-resistant αSyn oligomers (Ko et al., 2008). At 7 d of induction, but not before, a mid-to-
high molecular weight smear of αSyn immunoreactivity is observed in this cell line (Figure 
A1.1B). Though we believe this 14 kDa band represents both monomeric and helical tetrameric 
αSyn that is not stable in the presence of SDS (see Chapter 3 and Appendix 3), to distinguish 
these species from SDS-resistant, perhaps pathological oligomers, we refer collectively to the 
species that run at 14 kDa under denaturing conditions as “monomers”. In subsequent  
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Figure A1.1: Time-dependent induction of Monomeric and Oligomeric αSyn in 3D5 
Neuroblastoma cells. 
A. 3D5 human neuroblastoma cells express αSyn in a tetracycline-off manner. Uninduced cells 
(Un.) cultured in the presence of tetracycline express minimal endogenous αSyn, possibly 
resulting from promoter leak. After, at most, 4 days of culturing in the absence of tetracycline 
(induction), cells massively overexpress αSyn. B. SDS-resistant αSyn oligomers(noted by 
bracket) can be detected after 7 days of induction, but not before. * indicates a non-specific band 
detected by the Syn1 αSyn antibody.!
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experiments, uninduced (repressed) cells were compared to cells expressing monomers or 
monomers plus SDS-resistant oligomers. 
 
Examination of Resting [Ca2+]m:  
We first used 3D5 cells to examine whether αSyn overexpression, specifically the 
induction of oligomers, alters the basal [Ca2+]m. To address this, we compared the [Ca2+]m of 
cells overexpressing monomeric or monomeric plus oligomeric αSyn to uninduced cells using 
the [Ca2+]m indicator Rhod-2AM, which is trapped within cells after cleavage to Rhod-2. In 
contrast to the cytosolic Ca2+ indicator Fluo-3 that exhibits a diffuse fluorescence when loaded 
into cells, Rhod-2 shows a punctate fluorescence corresponding to mitochondrial localization 
(Figure A1.2A). We used flow cytometry to quantify the fluorescence of cells loaded with Rhod-
2 and the dye MitoTracker green that was used a control for mitochondrial mass. To ensure that 
only live cells were analyzed, we first excluded debris and dead cells by gating based on forward 
and side scatter parameters in the Flow Jo software (Figure A1.2B). A histogram of the Rhod-2 
fluorescence of live cells is displayed in Figure A1.2C. Cells induced for 4 d (blue) show a 
slightly shifted histogram compared to uninduced cells (green), and the histogram for cells 
induced for 7 d is shifted toward an even greater fluorescence. When normalizing for 
mitochondrial mass, we observed that the level of mitochondrial Ca2+ (Rhod-2/MitoTracker 
fluorescence) was elevated in cells overexpressing αSyn for 7-10. Though the data did not reach 
significance (p = 0.06 with paired comparisons to uninduced and 3-4 d induced cells from the 
same parental stock), they suggest that in 3D5 cells that overexpress αSyn to the point where 
oligomers can be detected, the mitochondria contain higher levels of Ca2+ under basal conditions 
than uninduced cells or those in which only monomer can be detected.  
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Figure A1.2: Extended induction of αSyn expression correlates with higher levels of 
mitochondrial Ca2+.  
A. 3D5 cells loaded with the cytosolic Ca2+ indicator Fluo-3 (at 2 uM) and mitochondrial Ca2+ 
indicator Rhod-2AM at 500 nM and analyzed by fluorescence microscopy. Note the cytosolic 
diffuse fluorescence for fluo-3 and the punctate fluorescence for Rhod 2 corresponding to 
mitochondrial localization. B. Individual cells analyzed by flow cytometry and plotted according 
their forward and side scattering (their size and complexity/granularity, respectively). Live cells 
were gated based on these parameters and this population was subsequently analyzed for 
fluorescence. C. A histogram showing the relative distribution of live cells according to their 
fluorescence in the DsRed fluorescence channel, corresponding to Rhod-2 fluorescence intensity. 
Uninduced (0d) cells and cells induced to overexpress αSyn for 4 and 7 days are compared. D. 
The ratio of median fluorescence intensity of Rhod-2 to mitotracker (control for mitochondrial 
mass) is plotted for uninduced, 3-4d induced, and 7d induced cells. Each color/symbol represents 
data collected using the same stock of cells that were either induced or uninduced. The level of 
mitochondrial Ca2+ (Rhod-2/mitotracker fluorescence) was elevated in cells overexpressing αSyn 
for 7-10 d.  
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Figure A1.2 (Continued): Extended induction of αSyn expression correlates with higher 
levels of mitochondrial Ca2+. 
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Ca2+ ionophore-induced toxicity:  
We then asked whether overexpression of αSyn sensitizes cells to Ca2+-induced toxicity. 
For these experiments, we compared uninduced 3D5 cells to those that had been induced to 
overexpress αSyn for 8 d. Cells were cultured in the presence of the Ca2+ ionophore A23187 for 
24 h and then analyzed for the degree of toxicity using flow cytometry. After ionophore 
treatment, cells were incubated with fluorescent “live cell” indicator calcein-AM and the “dead 
cell” dye ethidium homodimer-1 that binds to the DNA of cells with permeable membranes. As 
seen in Figure A1.3A, a percentage of uninduced cells were killed by exposure to A23187. Cells 
were considered “live” when they displayed calcein, but not ethidium homodimer-1 fluorescence 
(lower right quadrant). “Dead” cells were those that exhibited ethidium homodimer-1, but not 
calcein fluorescence (upper left quadrant). Examination of 8 d-induced 3D5 cells showed that 
A23187 treatment led to a reduction in the number of live cells and a corresponding increase in 
the number of dead cells compared to uninduced cells. Using a range of A23187 concentrations, 
we observed a dose-dependent increase in the percentage of dead cells for both uninduced and 
induced cells, and at each concentration we observed more cell death when αSyn was 
overexpressed (Figure A1.3B). When sets of induced and uninduced cells from the same 
experiment were analyzed pairwise, there were significantly more dead cells upon αSyn 
overexpression at concentrations ranging from 0.5–2 uM as exemplified by the data shown in 
Figure A1.3C. 
To rule out the possibility that the observed effects of induction were due to the removal 
of tetracycline rather than the overexpression of αSyn, we utilized the parental cell line to the 
3D5 cells (BE(2)M17D) that does not overexpress αSyn in response to tetracycline removal. We 
compared the percentages of dead cells in response to A23187 treatment in the presence or 
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Figure A1.3: Induced αSyn overexpression sensitizes cells to Ca2+-induced toxicity.  
A. Flow cytometry of uninduced and 8 d induced 3D5 cells treated with 1 uM A23187 Ca2+ 
ionophore for 24 hours and then loaded with calcein and ethidium homodimer 1. Each dot 
represents an individual cell. Quadrants were defined using samples containing unstained cells, 
cells stained with only calcein, and cells stained only ethidium homodimer 1. Induced samples 
contain more cells in the calcein-negative, ethidium homodimer 1-positive quadrant and less in 
the calcein-positive, ethidium homodimer-1-negative quadrant. B. Induced and uninduced cells 
were treated with vehicle or 0.5-4 uM A23187 and the percent dead cells (calcein-negative, 
ethidium homodimer 1-positive) was analyzed as in A. Error bars represent the standard 
deviation of 4 independent experiments. C. Statistical significance (p < 0.05) was reached when 
pairwise analysis was used for uninduced and induced sample pairs. Examples with 1 and 2 uM 
A23187 are shown. 
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Figure A1.3 (Continued): Induced αSyn overexpression sensitizes cells to Ca2+-induced 
toxicity.  
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absence (after 8 d) of tetracycline. We did observe a roughly-dose-dependent effect of A23187 
on cell survival, but we did not see any effect of tetracycline removal on the percent of dead cells 
(Figure A1.4). This suggests that αSyn overexpression and not tetracycline removal is 
responsible for the sensitization effects of induction. 
 
NMDA-induced changes in mitochondrial metabolism 
 To test whether αSyn overexpression is associated with impaired mitochondrial function 
in response to Ca2+ uptake, we exposed uninduced and 8 d-induced cells to NMDA and assessed 
the metabolism of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by 
mitochondrial dehydrogenases. NMDA stimulation is known to increase [Ca2+]m in neurons 
(Peng and Greenamyre, 1998; Peng et al., 1998). Preliminary results indicated that 25 and 50 uM 
NMDA application had no effect on MTT metabolism in uninduced cells, but it dose-
dependently reduced MTT metabolism in cells overexpressing αSyn (Figure A1.5). Treatment of 
cells with 0.1% Triton X-100 was used as a positive control to kill cells, thereby eliminating 
mitochondrial metabolism and MTT conversion. 
 
 We observed that αSyn overexpression, in particular to the degree that SDS-resistant 
oligomers can be detected, is associated with elevated resting [Ca2+]m, increased sensitivity to 
Ca2+ ionophore-induced toxicity, and reduced mitochondrial function in response to NMDA 
treatment. While these results are potentially interesting, there are many control experiments that 
need to be conducted. To gain more insight into the role of oligomeric αSyn, all experiments, 
including toxicity and mitochondrial function assays, need to be conducted with both 3-6 d-
induced as well as ≥ 7 d induced cells. Before claiming that treatments associated with toxicity  
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Figure A1.4: Sensitization of induced cells to Ca2+-induced toxicity is not due to the 
removal of tetracycline. 
The parental cell line of 3D5, called BE(2)M17D cells, dot no overexpress αSyn in response to 
tetracycline removal. BE(2)M17D cells were treated and analyzed as in Figure 3. Error bars 
represent the standard deviation of 3 independent experiments. 
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Figure A1.5: Induction of αSyn oligomer expression is correlated with increased sensitivity 
to NMDA.  
Uninduced and 8d induced cells were cultured in 1.8mM Ca2+ and treated for 1 hour with 25-50 
uM NMDA. Cells were then assessed for their ability to metabolize MTT reagent. The results for 
uninduced and induced cells are normalized to the NMDA vehicle for each group. Error bars 
represent the standard deviation of 3 biological replicates analyzed on the same day. 
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(A23187) and reduced mitochondrial function (NMDA) are related to mitochondrial Ca2+, it will 
be necessary to determine whether these stimuli do indeed raise [Ca2+]m. This can be 
accomplished by treating the cells with these chemicals, incubating them with Rhod-2AM (and 
also Fluo-3AM to measure cytosolic Ca2+), and then analyzing them via flow cytometry. The 
literature suggests that Ca2+ influx through NMDA receptors targets mitochondria (Peng et al., 
1998; Peng and Greenamyre, 1998); however, we would need additional controls to show that 
mitochondrial Ca2+ uptake is required for the reduction in MTT absorbance after NMDA 
treatment that we see in induced cells. This experiment should be repeated in the presence of an 
extracellular Ca2+ chelator (such as EGTA) or Ru360, an inhibitor of mitochondrial Ca2+ uptake. 
It would also be important to examine the sensitivity to Ca2+-induced toxicity using a technique 
that targets mitochondria more specifically. A23187 is an ionophore that will ultimately lead to 
the equilibration of Ca2+ across all cell membranes. Application of thapsigargin, the ER Ca2+ 
pump inhibitor, acts to deplete ER Ca2+ stores and trigger Ca2+ uptake into mitochondria (Hom et 
al., 2007) and would provide a more elegant means to examine the role of mitochondria in Ca2+-
mediated toxicity and possible sensitizing effects of αSyn. 
 These preliminary results are in agreement with those of Parihar and colleagues (2008) 
who also observed elevated Rhod-2 fluorescence in αSyn overexpressing neuroblastoma cells. 
Elevated [Ca2+]m would be expected to result in reduced resting ∆Ψm,, a phenomenon observed 
by other labs (Li et al., 2013; Marongiu et al., 2009; Parihar et al., 2009) and one that can be 
rescued by inhibiting mitochondrial Ca2+ uptake (Marongiu et al., 2009). It is possible that cells 
in which mitochondria exhibit higher [Ca2+]m at rest would be more vulnerable to the type of 
intracellular Ca2+ stress that is characteristic of neurons vulnerable in PD (Surmeier and 
Schumacker, 2013). Mitochondrial Ca2+ overload triggers the formation of the mPTP. In αSyn 
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overexpressing cells, this critical threshold of [Ca2+]m could potentially be reached with a more 
mild intracellular Ca2+ elevation that would not cause toxicity (or would cause less toxicity) in 
cells without overexpressed αSyn simply because overexpressing cells are effectively starting 
from a position of higher [Ca2+]m. It will therefore be interesting to determine whether mPTP 
inhibitors like CsA can rescue Ca2+-induced toxicity in αSyn overexpressing cells. Our isolated 
mitochondria data (Chapter 2) suggest that oligomeric αSyn can act directly on mitochondria to 
increase their susceptibility to Ca2+; however, in the context of a cell there are many potential 
sites of action for pathological αSyn species that could affect cellular and mitochondrial Ca2+ 
homeostasis. There is evidence that αSyn can affect Ca2+ flux at the endoplasmic reticulum and 
plasma membranes as well (Hettiarachchi et al., 2009; Marongiu et al., 2009), and it is possible 
that all of these pathways contribute to cell death in PD.  
 
Experimental Techniques 
SDS-PAGE / Western blotting (WB):  
Tet-off 3D5 human neuroblastoma cells (Ko et al., 2008) were induced to overexpress 
αSyn for the indicated number of days. Supernatant from 3,000 x g spins were used for Western 
blotting. Samples were prepared using MilliQ water and 4x sample buffer containing LDS plus 
20% β-mercaptoethanol (βME) Samples were electrophoresed on Nu-PAGE 4-12% Bis-Tris gels 
with MES-SDS running buffer. Gels were then transferred onto 0.45 µm Immobilon-P PVDF 
membranes for 60 min at 400 mA constant current at 4°C in transfer buffer consisting of 25 mM 
Tris, 192 mM glycine, and 20% methanol. After transfer, membranes were blocked in 5% non-
fat milk in PBS with 0.1% v/v Tween-20 (PBS-T) for 30 min at room temperature and then 
incubated in primary antibody either overnight at 4 °C or for 60 min at room temperature. 
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Membranes were then washed 3 times for 5 min in PBS-T, incubated with secondary antibody, 
washed 3 more times for 5 min in PBS-T, and then developed with ECL Plus or ECL Prime 
according to the manufacturer’s directions. 
 
Rhod2 Fluorescence Assay: Induced and uninduced 3D5 cells were gently scraped into 
microcentrifuge tubes in 1 ml of culture medium. Cells were incubated with 200nM Rhod2-AM 
and 100nM MitoTracker Green for 15min in the dark. Cells were then spun down, resuspended 
with ice cold PBS, and analyzed using an LSRII flow cytometer at using PE settings for Rhod-2 
and FITC settings for MitoTracker. Flow cytometry data were analyzed using Flow Jo software. 
 
Cell Viability Assay:  
3D5 cells were treated for 24hr with A23187 to induce Ca2+ influx and downstream 
effects. 1 ml of cells was transferred to microcentrifuge tubes at a concentration of 0.1-5x106 
cells/ml in warm culture medium. Calcein and ethidium homodimer 1 were added to cell 
suspensions to a final concentration of 100 nM and 8 uM, respectively, and the cells were 
incubated at room temperature in the dark for 15 min. Cells were pelleted and resuspended in 
300-500 µl ice cold PBS. Analysis was performed by flow cytometry using an LSRII flow 
cytometer and a 488 nm excitation laser, measuring emission at 530 nm (calcein) and 610 nm 
(ethidium homodimer 1). Data were analyzed using Flow Jo software. 
 
MTT Toxicity Assay: 
M17D neuroblastoma cells were seeded at a density of 1.5x105 cells/ml and treated at 37˚ 
for 24hr with PBS or 25-50 uM NMDA after which media was replaced with 50 µL of 0.5 
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mg/mL MTT in DMEM and incubated for 2hrs at 37°C. 200 µL of MTT lysis buffer (50% 
dimethyl formamide, 20% SDS, pH 7.4, 0.025N HCl, 2% acetic acid) was added to each well to 
solubilize the cells, and the plates were incubated at 37°C overnight and absorbance was 
determined using a luminometer. Plates were read at 570 nm for the reduction of MTT, 
subtracting baseline readings at 650 nm from each well. 
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Appendix 2 
 
Differential Effects of Recombinant and Erythrocyte-Derived α-Synuclein on the 
Fusion of Small Unilamellar Vesicles 
 
 
 
 
 
 
 
Contributions: 
Experiments were designed by Eric Luth, Tim Bartels, and Dennis Selkoe. 
Spectrophotometric assays of vesicle fusion were performed by Eric Luth and Vidiya 
Sathananthan. Electron microscopy was performed by Eric Luth with the help of Maria Ericsson. 
Purified αSyn from human erythrocytes was provided by Tim Bartels and Nora Kim. 
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Introduction 
For over two decades, αSyn has been thought to exist solely as an unstructured monomer 
under physiological conditions. Our lab recently described the purification and biophysical 
characterization of helical, oligomeric αSyn from human neuroblastoma cells and erythrocytes 
(Bartels et al., 2011). Because the purified helical αSyn is resistant to aggregation (unlike the 
unfolded monomer) and the pathological activity of αSyn is related to its aggregation (Volles and 
Lansbury, 2003), we hypothesized that helical oligomers represent a physiological form of the 
protein. This hypothesis would be supported by data showing that helical αSyn oligomers can 
carry out the physiological function of the protein; however, because the precise function of 
αSyn is has not been determined, there is no established functional assay for αSyn. In vitro 
experiments with recombinant protein (DeWitt and Rhoades, 2013; Varkey et al., 2010) and in 
vivo studies of knockout mice (Abeliovich et al., 2000; Anwar et al., 2011) support a 
physiological role for αSyn in the modulation of membrane dynamics – specifically related to 
synaptic vesicle release, though there is debate as to whether this occurs directly or via 
interactions with membrane proteins (Burré et al., 2010; DeWitt and Rhoades, 2013). In one 
recent study, Kamp and colleagues (Kamp et al., 2010) showed that recombinant αSyn dose-
dependently inhibits the fusion of small unilamellar vesicles (SUVs), a finding is consistent with 
one purported in vivo function. We therefore adopted this facile assay to begin to functionally 
characterize αSyn oligomers isolated from erythrocytes (RBC αSyn) and to gain insight into 
whether this form of αSyn behaved in a manner that could be considered “physiological”. 
Recombinant and RBC αSyn were compared in their ability to inhibit the fusion of SUVs 
as determined by light scattering, fluorescence and electron microscopy. Based on our previous 
observations that purified RBC αSyn can more avidly bind to a membrane surface, we 
!! 181 
hypothesized that RBC αSyn would have a similar but stronger effect in inhibiting vesicle fusion. 
We observed that recombinant αSyn acted as expected based on the literature (Kamp et al., 
2010), but RBC αSyn behaved qualitatively different from recombinant protein in that it 
promoted vesicle fusion, but only to a certain extent. Our data suggest that RBC αSyn acts to 
stabilize a particular size of vesicle, but further studies are needed to confirm the specificity of 
this effect.  
 
Results and Discussion 
Static light scattering:  
 We examined the effects of recombinant and RBC-derived αSyn on the fusion of SUVs 
composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC). We first used a static light 
scattering assay in which we added a non-ionic detergent, octaethylene glycol monododecyl 
ether (C12E8), to stimulate vesicle fusion after a stable baseline absorbance was achieved in the 
presence of vehicle, recombinant αSyn, or RBC αSyn (Figure A2.1A). The fusion of vesicle 
increases the average particle size, which corresponds to an increase in the absorbance of light at 
500 nm. In vehicle-treated samples (red trace), C12E8 steadily induced vesicle fusion until a 
stable plateau in scattering was reached after approximately 12 min. In agreement with published 
data, submicromolar concentrations of recombinant αSyn (blue and light blue traces) dose-
dependently reduced the rate of vesicle fusion (Kamp et al., 2010). In contrast, RBC-derived 
αSyn (orange) accelerated C12E8-induced fusion of DPPC vesicles. Interestingly, the increase in 
particle size stopped abruptly at a lower absorbance value than was achieved with vehicle 
addition. Quantification of the initial rate of fusion over the first 30 s showed that this 
acceleration was significant when compared to both vehicle and recombinant αSyn-treated  
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Figure A2.1: DPPC SUV fusion as measured by static light scattering. 
A. Representative traces of vehicle-, recombinant αSyn-, and RBC αSyn-treated vesicles. The 
time of C12E8 addition and initiation of vesicle fusion is noted. B. Quantification of the initial 
increase in light scattering in the 30 sec after C12E8 addition. C. the fold change in scattering 
from before C12E8 addition to 12 min after. Error bars represent the standard deviation of 3 
independent experiments. * = P < 0.05  
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vesicles (Figure A2.1B). To illustrate that this did not ultimately equate to an overall increase in 
scattering compared to vehicle-treated vesicles, we also quantified the fold increase in 
absorbance at 12 min, the time at which vehicle-treated vesicles reached a plateau (Figure 
A2.1C). At this time point, both recombinant αSyn- and RBC αSyn-treated vesicles were 
significantly smaller than vehicle-treated vesicles, but were roughly the same size as each other.  
 
Measurement of lipid mixing: 
 An increase in static light scattering intensity can correspond either to the fusion of 
vesicles or their clustering without fusion. To exclude the second possibility, we used a lipid 
mixing assay of vesicle fusion. This assay is conducted similarly to the static light scattering 
assay except that 10% of the lipids are labeled with both donor and acceptor fluorescent lipid 
probes such that the donor fluorescence emission is quenched by the acceptor fluorophore under 
conditions of limited lipid mixing. Initiation of fusion leads to mixing of the fluorescently 
labeled lipids with the unlabeled lipids and therefore a spatial separation of the donor and 
acceptor fluorophore. Fluorescence emission of the donor fluorophore is quantified over the 
course of the assay (Figure A2.2). We have carried out fewer experiments with this system, but 
initial studies confirm published data in that recombinant αSyn dose-dependently reduced the 
rate of lipid mixing compared to vehicle-treated vesicles (Kamp et al., 2010). As we had seen 
with static light scattering, RBC αSyn-treated vesicles fused and then reached a plateau faster 
than vehicle-treated vesicles. Together with the static light scattering results, this data suggest 
that recombinant acts to simply slow the fusion of SUVs, but RBC αSyn seems to rapidly 
promote the formation of and stabilize vesicles of a particular size and, presumably, curvature. 
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Figure A2.2: Lipid mixing of DPPC vesicles. 
A. Preliminary data showing lipid mixing in the presence of vehicle or recombinant αSyn. B. 
Preliminary qualitative comparison of the effects of recombinant and RBC αSyn on DPPC SUV 
fusion. 
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Additional controls: 
To show that the observed effects were specific, we incubated vesicles with cytochrome 
c, another small protein that associates with lipids. Addition of cytochrome c at concentrations 
up to 10 times what was used for αSyn had no effect on the rate or plateau in either static light 
scattering or lipid mixing assays (Figure A2.3A). Since some of the RBC αSyn samples 
contained glycerol, we also tested the effects of vehicle with 15% glycerol. As with cytochrome 
c, there was no effect of 15% glycerol in either assay of vesicle fusion. 
 
Electron microscopy of fused vesicles: 
 We next attempted to confirm the effect of the different αSyn species on vesicle fusion 
using an independent technique. To do this, we prepared samples as in the static light scattering 
assay but removed aliquots of the vesicle suspension for electron microscopy ~5 min after 
addition of C12E8, at a time when we could expect to see the greatest difference between all three 
samples (Figure A2.1A). Representative electron micrographs for these samples are shown in 
Figure A2.4A. Vehicle-, recombinant αSyn-, and RBC αSyn-treated samples are highlighted in 
red, blue, and orange, respectively. We measured the diameter of the vesicles and plotted their 
distributions (Figure A2.4B). As expected based on the light scattering data, recombinant αSyn-
treated vesicles showed a shift to the left indicating a smaller average vesicle diameter and 
confirming reduced fusion. Interestingly, the mean diameter of RBC αSyn-treated vesicles was 
similar to that of vehicle-treated vesicles (though slightly smaller), but there was a much 
narrower distribution of the vesicle sizes. This again suggests that RBC αSyn promotes the 
formation and/or stabilization of DPPC vesicles of a particular size (~60-65 nm in diameter). 
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Figure A2.3: Cytochrome C and 15% glycerol do not affect DPPC fusion. 
A. DPPC SUVs were mixed with cytochrome at a greater than 10 fold higher concentration 
compared to what was used or αSyn in the previous figures. B. We occasionally stored RBC 
αSyn samples in glycerol, but observed no alteration of vesicle fusion by this concentration of 
glycerol by itself. 
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Figure A2.4: Electron microscopy of fused vesicles supports spectrophotometric data. 
A. Representative electron micrographs of DPPC vesicles 5 min after initiation of fusion in the 
presence of vehicle (top panel, red outline), recombinant αSyn (middle panel, blue outline), and 
RBC αSyn (bottom panel, orange outline). Scale bar = 100nm B. The average diameter of  
vehicle-, recombinant αSyn-, and RBC αSyn-treated vesicles was measured from electron 
micrographs as in A and presented as histograms. 
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Hemoglobin behaves similarly to RBC αSyn: 
 In addition to αSyn, erythrocytes also abundantly express another helical tetramer: 
hemoglobin. We decided to test whether this potential contaminant also affected vesicle fusion.  
Hemoglobin-treated DPPC vesicles behaved similarly to RBC αSyn-treated vesicles in both 
static light scattering and fluorescent lipid mixing fusion assays (Figure A2.5A). We then asked 
whether our RBC αSyn samples were contaminated with hemoglobin. Western blot of 200 ng 
recombinant and RBC αSyn (Figure A2.5B, top panel, lanes 1 and 4, respectively) showed 
immunoreactivity for αSyn (though RBC αSyn was more difficult to detect), but not for 
hemoglobin (Figure A2.5B, bottom panel). A separate WB (Figure A2.5C) showed that we were 
able to detect as little as 100 ng of hemoglobin suggesting that at least 50% of the sample was 
not hemoglobin. That being said, considering the similarity in behavior of hemoglobin and RBC 
αSyn samples, the possibility of hemoglobin contamination must be carefully ruled out for each 
RBC αSyn samples tested in these functional assays. 
 
Our results suggest that recombinant αSyn and RBC αSyn have qualitatively and 
quantitatively different effects on the fusion of SUVs composed of DPPC. In agreement with 
published data, recombinant αSyn inhibits SUV fusion and lipid mixing. Based on the increased 
fusion rate and rapid plateau of light scattering and fluorescence changes, helical αSyn may act 
to stabilize a preferred size/curvature of vesicles. Electron micrographs of vesicles supported this 
interpretation. One important caveat is the effect of potential hemoglobin contamination in our 
RBC samples, though we were unable to detect hemoglobin. It is conceivable that similar 
secondary and quaternary structures of helical αSyn and hemoglobin (small, helical tetramers) 
may be responsible for their comparable effects on vesicle fusion. That being said, subsequent  
!! 189 
 
 
 
 
Figure A2.5: Hemoglobin behaves similarly to RBC αSyn in assays of vesicle fusion. 
A. Static light scattering analysis of DPPC SUVs treated with vehicle or hemoglobin at the same 
concentration as used for RBC αSyn in other figures. B. Fusion of DPPC SUVs incubated with 
vehicle or hemoglobin measured by the increase in increase in donor fluorophore fluorescence 
due to lipid mixing. C. The left panel shows a Western blot of a range of hemoglobin samples. 
Hemoglobin exists as a tetramer and loading high quantities of sample results in the detection of 
low amounts of species incompletely broken down by SDS. The right panels show 200 ng RBC 
αSyn probed for αSyn (C20) and hemoglobin. 
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studies of helical αSyn should be performed using a source that does not contain significant 
amounts of hemoglobin, such as human brain. We could find no publications describing the 
observed effects for hemoglobin, and it may be interesting to further examine this activity in 
future studies.  
These preliminary results should be followed up in several ways. A dose-response 
titration of RBC αSyn would allow us to determine at what protein:lipid molar ratio the effects of 
αSyn are saturated for comparison to published data for recombinant αSyn. Though Kamp et al. 
(2010) showed that recombinant protein inhibits the fusion of a variety of SUVs, it is possible 
that there may be preferential effects of RBC αSyn on different lipid types. Importantly, RBC 
αSyn is acetylated at its N terminus, a post-translational modification absent in recombinantly 
expressed protein. Unpublished observations from our lab indicate that N-acetylated αSyn binds 
with greater affinity to monosialoganglioside GM1, a lipid enriched in presynaptic membranes, 
than does non-acetylated protein. In the future it will also be interesting to compare the ability of 
helical and unfolded αSyn to inhibit the fusion of purified synaptic vesicles.  
Mitochondria provide another potential subcellular target for the activity of αSyn (Kamp 
et al., 2010; Nakamura et al., 2011; 2008). We could apply RBC and recombinant αSyn to 
suspensions of isolated mitochondria and monitor changes in size by light scattering and electron 
microscopy, though higher a protein:lipid ratio may be needed. High concentrations of 
recombinant αSyn have been shown to fragment large and giant unilamellar vesicles (Varkey et 
al., 2010). Findings from a recent paper from Westphal and Chandra (2013) suggest that RBC 
αSyn may have less of an effect on larger membrane structures. They show that monomeric but 
not RBC-derived tetrameric αSyn caused membrane tabulation of large vesicles. It has been 
suggested that fragmentation of mitochondria by αSyn is a potential neurotoxic mechanisms for 
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αSyn oligomers (Nakamura et al., 2011), and the reported curvature-sensing of αSyn (Jensen et 
al., 2011) may manifest as curvature-generation when the concentration of αSyn is sufficiently 
high – perhaps due to the formation of misfolded oligomers. A negative result with RBC αSyn in 
such an assay would further support that idea the abundant oligomers our lab detects under 
physiological conditions (Bartels et al., 2011; Dettmer et al., 2013) represent a physiological 
form of the protein and not one that is associated with disease.  
 
Experimental Techniques 
Purification of αSyn: 
Purification of recombinant αSyn was performed as described by Weinreb et al. (1996), 
and RBC αSyn was purified as described by Bartels et al. (2011). 
 
Preparation of vesicles: 
 DPPC (at a final concentration of 4 mM) was suspended in 20 mM Tris pH 7.4 and 
incubated for 30 min at 65°C. This suspension was then sonicated for 5 min to produce ~30 nm 
vesicles and spun for 5 min at maximum speed on a benchtop centrifuge. The supernatant 
(unlabeled vesicles) was stored at 65°C until use. For fluorescently labeled vesicles to be used in 
lipid mixing assays, 13 mM DPPC in chloroform was also prepared in glass vials. N-(7-
Nitrobenz-2-Oxa-1,3-Diazol-4-yl)-1,2-Dihexadecanoyl-sn-Glycero-3-Phosphoethanolamine 
(NBD-PE) fluorescence donor and rhodamine B 1,2-Dihexadecanoyl-sn-Glycero-3-
Phosphoethanolamine (N-Rh-PE) acceptor probe were added at 1 and 2 mol%, respectively, to 
13 mM DPPC. Labeled lipid solutions were dried using an air hose, lyophilized, and then 
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brought up in 20 mM Tris pH 7.4 to a concentration of 13 mM DPPC. Labeled lipids were then 
sonicated as described above for unlabeled vesicles. 
 
Assays of vesicle fusion: 
For static light scattering, 2100 µl of 20 mM Tris pH 7.4 were added to a quartz cuvette and 400 
ul of 4 mM unlabeled vesicles were added after 30 sec of recording. At 60 s either vehicle, αSyn, 
or other controls were added, and at 120 s 15 µl of the non-ionic detergent C12E8 was added to 
initiate vesicle fusion. Fusion was monitored continuously for 12-15 min by the increase in light 
scattering at 500 nm. For fluorescent lipid mixing assays, 2100 µl of 20 mM Tris pH 7.4 were 
added to a quartz cuvette along with αSyn or control samples. At 30 s into recording, 364 µl of 
unlabeled vesicles were added. At 60 s 36 u µl l of labeled vesicles were mixed in, and at 120 sec 
15 µl of C12E8 was added to initiate vesicle fusion. The reduction in donor fluorescence 
quenching (an indicator of lipid mixing) was monitored at excitation/emission of 450/530 nm for 
15 min. All experiments were performed in a Cary Eclipse fluorescence spectrophotometer at 
40°C with stirring. 
 
Electron microscopy: 
10 ul Aliquots from vesicle suspensions were adsorbed for 1 minute to a carbon coated 
grid that had been made hydrophilic by a 30 s exposure to a glow discharge.  Excess liquid was 
removed with filter paper and the samples were stained with 0.75% uranyl formate for 30 s. 
After removing the excess uranyl formate with filter paper, the grids were examined using a 
TecnaiG² Spirit BioTWIN transmission electron microscope. Images were acquired with an 
AMT 2k CCD camera. Vesicles diameters were measured using ImageJ. 
!! 193 
 
References 
 
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, 
N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., Rosenthal, 
A., 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal 
dopamine system. Neuron 25, 239–252. 
 
 
Anwar, S., Peters, O., Millership, S., Ninkina, N., Doig, N., Connor-Robson, N., Threlfell, S., 
Kooner, G., Deacon, R.M., Bannerman, D.M., Bolam, J.P., Chandra, S.S., Cragg, S.J., 
Wade-Martins, R., Buchman, V.L., 2011. Functional alterations to the nigrostriatal system in 
mice lacking all three members of the synuclein family. Journal of Neuroscience 31, 7264–
7274. 
 
 
Bartels, T., Choi, J.G., Selkoe, D.J., 2011. α-Synuclein occurs physiologically as a helically 
folded tetramer that resists aggregation. Nature 477, 107–110. 
 
 
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R., Südhof, T.C., 2010. Alpha-
synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663–
1667. 
 
 
Dettmer, U., Newman, A.J., Luth, E.S., Bartels, T., Selkoe, D., 2013. In vivo cross-linking 
reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-
neural cells. J. Biol. Chem. 288, 6371–6385. 
 
 
DeWitt, D.C., Rhoades, E., 2013. α-Synuclein Can Inhibit SNARE-Mediated Vesicle Fusion 
through Direct Interactions with Lipid Bilayers. Biochemistry. 52, 2385–2387. 
 
 
Jensen, M.B., Bhatia, V.K., Jao, C.C., Rasmussen, J.E., Pedersen, S.L., Jensen, K.J., Langen, R., 
Stamou, D., 2011. Membrane curvature sensing by amphipathic helices: a single liposome 
study using α-synuclein and annexin B12. J. Biol. Chem. 286, 42603–42614. 
 
 
Kamp, F., Exner, N., Lutz, A.K., Wender, N., Hegermann, J., Brunner, B., Nuscher, B., Bartels, 
T., Giese, A., Beyer, K., Eimer, S., Winklhofer, K.F., Haass, C., 2010. Inhibition of 
mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J 29, 
3571–3589. 
 
 
Nakamura, K., Nemani, V.M., Azarbal, F., Skibinski, G., Levy, J.M., Egami, K., Munishkina, L., 
!! 194 
Zhang, J., Gardner, B., Wakabayashi, J., Sesaki, H., Cheng, Y., Finkbeiner, S., Nussbaum, 
R.L., Masliah, E., Edwards, R.H., 2011. Direct membrane association drives mitochondrial 
fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 286, 
20710–20726. 
 
 
Nakamura, K., Nemani, V.M., Wallender, E.K., Kaehlcke, K., Ott, M., Edwards, R.H., 2008. 
Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with 
mitochondria. Journal of Neuroscience 28, 12305–12317. 
 
 
Varkey, J., Isas, J.M., Mizuno, N., Jensen, M.B., Bhatia, V.K., Jao, C.C., Petrlova, J., Voss, J.C., 
Stamou, D.G., Steven, A.C., Langen, R., 2010. Membrane curvature induction and 
tubulation are common features of synucleins and apolipoproteins. J. Biol. Chem. 285, 
32486–32493. 
 
 
Volles, M.J., Lansbury, P.T., 2003. Zeroing in on the pathogenic form of alpha-synuclein and its 
mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42, 7871–7878. 
 
 
Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A., Lansbury, P.T., 1996. NACP, a protein 
implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 
13709–13715. 
 
 
Westphal, C.H., Chandra, S.S., 2013. Monomeric synucleins generate membrane curvature. J. 
Biol. Chem. 288, 1829–1840. 
 
  
 
 
 
 
Appendix 3 
 
Visualization of Cellular α-Synuclein Oligomers Using Intact Cell Crosslinking 
 
 
 
 
 
 
 
 
Contributions: 
Experiments were designed by Eric Luth and Dennis Selkoe. 
All experiments were performed by Eric Luth and Vidiya Sathananthan. 
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Introduction 
The secondary structure and oligomerization state of αSyn under physiological conditions 
is a matter of great interest and debate. We recently challenged the longstanding view that αSyn 
normally exists exclusively as an unstructured monomer by demonstrating that αSyn purified 
from human erythrocytes and neuroblastoma cells exists as a helically-folded oligomer that sizes 
as a tetramer and resists aggregation (Bartels et al., 2011).  Independent laboratories have since 
confirmed the existence of helical oligomers of αSyn purified from erythrocytes (Westphal and 
Chandra, 2013) or, under favorable conditions, from bacteria (Trexler and Rhoades, 2012; Wang 
et al., 2011). Another group was unable to detect such species (Fauvet et al., 2012). Our goal was 
to further probe the assembly state of αSyn as it exists within cells by developing a facile and 
reproducible method for detecting oligomers. Evidence of abundant cellular oligomers under 
non-pathological conditions would support the idea that our previous findings are not an artifact 
of purification but rather represent an endogenous state of the protein. 
To this end, we applied cell permeable crosslinking reagents to live cells in order to 
stabilize intermolecular αSyn-αSyn interactions. We elected to use a crosslinker-based strategy 
since an alternative FRET/FLIM approach would require the use of fluorescent tags, which could 
affect these interactions. We restricted our efforts to amine-reactive crosslinking agents because 
sulfhydryl crosslinkers would be ineffective, due to the absence of cysteine residues in the αSyn 
protein sequence. We first worked out favorable crosslinking and detection conditions in cells 
overexpressing the protein and then applied our protocol to the detection of αSyn oligomers 
under endogenous expression conditions. Application of the 7.7 Å crosslinker disuccinimidyl 
glutarate (DSG) at a concentration of 0.5-1 mM at room temperature was most effective in 
trapping midrange oligomeric species for detection on SDS-PAGE. αSyn oligomers could be 
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detected by multiple αSyn antibodies and also immunoprecipitated. We also show that certain 
oligomeric assemblies are apparently destabilized by cells lysis. These preliminary results 
provide a basis for future investigations into factors that affect the stability of αSyn oligomers in 
intact cells. 
 
Results and Discussion 
The 7.7 Å crosslinker DSG effectively traps αSyn oligomers within cells:  
We applied a variety of crosslinking agents to intact 3D5 human neuroblastoma cells 
overexpressing αSyn with the goal of covalently stabilizing αSyn-αSyn interactions that exist 
within intact cells. We exclusively tested homobifunctional, amine reactive crosslinkers. αSyn 
lacks cysteines, and therefore thiol reactive agents would not be effective at crosslinking the 
protein. The 3 Å crosslinker 1,5-difluoro-2,4-dinitrobenzene (DFDNB) did not trap any αSyn 
oligomers as seen by SDS-PAGE of the lysed cells (Figure A3.1). Additional monomeric protein 
was detected after crosslinking, but this is due to the fact that crosslinker-induced modification 
of αSyn monomer allows for improved immunodetection upon Western blotting (Newman et al., 
2013). We were able to trap abundant oligomeric species with the 12 Å crosslinker 
dithiobis(succinimidylpropionate) (DSP). After running lysed cells on SDS-PAGE, the dominant 
band ran at the position of an αSyn dimer (αSyn-35) with weaker bands migrating around 60 and 
80 kDa as well as some high molecular weight smearing (Figure A3.1). Based on the 14.5 kDa 
molecular weight of the αSyn monomer, we interpreted the αSyn-60 band as a tetramer (4 x 14.5 
kDa = 58 kDa).  Application of the 7.7 Å crosslinker DSG consistently led to a reduction in the 
amount of detectable αSyn monomer (an expected consequence of trapping oligomeric protein) 
and a prominent stabilization of the putative tetramer, with a less immunoreactive dimer band 
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Figure A3.1: The 7.7 Å crosslinker effectively traps a 60 kDa αSyn species. 
Intact neuroblastoma cells overexpressing αSyn were crosslinked with either the 3 Å crosslinker 
DFDNB, the 7.7 Å crosslinker DSG, or the 12 Å crosslinker DSP at the concentrations and times 
(in minutes) as indicated. The lystates were run on denaturing gels and blotted for αSyn. The 
positions of specific αSyn immunoreactive bands are noted. Monomeric αSyn runs at 14.5 kDa 
and a crosslinked tetramer would be expected to run at 58 kDa. DFDNB fails to trap oligomeric 
αSyn. DSP traps mostly dimeric αSyn. The predominant oligomeric band trapped by DSG is at 
60 kDa. 
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 (Figure A3.1). Under these conditions, we also observed some smearing with DSG. Because of 
our recent publication that characterized αSyn purified from both human erythrocytes and this 
neuroblastoma cell line as a tetramer, we chose to pursue crosslinking conditions that favored the 
stabilization of the αSyn-60 tetrameric band – in this case the crosslinker DSG. 
 
Optimization of crosslinking conditions: 
We tested a multiple DSG concentrations within the range recommended by the 
manufacturer and saw the best results with 0.5-1 mM (shown in Figure A3.2A). With 0.5 mM 
DSG, we observed a time-dependence of both monomer reduction and tetramer stabilization. At 
1 mM DSG, the intensity of oligomeric bands was less time dependent, but there was a greater 
presence of smearing in the mid-to-high molecular weight region that is indicative of non-
specific crosslinking to a variety of other molecules. We then compared DSG crosslinking at 
room temperature and 4°C in their ability trap putative tetramers. We consistently observed that 
crosslinking at 4°C, even for twice as long, was less efficient that crosslinking at ambient 
temperature. At room temperature, we saw strong stabilization of the αSyn-60, -80, and -100 
kDa bands (Figure A3.2B). The precise relationship between these bands is currently under 
investigation. On the other hand, αSyn-35 (dimer) was readily detected after crosslinking at 4°C, 
and we interpreted this as a partial crosslinking of tetramers (Figure A3.2B).  This was true when 
samples were probed with two different αSyn antibodies, C20 and Syn1. While a variety of αSyn 
antibodies can detect the trapped oligomeric species, they occasionally exhibit preferences for 
different species. For example, C20 more readily detects monomer compared to Syn1 (Figure 
A3.2B). 
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Figure A3.2: Optimization of DSG crosslinking conditions. 
A. The ability of 0.5 and 1 mM DSG for various durations to crosslink αSyn (top) and DJ1 
(bottom) at room temperature were compared. B. Two different αSyn antibodies (C20 and Syn1) 
were used to compare the ability of 0.5 mM DSG to trap mid-molecular weight αSyn oligomers 
after 60 min incubations at either room temperature or 4°C. Note the presence of dimers (i.e. less 
efficient crosslinking) associated with crosslinking performed at 4°C. *= non-specific Syn1 
immunoreactive band. 
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Crosslinked oligomers can be immunoprecipitated: 
As a means of laying the groundwork for future pulse-chase studies to look at the 
stability of oligomeric αSyn, we asked whether any of our αSyn antibodies could 
immunoprecipitate (IP) crosslinked species. As shown with non-crosslinked samples, Syn1 could 
efficiently IP αSyn from cell lysate. When we used Syn 1 to IP from lysate that was prepared 
after crosslinking intact cells with DSG, it was able to pull down both monomeric and oligomeric 
αSyn (Figure A3.3A) Based on the presence of monomer in the post-IP supernatant, it is possible 
that Syn1 IPs relatively more oligomeric αSyn than monomeric αSyn, but this will need to be 
examined further. Two other αSyn antibodies, LB509 and 5C2 failed to IP any αSyn species 
(Figure A3.3B), suggesting that their epitopes may be inaccessible under native conditions 
regardless of whether the protein is in a monomeric or oligomeric assembly state. 
 
Crosslinking of endogenous αSyn oligomers in intact cells: 
 Thus far, we have demonstrated an ability to trap oligomeric αSyn in overexpressing 
cells. It is possible that the formation of these assemblies of αSyn is a result of overexpression 
and/or pathological accumulation of the protein. We therefore sought to similarly trap oligomeric 
species in cell expressing endogenous or near endogenous levels of αSyn. The overexpression of 
αSyn in 3D5 cells is induced when the cells are cultured in the absence of tetracycline. In the 
presence of tetracycline, there is minimal αSyn overexpression. Though higher concentrations of 
crosslinker were required when compared to overexpressing 3D5 cells, we were able to detect 
oligomeric αSyn-immunoreactive bands (αSyn-35, -60, -80, -100) in uninduced cells (Figure 
A3.4A). We then tested a completely endogenous neuroblastoma system, SKNMC cells. Intact 
cell crosslinking in SKNMC cells revealed the same pattern of oligomeric bands that we  
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Figure A3.3: Immunoprecipitation of crosslinked αSyn oligomers. 
A. αSyn was immunoprecipitated from the lysates of non-crosslinked and crosslinked 
neuroblastoma cells by the Syn1 antibody. Post = the supernatant following immunoprecipitation 
of αSyn. IP lanes = precipitated samples boiled in sample buffer containing βME to elute 
precipitated protein from agarose beads. B. Immunoprecipitations from crosslinked cells were 
carried out using the αSyn antibodies LB509 and 5C2. Note the strong signal in the Post but not 
IP lanes. 
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Figure A3.4: Crosslinking of endogenous αSyn oligomers within cells. 
A. DSP crosslinking of human neuroblastoma cells under conditions that repress αSyn 
overexpression. Note the presence of 35, 60, 80, and 100 kDa bands in lanes with 1 and 5 mM 
DSP. B. DSG crosslinking of SKNMC human neuroblastoma cells expressing only endogenous 
αSyn. Crosslinking of intact cells (lanes 2 and 3) was compared to crosslinking of cell lysate 
(lanes 4 and 5). The standard pattern of oligomers is observed upon intact cell crosslinking, but 
much of the mid-molecular weight oligomers were not observed after crosslinking of cell lysates. 
Only the 80 kDa band appeared resistant to lysis. 
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observed in induced and uninduced 3D5 cells (Figure A3.4B). When SKNMC cells were lysed 
prior to crosslinking, DSG trapped a different pattern of oligomers; we saw a profound 
destabilization of the 60 and 100 kDa bands in favor of a strong 17 kDa band and enhanced 
immunoreactivity for the 80 kDa band. This suggests some of the oligomeric assemblies trapped 
within live cells by DSG are lysis sensitive. 
 
An attempt to alter the oligomer to monomer ratio: 
 It has previously been reported that HSP-70 expression can affect the intermolecular 
interactions of lysis-sensitive αSyn oligomers within cells (Klucken et al., 2006). To learn more 
about the potential role of HSP-70 in the formation of oligomers in our system, we transfected 
induced 3D5 cells with an siRNA for HSC-70 (a constitutively active isoform) and examined the 
pattern of crosslinker-trapped oligomers. Untransfected cells showed the familiar strong 60, 80, 
and 100 kDa band with a faint dimer band (Figure A3.5). Cells transfected with HSC-70 siRNA 
showed a somewhat reduced staining for oligomeric bands, but a similar effect was seen with 
mock-transfected cells. Moreover, probing for HSC-70 showed no evidence of lower protein 
expression levels. Though this experiment failed to alter the oligomer to monomer ratio (perhaps 
due to technical issues with the siRNA transfection), live cell crosslinking promises to be an 
effective tool for analyzing conditions that modulate the native cellular state of αSyn. 
 
The crosslinking technique that I developed for the detection of αSyn oligomers has been 
further optimized by my colleagues and recently published (Dettmer et al., 2013). In that paper, 
we show that removing membranous components using an ultracentrifugation step after cell lysis 
dramatically reduced smearing in the mid-to-high molecular weight region.  The use of cells with  
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Figure A3.5: An attempt to alter the oligomer to monomer ratio. 
Intact 3D5 cells were crosslinked after transfection with siRNA to the chaperone HSC-70 and the 
pattern of αSyn immunoreactivity was compared to untransfected and mock transfected cells 
(top). Western blot for HSC-70 (bottom) shows no reduction of protein levels with siRNA 
transfection. 
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higher endogenous αSyn expression, such as human erythroleukemia cells and primary rat 
neurons, coupled with more sensitive αSyn antibodies have improved the detection of 
endogenously expressed oligomeric species trapped within cells. The diffusion controlled 
crosslinking of recombinant protein produced a pattern of oligomeric bands whose intensity 
decreased as their size increased. This is distinct from the strong 60 kDa band that we observe 
after crosslinking live cells, arguing against the likelihood that the pattern of immunoreactivity 
we observe with intact cell crosslinking is due to a stochastic process. We expanded upon my 
initial observation that certain immunoreactive oligomeric bands are lysis sensitive by showing 
that they can be recovered when cells are lysed at high protein concentrations (above 15 mg/ml). 
This suggests that macromolecular crowding is favorable for stability of oligomeric species, 
specifically the 60 and 100 kDa bands. We are currently trying to identify the relationship 
between these oligomeric bands to determine whether they are distinct oligomeric species or 
conformers that are differentially modified by DSG. To this end, we are purifying crosslinked 
species for intact mass determination by mass spectroscopy. 
We used multiple approaches, including the co-immunoprecipitation of differentially 
tagged αSyn species and the exclusion of putative interactors by Western blot or other means to 
show that these mid-molecular weight oligomers are homo-oligomers rather than monomer 
crosslinked to a distinct protein. Furthermore, we showed that non-aggregation prone βSyn and 
αSyn lacking an intact NAC domain can be similarly crosslinked in a pattern that mirrors that for 
αSyn (Dettmer et al., 2013). These observations further support the idea that the oligomers we 
trap by live-cell crosslinking are physiological and not pathological species.  
This now-optimized technique will be useful in identifying intracellular factors that 
influence the formation or stability of physiological αSyn oligomers. Such factors can be 
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intrinsic to αSyn, such as mutations or extrinsic, such as the activation of other cellular 
pathways. We have preliminary data suggesting that PD-linked αSyn missense mutations reduce 
the ratio of αSyn-60 : αSyn-14. These data further highlight the physiological nature of these 
αSyn oligomers and support the hypothesis that toxic αSyn species arise from the aggregation of 
unfolded monomers but not helical oligomers. It will also be important to investigate whether 
other conditions, such as chronic rotenone treatment (Sherer et al., 2002) that promote αSyn 
aggregation are also associated with a reduction in endogenous mid-molecular weight oligomers 
in favor of monomers. 
 
Experimental Techniques 
Crosslinking: 
For intact cell crosslinking, cells were crosslinked in 10 cm culture dishes. Culture media 
was aspirated and cells were gently washed with Dulbecco’s phosphate buffered saline (DPBS) 
after which 4 ml of DPBS plus a crosslinking agent (dissolved in DMSO) or DSMO vehicle was 
carefully added so as not to disturb the monolayer of cells. Dishes were rocked at room 
temperature or 4°C for the indicated time. To quench the crosslinking reaction Tris pH 7.6 was 
added to a final concentration of 50 mM and dishes were rocked at room temperature for an 
additional 15 min. The liquid was then aspirated from the dishes and cells were scraped in 1 ml 
PBS into microcentrifuge tubes. Cells were pelleted by spinning at 1,000 g for 5 min at 4°C, 
resuspended in 150 µl PBS and sonicated 3 times for 15 s each. Lysates were spun at 20,000 g 
for 30 min and the supernatant was collected. For crosslinking of lysed cells, cells were scraped 
in 1 ml DPBS into microcentrifuge tubes and spun at 1,000 g for 5 min at 4°C. The intact cell 
pellets were resuspended in 200 ul DPBS and homogenized by sonication for 3 times for 15 s. 
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Lysates were spun at 20,000 g for 30 min and the supernatant was collected. DSG was added to a 
final concentration of 1 or 2 mM in DMSO and the samples were incubated for 30 min at room 
temperature under nutation. To quench the crosslinking reaction Tris pH 7.6 was added to a final 
concentration of 50 mM and samples were incubated for an additional 15 min at room 
temperature. 
 
Immunoprecipitation: 
 Protein A or G agarose beads stored in ethanol were washed in PBS. For pre-clearing, 
500 µg of crosslinked or non-crosslinked samples were incubated with 10 ul protein A or G 
agarose beads and PBS for a total of 300 ul. In parallel, agarose beads were conjugated to 
antibodies directed against αSyn. 1 µg of antibody was incubated with 20 ul of agarose beads 
and PBS for a total of 300 µl. Samples were nutated at 4°C for 90 min after which the 
supernatant from the pre-clear step was added to the pelleted antibody-bead conjugates and then 
incubated overnight at 4°C. The following day, beads were pelleted by spinning at 5,000 g for 5 
min at 4°C. The post-IP supernatant was collected. The pellet was washed with PBS and spun 
again and the protein in the resultant pellet was eluted by boiling the beads in 2x LDS sample 
buffer without βME for 5 min at 85°C. 
 
SDS-PAGE / Western blotting (WB):  
Samples were prepared using MilliQ water and 4x sample buffer containing LDS plus 
20% βME Samples were electrophoresed on Nu-PAGE 4-12% Bis-Tris gels with MES-SDS 
running buffer. Gels were then transferred onto 0.45 µm Immobilon-P PVDF membranes for 60 
min at 400 mA constant current at 4°C in transfer buffer consisting of 25 mM Tris, 192 mM 
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glycine, and 20% methanol. After transfer, membranes were blocked in 5% non-fat milk in PBS 
with 0.1% v/v Tween-20 (PBS-T) for 30 min at room temperature and then incubated in primary 
antibody either overnight at 4 °C or for 60 min at room temperature. Membranes were then 
washed 3 times for 5 min in PBS-T, incubated with secondary antibody, washed 3 more times for 
5 min in PBS-T, and then developed with ECL Plus or ECL Prime according to the 
manufacturer’s directions. 
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